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Abstract  
Coronary artery disease (CAD) is inflammatory and caused by genetic/environmental 
factors. Interleukin (IL) 6 is a pro-inflammatory cytokine implicated in CAD. Selenoprotein S 
(SelS) has recently been implicated in inflammation and endoplasmic reticulum (ER) stress. 
Several IL6 and SelS polymorphisms are associated with increased CAD risk. The aim of this 
project was to investigate the role of polymorphisms of IL6 (-6331 T/C,-597 G/A ,-572 G/C), 
IL-6R (rs8192284A/C, Asp358Ala) and SelS (-1500 A/C,+3705 G/A,+5227 C/T, and +9000 C/G) 
on the expression of their mRNA/proteins. This will help us understand the role of these 
SNPs in risk of CAD/ Myocardial infarction (MI).  
Flow cytometry was used to assess the surface expression of the macrophage 
differentiation-specific markers CD14 and CD11c, and IL-6R by peripheral blood 
mononuclear cell (PBMC)- derived macrophages. Messenger RNA levels were determined by 
quantitative PCR (QPCR) in lipopolysaccharide (LPS) and IL-1β-stimulated THP-1 cells and in 
PBMC-derived macrophages from healthy donors. SelS protein expression was analysed by 
Western blotting. Cell culture supernatants were assayed for cytokine production by flow 
cytometry (Cytokine Bead Array). Gene expression (mRNA and protein) was compared to IL6 
and SelS genotype and haplotype. 
CD11c-hi, CD14-lo expression on 8-day cultured PBMCs confirmed their differentiation state 
as macrophage. The effect of LPS or IL-1β at 8 hours on SelS mRNA expression of SelS 
combined data did not show a significant increase but SelS mRNA was upregulated in LPS-
induced +CATG SelS haplotype in PBMC-derived macrophages. +CATG SelS Haplotype did 
not increase the SelS protein concentration in either LPS or IL-1β stimulated PBMC-derived 
macrophages at 8 hours time point. SelS-1500 CC genotype was associated with high SelS 
fold induction in PBMC-derived macrophages treated by LPS. IL6 mRNA was significantly up-
regulated in LPS-stimulated THP-1. IL-1β- and LPS-induced +TGG, +TAG and +CGG 
haplotypes in PBMC-derived macrophages. IL6 protein production was also significantly 
increased in the LPS-induced +TAG and +CGG haplotypes. IL6-597A allele increased the IL6 
mRNA fold induction. Interestingly, PBMCs from people with the IL6 TAG haplotype (or –
597A allele) have higher IL6 and in contrast, lower SelS at baseline and IL-1β. CD126 (IL-6R) 
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expression was very low on PBMC-derived macrophages, suggesting that classical IL6 
signalling may not occur in these PBMCs.  
 In conclusion, SelS mRNA was up-regulated in LPS-induced +CATG SelS haplotype in PBMC-
derived macrophages. +CATG SelS Haplotype did not increase the SelS protein concentration 
in either LPS or IL-1β stimulated PBMC-derived macrophages at 8 hours time point. SelS-
1500 CC genotype was associated with high SelS fold induction in PBMC-derived 
macrophages treated by LPS. The individuals with +TAG IL6 haplotype (or IL6-597 A allele) 
show greater induction with pro-inflammatory stimuli. In contrast, PBMCs from people with 
the IL6 TAG haplotype (or –597A allele) have lower SelS at baseline and following IL-1β (and 
probably also LPS) stimulation.  
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Chapter 1. Introduction 
1.1 Inflammation and inflammatory mediators 
Inflammation can be defined as a protective biological process that happens in response to 
a number of different stimuli that damage cells and tissues. In other words, it supports the 
immune system by producing the leukocytes that destroy or ameliorate these harmful 
stimuli, and the vascular system by facilitating transport of these leukocytes into the 
vascular and perivascular tissues (Libby, 2008). Failure of leukocytes to remove these 
threats in the vessel wall may trigger atherosclerosis and coronary artery disease (CAD; see 
Section 1.3).   
Inflammatory mediators are molecules such as cytokines and chemokines and their 
receptors that co-ordinate the innate and adaptive inflammatory and immune responses to 
harmful stimuli/pathogens. Much of the regulation of inflammation is achieved at the 
transcriptional level, for example by rapid production of cytokines in response to 
proinflammatory stimuli. 
1.2 General transcription and gene regulation  
The process of protein-encoding gene expression requires three main stages: DNA 
transcription (mRNA synthesis), RNA processing and mRNA translation (protein synthesis) 
(Venters and Plug, 2009). Transcription means that the nucleotide sequence of template 
DNA is copied or transcribed into the nucleotide sequence of an RNA molecule that must be 
exported to the cytoplasm prior to its translation into amino acids. Several key factors are 
involved in the transcription process including DNA, transcription factors, RNA polymerase 
and ATP. The promoter determines where the transcription of the DNA template begins. 
This promoter contains several different DNA sequences that direct the RNA polymerase ΙΙ 
to initiate transcription. These DNA sequences include the TATA box, initiators and CpG 
islands. The TATA box is located at -26 to 31bp upstream of the transcription start site. Any 
deletion in the sequence between the TATA box and the start site will alter the transcription 
level. Moreover, any mutation in the TATA box sequence will reduce the transcription level. 
RNA polymerase ΙΙ requires binding of initiation factors called general transcription factors 
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with the TATA box to initiate the transcription. These factors include TFΙΙA, TFΙΙB, TFΙΙF, TFΙΙE, 
TFΙΙH and TFΙΙD, which is the largest factor, consisting of a single 38-kDa TATA box binding 
protein (TBP) and 13 TBP-associated factors (TAFs). The helicase, which is one of TFΙΙH 
subunits, utilizes ATP to separate the DNA duplex at the transcriptional start site. To initiate 
transcription TBP folds the DNA helix. Binding of RNA polymerase ΙΙ with its general 
transcription factors to the promoter forms the preinitiation complex. Most of these general 
factors except TBP are released once transcription begins. This preinitiation complex is 
ready to begin the transcription process, which include three essential steps: transcriptional 
initiation, elongation and termination. In transcription initiation, RNA polymerase ΙΙ with the 
help of initiation factors, recognises and binds to a promoter in dsDNA. After binding, the 
helicase separates the dsDNA, allowing access of RNA polymerase II to the bases in the DNA 
template for base pairing with the bases of the ribonucleoside triphosphates. This allows 
the DNA template strand to enter the active site of RNA polymerase II, the enzyme that 
catalyses phosphodiester bond formation between ribonucleotide triphosphates that are 
complementary to the template DNA strand at the start site of transcription. The 
transcription initiation step is considered complete when the first two ribonucleotides of 
the RNA chain are linked by a phosphodiester bond. The elongation steps require 
movement of the RNA polymerase along the DNA template, opening the dsDNA in the 
direction from 3’ to 5’ and adding ribonucleoside triphosphates sequentially to growing 
RNA. In transcription termination, the completed RNA is released from RNA polymerase, 
which dissociates from the template DNA.  
Even though the regulation of any gene may occur at any stage of gene expression 
(transcription initiation, elongation, RNA processing, mRNA export from nucleus to 
cytoplasm and translation to protein), control of transcription initiation and elongation are 
thought to be the most essential steps for determining whether a particular gene is 
expressed and how much the protein encoded by that gene is produced. Several proteins 
including transcription factors such as repressor and activator proteins, mediators or co-
activators/co-repressors, DNA methyltransferases and chromatin remodelling enzymes (eg 
histone acetyltransferase) may participate in eukaryotic gene regulation/transcription 
through their interactions with enhancer and promoter elements. Transcription factors can 
activate or repress transcription through binding with promoter or enhancer regulatory 
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elements in eukaryotic DNA. Transcriptional regulation can also be achieved through 
interaction of two transcription factors (protein-protein interactions); for example, the 
interaction of transcription factors AP-1 and NFAT regulates the transcription of the IL2 
gene. The repressors and activators that bind to specific sites in DNA regulate gene 
expression by several mechanisms: firstly, these regulatory proteins act with other proteins 
to modulate the chromatin structure, inhibiting or stimulating the ability of general 
transcription factors to bind to promoters. Some modifications affect the relative 
condensation of chromatin and thus its accessibility to protein required for transcription 
initiation. Secondly, activators and repressors interact with the mediator (co-activator) that 
binds RNA polymerase Π and directly regulates formation of the transcription preinitiation 
complex. Co-activators can form a ‘bridge’ between several different transcription factor 
activation domains and RNA polymerase ΙΙ, which helps to integrate the effects of multiple 
activators on a single promoter. Heterochromatin regions, which are more highly condensed 
and contain closed chromatin, show reduced gene expression compared with DNA in 
euchromatin. The term ‘chromatin remodelling’ simply refers to changes in chromatin 
condensation in DNA regions and it determines the accessibility of specific DNA sequences 
in the chromatin to transcription factors. DNase 1 is used experimentally to determine 
regions that contain closed chromatin (resistant to DNase 1 digestion) and in turn inactive 
genes, and therefore by implication the regions that include open chromatin. 
1.3 Coronary artery disease (CAD) 
CAD is a complex inflammatory disease which is one of the main causes of death globally, 
especially in the western world as defined by the World Health Organisation (WHO).  
Although considerable research has been carried out on CAD risk factors, controversy still 
surrounds the causal factors for CAD. However, it is clear that lifestyle habits, environmental 
and genetic factors, and their interactions are involved in the aetiology of CAD. Risk factors 
can be classified into modifiable and unmodifiable risk factors: modifiable factors include 
obesity, smoking, hypercholesterolaemia, increased circulating lipoprotein levels, diabetes, 
hypertension, physical inactivity and alcohol intake; the unmodifiable risk factors include 
advanced age, gender, family history, ethnicity, autoimmune disease (Roeters van Lennep et 
al., 2002). Genetically, CAD is not a specific disease with a single cause compared with other 
genetic diseases that are caused by a mutation in a gene. This means that several genes, in 
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particular single nucleotide polymorphisms (SNPs) in these genes, are associated with an 
increased risk of CAD (Sing et al., 2003).  
CAD is characterized by accumulation of pro-inflammatory fatty deposits known as plaques 
in the arterial walls. It is clinically asymptomatic for many years and it probably begins in 
young individuals (Casas et al., 2006). Some studies show that the fatty streak, a thickening 
of the intimal region of the artery wall consisting of several cell types such as macrophages, 
lymphocytes and smooth muscle cells, is the first mark of atherosclerosis (Woods et al., 
2000). CAD underlies angina, thrombotic strokes and myocardial infarction, the major 
clinical manifestations of atherothrombosis.  
Atherosclerosis and thrombosis are the two main components of CAD. Atherosclerosis is a 
chronic inflammatory process characterized by a progressive accumulation of plasma low-
density lipoprotein (LDL) and fibrous components in the arterial wall. The multiple processes 
of atherosclerosis which lead to CAD begin with endothelial dysfunction as shown in Figure 
1.1 (Watkins and Farrall, 2006). When the endothelium loses its permeability, circulating LDL 
will pass through the endothelium into the intima and become oxidised. Another feature of 
endothelial dysfunction is exposure of adhesion molecules on the endothelial cell surface, 
which leads to recruitment of monocytes. Once the monocytes are in the intima, they 
differentiate into mature macrophages. The macrophages will then phagocytose the 
oxidised LDL, forming foam cells. When foam cells die, they usually do so via apoptosis or 
necrosis, leaving necrotic bodies and degraded extracellular matrix in the intima. These 
materials are pro-inflammatory and pro-thrombotic and give the atherosclerotic plaque 
many of its properties. If/when an atherosclerotic plaque becomes unstable, it will rupture, 
resulting in release of these materials into the blood stream and formation of thrombus. 
The thrombus may cause the vessel to block completely, giving rise to the most severe 
consequence of CAD, myocardial infarction (MI). 
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Figure 1.1 Atherosclerosis processes. Low density lipoprotein (LDL) particles migrate through 
dysfunctional endothelium into the intima where they are oxidised. Monocytes are stimulated due 
to release of cytokines, adhesion molecules and growth factors. Accumulation of foam cells (lipid-
laden macrophages) and proliferation of smooth muscle cells increase the growth of lesions. Death 
of smooth muscle cells due to apoptosis, and degradation of extracellular matrix through proteolysis 
by matrix metalloproteinases (MMPs), can result in destruction of the fibrous cap of a plaque, 
causing plaque rupture.  Plaque rupture can cause thrombosis which might lead to artery blockage 
and MI.  (Watkins and Farrall, 2006). 
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1.4 Coronary artery disease as an inflammatory disease 
Inflammation plays a key role in the development of atherosclerosis and in turn stimulates 
cardiovascular events.  Normally, the endothelial cells that line the artery wall do not allow 
leukocytes to adhere to the vessel wall (Libby, 2006). However, the presence of some 
inflammatory stimuli including smoking, obesity and pathogens, can induce the endothelial 
cells to produce adhesive molecules such as VCAM-1 that bind with leukocytes (monocytes 
and T-lymphocytes) and allow them to migrate through the arterial wall. This then triggers 
the inflammatory processes that unresolved, leads to atherosclerosis. 
 
1.5 Genetics of CAD                              
There is considerable evidence to support the involvement of genetic factors in determining 
the susceptibility of individuals/populations to complex diseases such as CAD. According to 
the CADgene database (http://www.bioguo.org/CADgene/), there are more than 300 
candidate genes associated with increased risk of CAD. However, determination of the size 
and number of contributing influences of these genes on CAD is difficult because other 
susceptibility genes to CAD are still unknown and they need to be identified (Watkins and 
Farrall, 2006). Large-scale genome-wide association studies (GWAS) have been used in 
several published studies to determine the association of single nucleotide polymorphisms 
(SNPs) with CAD. The causal genes or causal variants behind the susceptibility loci are not 
well-established yet (Chen et al., 2011).  
 
Some of these predisposing genes have been identified by genome-wide linkage and 
association studies. These approaches complement the candidate gene studies that focus 
on well-known risk factors (Watkins and Farrall, 2006). The International HapMap Project is 
also used to minimise the number of variants that need to be genotyped to cover the whole 
genome. The first three successful independent GWAS for CAD were reported from Ottawa 
Heart Study (McPherson et al., 2007), from deCODEGenetics (Helgadottir et al., 2007), and 
from the Wellcome Trust Case-Control Consortium (Samani et al., 2007). A case-control 
design was adopted, using discovery and replication cohorts. This involved genotyping those 
SNPs that provided the best scoring in the discovery cohort in further, replication cohorts; if 
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replicated, combined analysis of the entire cohort was then performed. Examples of these 
GWAS for CAD/MI are summarized in Table 1.1. 
Although the above three GWAS used different cohorts, they identified the same CAD risk 
locus on chromosome 9p21.3. This locus is adjacent to cell cycle regulatory tumour 
suppressor genes including cyclin-dependent kinase inhibitors, CDKN2A and CDKN2B and 
also overlaps the ANRIL gene (also known as CDKN2BAS) that is expressed in atherosclerotic 
tissues and in abdominal aortic aneurysm, amongst other tissues (Bown et al., 2008; 
McPherson et al., 2007). McPherson et al., (2007), identified two SNPs (rs10757274 and 
rs2383206) at the 9p21.3 locus associated with CHD. The GWAS carried out by Helgadottir 
et al., (2007), on Icelandic subjects with/without myocardial infarction (MI), using a 
genotyping array of 305,953 SNPs in 1607 MI cases and 6728 controls, found that three 
SNPs (rs1333040, rs2383207 and rs10116277) on 9q21 had a robust association with MI and 
each one had ORs of 1.22 for the risk allele and P value of approximately 1 × 10-6. In the 
same study, these three SNPs were validated in a replication cohort showed the same 
significant results with MI. Wellcome Trust Case Control Consortium (WTCCC) GWAS data 
and German MI studies also found that rs1333049 on the 9p21.3 risk locus had the  
strongest association with CAD (P=1.8 × 10-14 and P=3.4 × 10-6 respectively) (Samani et al., 
2007).  The WTCCC study also identified an additional nine loci linked to CAD (P= 1.2 × 10-5). 
The German MI study carried by Samani, et al. replicated two of these nine SNPs and also 
found clear association of rs6922269 on chromosome 6q25.1 and rs2943634 on 2q36.3 with 
CAD. The combined data from these two studies identified further loci associated with CAD 
including 1p13.3 which contains the PSRC1 gene, 1q41 (MIA3), 10q11.21 (CXCL12) and 
15q22.33 (SMAD3) (Samani et al., 2007).   
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Table 1.1 Examples of loci associated with myocardial infarction or coronary artery disease.  
Abbreviations: SNP= single nucleotide polymorphism; Chr =chromosome, CI, confidence interval 
Table adapted from (Clarke et al., 2009; Erdmann et al., 2009; Gudbjartsson et al., 2009; Kathiresan et al., 2009; Luke et al., 2007) . 
Chr SNP 
Risk allele 
frequency 
Odds ratio (95% CI) per risk 
allele 
Gene(s) of interest within/near 
associated interval 
Associated with 
LDL chol or Lp(a)? 
Reference 
9p21 rs4977574 0.56 1.29 (1.25–1.34) CDKN2A-CDKN2B-ANRIL - 
(Helgadottir et al. 2007; McPherson et al. 
2007; Samani et al. 2007; Kathiresan et al. 
2009). 
1p13 rs646776 0.81 1.19 (1.13–1.26) CELSR2-PSRC1-SORT1 Yes 
(Samani et al. 2007; Kathiresan  et al. 
2009). 
21q22 rs9982601 0.13 1.20 (1.14–1.27) SLC5A3-MRPS6- KCNE2 - 
(Kathiresan et al. 2009) 
1q41 rs17465637 0.72 1.14 (1.10–1.19) MIA3 - 
(Samani et al. 2007; Kathiresan et al. 2009) 
10q11 rs1746048 0.84 1.17 (1.11–1.24) CXCL12 - (Samani et al. 2007; Kathiresan et al. 2009) 
6p24 rs12526453 0.65 1.12 (1.08–1.17) PHACTR1 - (Kathiresan et al. 2009) 
19p13 rs1122608 0.75 1.15 (1.10–1.20) LDLR Yes (Kathiresan et al. 2009) 
2q33 rs6725887 0.14 1.17 (1.11–1.23) WDR12 - (Kathiresan et al. 2009) 
1p32 rs11206510 0.81 1.15 (1.10–1.21) PCSK9 Yes (Kathiresan et al. 2009) 
12q24 rs2259816 0.37 1.08 (1.05–1.11) HNF1A Yes (Erdmann et al. 2009) 
12q24 rs3184504 0.40 1.13 (1.08–1.18) SH2B3 - (Gudbjartsson et al. 2009) 
3q22 rs9818870 0.15 1.15 (1.11–1.19) MRAS - (Erdmann et al. 2009) 
6q26-  
rs3798220 0.02 1.47 (1.35–1.60) LPA Yes (Luke et al. 2007; Clarke et al. 2009) 
rs10455872 0.07 1.68 (1.43–1.98) LPA Yes (Clarke et al. 2009)  
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Many other candidate genes have been found for CAD and two of these, both related to 
inflammatory aspects of the disease, are selenoprotein S (SelS) and interleukin 6 (IL6). IL6 is 
a pro-inflammatory cytokine that is considered as a key factor in CAD aetiology. SelS has 
recently been shown to be involved in the pathogenesis of CAD through up-regulation of 
pro-inflammatory cytokines including IL6, IL1β and TNF-α that are themselves associated 
with increased risk of CAD. Because of the evidence for association of SelS, IL6, and IL-6 
receptor (IL-6R) polymorphisms with CAD (Section 1.6.4 and 1.7.5), investigation of their 
potential functional role in CAD forms the basis for this study. 
 
1.6. Selenoprotein S and the role of its polymorphisms in CAD 
1.6.1 Overview  
Selenium (Se) is a dietary trace element essential for human health, although it is toxic at 
high levels. Se is transferred to plants and thence to us through its bioavailability in the soil. 
It is incorporated into proteins through a specifically encoded amino-acid, selenocysteine 
(Sec).  Sec is present in a family of selenoproteins, which include for example glutathione 
peroxidases, thioredoxin reductases, iodothyronine deiodinases and selenoprotein S. These 
selenoproteins have roles in immune function, anti-oxidative stress and apoptosis, and have 
anti-inflammatory and anti-viral properties (Rayman, 2000). Deficiency of different types of 
selenoprotein is associated with a number of different diseases including compromised 
immune function, susceptibility to viral infection, impaired fertility, depression, 
cardiovascular disease, cancer, inflammatory disorders such as arthritis, dysfunctional 
thyroid hormone metabolism, cardiopathy, Keshan disease  and Kashin-Beck disease 
(Beckett and Arthur, 2005; Behne et al., 1996; Ge and Yang, 1993; Rayman, 2000, 2002; 
Utiger, 1998; Vanderpas et al., 1990). These disorders are caused by different aetiologies as 
shown in Table 1.2. Sec is the 21st amino acid and takes part in ribosome-mediated protein 
synthesis; it has the same structure as cysteine but the sulphur group is replaced by 
selenium (Bellinger et al., 2009; Berry et al., 2001). Interestingly, the incorporation of sec is 
encoded by the UGA codon, which is a stop codon in non-selenoprotein genes (Figure 1.2) 
(Small-Howard and Berry, 2005). This process requires an element in the 3’ UTR of 
eukaryotic mRNA named the sec insertion sequence (SECIS) that permits decoding of UGA 
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as the Sec codon (Berry et al., 1993). The SECIS element forms a stem loop structure and 
binds with SECIS-element binding protein 2 (SBP2). This complex links with the 
selenocysteine specific elongation factor (EFsec) and in turn binds with the Sec-tRNA which 
recognises the stop codon and allows the incorporation of sec (Squires and Berry, 2008). 
The human genome encodes 25 known selenoproteins including selenoprotein S (SelS) 
(Kryukov et al., 2003).  
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Table 1.2. Examples of selenoproteins in human diseases 
Disorder Cause Selenoprotein or 
cofactor 
Function Reference 
Keshan disease Selenium 
deficiency/coxsackie B 
virus 
Various, GPX? ?? (Papp et al., 2007) 
Kashin–Beck disease Selenium/iodine 
deficiency 
DIO Thyroid hormone 
production 
(Moreno-Reyes et al., 
2003) 
Epilepsy Selenium deficiency? GPX? Oxidative stress (Ashrafi et al., 2007)  
Multiminicore 
disease 
Mutations SelN Calcium signalling (Zorzato et al., 2007)  
Thyroid dysfunction Mutations SBP2 Selenoprotein 
synthesis 
(Dumitrescu et al., 
2005)  
Inflammation 
responses 
Polymorphisms SelS Removal of 
misfolded proteins 
Curran et al., 2005 
Cancer Polymorphisms/ 
Expression 
GPX1, GPX2 and 
GPX4, SelS, SelP, 
Sep15, TRXR 
Various (Brigelius-Flohe, 2008; 
Papp et al., 2007; 
Shrimali et al., 2008; 
Squires and Berry, 2006) 
 
 
  
 
 
Figure 1.2 Selenoprotein syntheses. The SECIS (selenocysteine insertion sequence) is the main 
element required by the ribosome to differentiate a stop codon from selenocysteine codon. It is a 
secondary structure of mRNA, consisting of 60 nucleotides that adopts a stem-loop structure. This 
complex structure guides the cell to translate UGA codons for selenocysteine incorporation instead 
of a stop codon. The SECIS element is found in the 3' UTR of the mRNA. It binds with SECIS Binding 
Protein 2 (SBP2) that binds and recruits a complex of EFsec/Sec-tRNA. Messenger RNA translation 
continues until the ribosome recognises a new stop codon (Hatfield and Gladyshev, 2002). 
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Human SelS is a member of the endoplasmic reticulum (ER)-resident selenoprotein family. It 
is a 21-KDa protein that comprises 189 amino acids, with a short fragment in ER lumen and a 
longer (132 amino acids) selenocysteine (Sec)-containing tail (188 amino acids) in the 
cytosol (Shchedrina et al., 2010). The SelS tail forms a coiled-coil region (amino acids 52-122) 
and this domain may be responsible for dimerization of SelS or for linking with other 
proteins (Ye et al., 2004). Accumulation of misfolded proteins in the ER lumen occurs due to 
several factors (see next Section), and leads to ER stress activation.  
1.6.2 SelS and the ER stress pathway 
ER is the site of protein synthesis and maturation. Folding of the proteins in the correct 3-
dimensional conformation is important for protein function. Therefore, unfolding or 
misfolding of proteins lead to a loss of the normal function of these proteins. Accumulation 
of misfolded/unfolded proteins in the ER lumen due to several factors such as low selenium 
(low dietary selenium intake) or SelS polymorphisms leads eventually to the activation of a 
stress response called “ER stress”. The accumulation of misfolded/unfolded proteins 
activates an unfolded protein response (UPR) pathway which aims to reduce the protein 
load on ER and enhance cell survival. UPR consists of the activation of three distinct 
pathways as shown in Figure 1.3 (Flamment et al., 2012; Gorman et al., 2012). 
 
In the UPR pathway, three distinct signalling systems including protein kinase R-like ER 
kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) 
maintain the ER homeostasis. Under basal conditions, all these sensors are maintained in an 
inactive form by interacting with an ER-resident chaperones called glucose regulated protein 
78 (GRP78) [also named binding immunoglobulin protein (BiP)]. However, when the 
accumulation of misfolded protein occurs, BiP will dissociate from these three sensors to 
play its role as chaperone in improving protein folding, but this will also activate the UPR 
sensors (Gorman et al., 2012). Active PERK dimerises and activates a kinase activity which 
leads to the phosphorylation of PERK and the eukaryotic initiation factor (eIF2-α). The 
consequence of inactivating of eIF2-α is to stop producing new proteins through translation 
and that will reduce the protein load on ER. However, in a selective way, some transcription 
factors such as Activating Transcription Factor 4 ATF4 are still translated although inhibition 
of general protein translation. AFT4 is responsible for the transcription of several genes 
13 
 
involved in the production of chaperones (e.g. GRP78) which then go and help improving 
the folding of misfolded proteins, contributing thus to ER homeostasis. ATF4 also induces 
the transcription of apoptotic genes such as CHOP. Similarly, BiP-free IRE1 dimerization 
activates a kinase and endonuclease activity. Active IRE1will be then auto-phosphorylated 
and will induce through its endonuclease activity the mRNA splicing of X-box binding protein 
1(XBP1) to produce an active transcription factor called XBP1s (Yoshida et al., 2001). It is 
longer form protein that does not exist under normal state. XBP1s will translocate to 
nucleus and activate the transcription of chaperones and proteins of ERAD machinery which 
help for degrading the proteins that are not fixed (Lee et al., 2003). Finally, the dissociation 
of BiP will facilitate the translocation of ER trans-membrane protein ATF6 to the Golgi lumen 
where it will be cleaved by proteases (S1P and S2P) (Gorman et al., 2012). The cleavage of 
the full length (p90) ATF6 will produce a shorter and active ATF6 transcription factor (p50). 
ATF6 (p50) will then translocate to nucleus and cause transcription of XBP1 and target genes 
associated with cell survival such as chaperones and ERAD (Yoshida et al., 2000).    
  
14 
 
 
 
 
Figure 1.3. Unfolded protein response pathway (UPR). Three distinct pathways (PERK, IRE1 
and ATF6) participate in this system. Accumulation of misfolded protein lead to dissociation of RE-
resident chaperones BiP (GRP78) from these three sensors and binding with unfolded proteins in ER 
lumen, attempting to improve the protein folding but this will trigger UPR markers. Activated PERK 
will dimerize and phosphorylate itself and then   phosphorylation elF2α and hence inhibition of 
producing new proteins through translation. However, ATF4 is still translated; triggering 
transcription of several genes involved in production of chaperones (GRP78) and apoptotic genes 
(CHOP). Activated and phosphorylated IRE1 induce the mRNA splicing of  XBP1 mRNA to produce 
XBP1s that activate the transcription of chaperones and ERAD genes in nucleus. Activated ATF6 
allows itself to move to the Golgi where it undergoes cleavage by S1P and S2P proteases, producing 
shorter and active ATF6 (p50) that in turn induce the transcription genes of XBP1, chaperones and 
ERAD. Adapted from Flamment et al., 2012; Gorman et al., 2012.  
 
 
However, if the stress at the origin persists, the UPR becomes chronic, resulting in ER stress. 
Activation of ER stress is associated with pathological consequences through the activation 
of different inflammatory pathways. For instance, phosphorylated IRE1 will activate cJUN 
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NH2-terminal kinase (JNK) inflammatory pathway which then lead to the activation of NF-κB 
pathway. Furthermore, the inhibition of eIF2-α leads to the inactivation of I-κB and thus to 
further activation of NF-κB. In addition, active ATF6 (p50) can also trigger NF-κB activation 
[Figure 1.4 and (Flamment et al., 2012)]. Collectively, the activation of NF-κB signalling 
pathway can lead to the overexpression IL6 that is associated with CAD. ER stress can occur 
due to different factors including high cholesterol, changes in redox status, inhibition of 
protein glycosylation, protein flux and decreased Ca2+ in ER lumen. Of particular interest, 
SelS deficiency through either a low dietary Se intake or a polymorphism in SelS gene can 
cause the activation of ER stress response dependent inflammatory pathways. Indeed, SelS 
normally participates with other proteins such as derlin in the removal of misfolded proteins 
from the ER lumen to the cytosol for degradation by proteolysis (Alanne et al., 2007). 
Therefore, SelS protects cells against ER stress response (Alanne et al., 2007). However, 
accumulation of misfolded proteins in the ER lumen due to down-regulation of SelS that 
might be associated with SelS SNPs leads to ER stress acativation. Curran et al. (2005) 
pointed out that genetic variations in the SelS gene may be implicated in some 
inflammatory conditions through their effects on SelS mRNA expression and in turn 
production of pro-inflammatory cytokines such as TNF-α, IL-1β and IL6 (see Section 1.6.4).  
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Figure 1.4. ER-stress- induced inflammation pathways. Chronic UPR-induced ER stress 
associated with several factors including down-regulation of SelS activate inflammatory pathways. 
Phosphorylated IRE1 stimulate JNK pathway that activate NF-κB. Inactivated iκB due to eIF2-α lead 
to further activation of NF-κB. Activated NF-κB can induce the transcription of pro-inflammatory 
genes including IL6. Adapted from  Flamment et al. (2012).  
 
Prolonged ER stress activation can induce apoptosis through at least two pathways in 
humans. The first pathway is activation of CHOP expression under the control of PERK and 
ATF6 effectors (Scull and Tabas, 2011). The second mechanism is the activation of JNK 
pathway which is mediated by the formation of the IRE1-TNF receptor-associated factor 2 
(TRAF2)-apoptosis signal-regulating kinase1 (ASK1)’ complex (Figure 1.5). These apoptosis 
mediators are triggered by the UPR sensors (PERK, IRE1 and ATF6) in addition to other 
factors associated with ER calcium depletion and redox homeostasis (Malhi and Kaufman, 
2011; Scull and Tabas, 2011). ER stress-induced overexpression of CHOP causes 
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transcriptional down-regulation of anti-apoptotic Bcl-2 family proteins. The pro-apoptotic 
proteins (Bax and Bak) and anti-apoptotic Bcl-2 family proteins regulate Ca2+ homeostasis. 
Absorption of Ca2+ by mitochondria induces its permeablilisation and activates CHOP which 
can then trigger BCL-2 homology domain 3 (BH3) proteins, the cell surface death receptor 
TRAIL receptor 2 and inhibit Bcl-2 transcription. In addition, CHOP-induced apoptosis 
involves a calcium signalling pathway. CHOP-dependent activation of the ER oxidase 1α 
(ERO-1α) triggers ER calcium release by activating the ER calcium channel IP3R1 (Li et al., 
2009). Cytoplasmic calcium activates the calcium-sensing enzyme Calcium/calmodulin-
dependent protein kinase II (CaMKII), which in turn triggers a number of downstream 
apoptotic pathways, including induction of the Fas death receptor, activation of JNK, and 
activation of mitochondrial apoptotic pathways (Timmins et al., 2009).  
 
 
Figure 1.5. ER stress-induced apoptosis. Apoptosis associated with severe/prolonged activation 
of UPR and ER Ca2+ depletion can occur through two different pathways (JNK activation and CHOP 
induction).  
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1.6.3 Selenoprotein S (SelS) gene  
The SelS gene is widely expressed in many different tissues and cells including hepatocytes, 
adipose, neuronal and muscle cells. It maps to chromosome 15q26.3 and comprises six 
exons and five introns. This locus has previously been implicated in several inflammatory 
diseases such as Alzheimer disease, Coeliac disease and diabetes mellitus (Curran et al., 
2005). More specifically, a number of studies have shown that some candidate 
polymorphisms in the SelS gene are associated with susceptibility to these disorders. The 
association of SelS polymorphisms with CAD have been shown in several studies (see next 
Section). 
 
1.6.4 Evidence for the role of SelS polymorphisms in CAD 
Polymorphisms in the SelS gene (Figure 1.6) are associated with increased risk of 
cardiovascular events (CHD, CAD and ischaemic stroke) directly or through their roles in 
increasing the levels of pro-inflammatory cytokines, in particular IL6, IL-1β and TNF-α 
through impairment of SelS expression. Two independent prospective Finnish cohorts were 
collected by Alanne et al., (2007) to study the association of SelS polymorphisms with the 
risk of CHD and ischaemic stroke. They showed that A allele of the rs8025174 (-1500 A/C) 
SNP increased the risk of CHD in females (HR 2.95; 95% CI 1.37 to 6.39) and rs7178239 G 
allele (+9000 C/G) increased the ischaemic stroke risk in females (HR 3.35; 95% CI 1.66- 
6.76) and in combined analysis of both sexes (HR 1.75; 95% CI 1.17 to 2.64). Five main 
haplotypes were also identified in this study and these haplotypes were derived from five 
polymorphisms (-1500 A/C (rs8025174); -105 G/A (rs28665122); +5227 C/T (rs4965373); 
+6218 A/G (rs9874) and +9000 C/G (rs7178239)) as shown in Figure 1.6. The haplotype 
analysis shows that Haplotype 2 (H2) was associated with increased the risk of  CAD in males 
and also in combined analysis of both male and female cohorts. However, Haplotype 4 (H4) 
was associated with increased risk of stroke in combined data of female cohorts and also 
with increased CHD risk in males. For the role of SelS SNPs in increase the levels of pro-
inflammatory cytokines through impairment of mRNA/protein expression of SelS itself, 
Curran et al., (2005), showed that three SelS polymorphisms (-105 G/A (rs28665122), +3705 
G/A (rs4965814) and +5227 C/T (rs4965373) in Wisconsin population were associated with 
increased plasma levels of at least one cytokine of three cytokines including IL6, IL-1β and 
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TNF-α and Curran et al. found that -105 G/A and +3705 G/A increased the levels of all three 
cytokines . This study showed also that G allele of -105 G/A SNP was associated with higher 
production of all these three cytokines (P=0.000016, P=0.0005, P=0.00089 respectively) and 
because of that, Curran et al. tested the effect of this SNP in the promoter activity of SelS 
using HepG2 cell lines stressed by tunicamycin. The reporter assay data analysis  show that -
105 A allele has less effect on the promoter activity of SelS compared with G allele 
(P=0.000061) and this is a strong evidence that this SNP is likely to be functional. SelS 
promoter contains two functional NF-kB transcription factor binding sites and ER stress 
response element (ERSE) as shown in Figure 1.6 (Gao et al., 2006).  SelS-105 SNP locate 
within the ERSE element and therefore, -105 alleles may interact with this element, 
resulting in down and/or up regulation of SelS expression that induce the production of 
some inflammatory cytokines. Because the effect of -105 A allele on SelS promoter activity, 
Curran et al. also tested this influence on increasing the levels of the three pro-inflammatory 
cytokines among Mexican-American individuals and they found that the -105 A allele was 
associated with significantly increased levels of these cytokines (P=0.0000007 for IL-1β and 
P=0.00015 for TNF-α). Curran et al. also investigated the influence of these SNP alleles on 
the level of mRNA/protein of SelS and in turn cytokine production in RAW264.7 macrophage 
cell line by suppression using short interfering RNA (siRNA), followed by Phorbol myristate 
acetate (PMA) treatment. The data show that suppression of SelS by siRNA induced lower 
expression of SelS mRNA and protein, and this resulted in significantly increased levels of 
these three cytokines. Taken together, these results suggest that SelS may play a critical role 
in regulating inflammatory processes and is therefore implicated in inflammatory diseases 
such as CAD. The effect of particular alleles on transcription factor binding, that may in turn 
induce the expression of SelS, are covered in the Discussion (Chapter 6).  
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Figure 1.6. Selected polymorphisms in the SelS gene. The SelS gene consists of six exons and 
five introns. These SNPs have been associated with CAD or stroke risk. Five haplotypes constructed 
from five SNPs (-1500 A/C, -105 G/A, +5227 C/T, +6218 A/G and +9000 C/G). The fifth haplotype is 
comprised of several different, individually rare haplotypes. The minor allele of each SNP is circled. 
(Gao et al., 2006; Alanne et al., 2007). 
 
1.6.5 Evidence for the role of SelS polymorphisms in other diseases 
In addition to the critical role of SelS polymorphisms in increase the risk of CAD, it has been 
investigated in other several inflammatory diseases. For example, in a case and control 
study published by Shibata et al. (2009), the authors examined the stomach biopsies of 268 
Japanese patients with gastric cancer (193 males and 75 females, average age 65.3), and 
306 healthy volunteers (184 males and 122 females, average age 62.7) and they found that 
SelS-105 A allele increased the risk of gastric cancer and gastric cancer compared with 
control among Japanese population (OR: 2.0, 95%CI 1.0–3.9, p < 0.05; OR: 2.0, 95% CI 1.0–
4.1, p = 0.07 respectively). Another case (n= 1139) and control (n=2269) study carried out 
(Moses et al., 2007) to investigate the role of this SNP in preeclampsia among Norwegian 
women showed that A allele at SelS-105 G/A SNP was associated with increase the risk of 
preeclampsia in this population (P= 0.023). SelS-105 A allele was significantly higher 
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frequencies between 232 Kashin-Beck disease (KBD) patients compared with 331 controls 
(P<0.0001) (Du et al., 2014). More recently, Li et al. (2015) found also that +3705 G/A 
(rs4965814) SNP was associated with ischaemic stroke between Chinese individuals with 
(n=239) or without (n=240)  ischaemic stroke.  A study of 481 patients with Hashimoto’s 
thyroiditis (HT) and 516 healthy controls suggests that SelS-105 AA genotype was more 
distribution frequency (P=0.0268) between the patients compared with controls in north 
Portugal, Porto (Santos et al., 2014).      
 
However, other studies did not show any association between SelS SNPs and some 
inflammatory diseases. Seiderer et al. (2007) point that the frequencies of -105 G/A alleles 
were similar between 359 patients with inflammatory bowel disease (IBD) and 204 healthy 
individuals and also this SNP did not increase the serum level of TNF-α in those patients. 
There was also no significant difference in -105 allele frequencies between the stroke 
patients and controls, suggesting that -105 A allele may not be associated with the stroke 
risk (Hyrenbach et al., 2007).  
 
1.7 Interleukin-6 (IL6) and the role of IL6 and IL-6R polymorphisms in 
CAD  
1.7.1 Overview  
Interleukin 6 (IL6) is a 26 kDa pleiotropic cytokine that has biological roles in inflammation, 
regulation of endocrine, metabolic, nervous and haematopoietic systems. It is normally 
present at a low level in plasma of healthy individuals. It is produced by a variety of immune 
and non-immune cells including T and B- lymphocytes, polymorpho-nuclear leukocytes, 
eosinophils, monocytes, macrophages, mast cells, dendritic cells, chondrocytes, osteoblasts, 
endothelial cells, skeletal muscle cells, smooth muscle cells, islet cells, thyroid cells, 
fibroblasts, mesangial cells, keratinocytes, some tumour cells and adipose tissue as well as 
microglial cells and astrocytes (Figure 1.7).   
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IL6 has a spectrum of actions including biological and pathological actions (Figure 1.7). 
Therefore, it has been named several times based on its action (Riedemann et al., 2003) but 
it now usually designated IL6. Alternative names include hepatocyte stimulating factor, 
interferon β2, B-cell stimulating factor 2, and cytotoxic T cell differentiation factor. Several 
studies demonstrate that increased IL6 level is associated with pathology of multiple 
diseases including systemic onset juvenile chronic arthritis (Fishman et al., 1998), 
rheumatoid arthritis (Hirano et al., 1988), osteoporosis (Jilka et al., 1992; Poli et al., 1994), 
psoriasis (Grossman et al., 1989), cardiac myxoma (Hirano et al., 1987), and inflammatory 
bowel disease and diabetes mellitus type 1 and 2 (Bettelli et al., 2006). Overexpression of 
IL6 also was found at 10-40 fold higher level in atherosclerotic vessels compared with non-
atherosclerotic arteries (Seino et al., 1995).IL6 gene expression has been found to be higher 
in the plaques of symptomatic compared with asymptomatic patients (Abe et al., 2010; 
Erbel et al., 2011).This suggests that IL6 may have a role in the progression of human 
atherosclerosis. IL6 can trigger the hypothalamic-pituitary-adrenal axis and secretion of 
growth hormone (Papanicolaou et al., 1996; Ray et al., 1990). It is released during stress or 
exercise and it is positively regulated by catecholamines (Papanicolaou et al., 1996). IL6 also 
activates acute phase proteins including C-reactive protein and fibrinogen in response to 
stimuli such as infection, macrophage and T cell development and differentiation (Fey et al., 
1991). Production of glucocorticoids as a part of the inflammatory response supports IL6 
synthesis of acute phase proteins (Fey et al., 1991).  
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Figure 1.7 Production of IL6 and its actions. IL6-produced by many different cells and it has a 
variety of actions. Adapted from (Naka et al., 2002). 
 
According to several published studies, IL6 and soluble IL-6 receptor (sIL-6R) levels also 
represent independent markers for coronary heart disease (CHD) and CAD.  IL6 plasma 
levels can be considered as a predictor of future CHD (Harris et al., 1999). Increased IL6 
plasma levels have been found in affected individuals with unstable angina compared with 
patients who had stable angina (Biasucci et al., 1996). The condition of those patients may 
also get worse when the elevated IL6 levels persist. Smoking and stress are examples of 
cardiovascular and psychological factors that may increase IL6 plasma levels and in turn 
increase the CHD risk. Pai et al., (2004) concluded that after adjustment for age, smoking 
and fasting status, increased IL6 and CRP levels were associated with significantly increased 
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risk of CHD in females and males (P =0.01 and P <0.001 respectively). Bennet et al., (2003) 
also found that elevated IL6 levels were present in male patients with cardiovascular disease 
compared with controls. sIL-6R level was also found to be significantly higher in affected 
individuals with CAD (Karaduman et al., 2006). 
However, the relationship between IL6 and cardiovascular events is controversial. For 
example, the outcomes of a study that carried out on 57 affected individuals post 
myocardial infarction compared with 46 controls has shown that there is no correlation 
between this disorder and the plasma levels of TNF-α, CRP and IL6 (Schins et al., 2005), but 
this is a very small study and so may not be reliable. Similarly, another study did not show 
obvious evidence about the association of IL6 promoter SNPs with cardiovascular and 
myocardial infarction risk (Bennet et al., 2003). However, other studies have shown 
evidence for the role of IL6 promoter polymorphisms in increased risk of cardiovascular 
diseases (Section 1.7.5).  
1.7.2 IL6 signal transduction and Interleukin-6 receptor (IL-6R)  
The IL6 protein has a helical structure (Figure 1.8), with four long α-helices (A, B, C and D). 
Two types of IL-6 receptors (IL-6R) exist in the form of two different membrane 
glycoproteins (gp) which are produced by two distinct genes. These receptors include a 
trans-membrane receptor, glycoprotein 130 (gp130) that is involved in signal transduction 
and is shared with other cytokines. Another form of IL-6R is gp80 that forms a ligand-binding 
subunit (Heinrich et al., 2003). The gp80 receptor is encoded by the genes that are located 
on chromosomes 1q21 but the gp130 receptor is encoded by genes on chromosome 5 as 
shown in the UCSC Genome Database. Glycoprotein 130 is present in most organs including 
heart, kidney, spleen, liver, lung, placenta and brain (Saito et al., 1992). However, the 
presence of gp80 is limited and it is expressed only by liver cells and white blood cells 
(monocytes, neutrophils, T and B cells) (Jones et al., 2001). Therefore, IL6 can stimulate a 
restricted number of cells through classical IL-6R signalling. The sIL-6R is produced by two 
different mechanisms: firstly the extracellular domain of gp80 receptor is subject to 
proteolytic cleavage (or shedding) of the membrane bound receptors, secondly by 
translation of alternatively spliced mRNA. Binding of IL6 with sIL-6R forms IL6/sIL-6R 
complexes that themselves interact with membrane-bound gp130 which initiates the signal 
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transduction process (Rose-John and Heinrich, 1994). IL6 mRNA expression can be induced 
by IL-1 signalling pathway and LPS-induced Toll-like Receptor (TLR) signalling pathway. 
 
 
 
 
 
 
 
 
 
Figure 1.8. Structure of IL6. It has four long helices A, B, C and D which are highlighted in different 
colours. Receptor-binding sites I, II, and III of IL6 are indicated by circles (Heinrich et al., 2003). 
 
 
LPS and IL-1 lead to increased expression of pro-inflammatory cytokines including IL6 
through the TLR4 (Faure et al., 2000) and IL-1 receptor 1 (IL-1R1) signal transduction 
pathways (Garat and Arend, 2003). The outcome of these pathways is activation of 
transcription factors NF-κB and AP-1, releasing IL6 as shown in Figure 1.9A and B (Karin and 
Ben-Neriah, 2000; Monick and Hunninghake, 2002). A variety of components including the 
IRAK family, TRAFs, MyD88, TAK-1/TAB-1 and TPL-2 play important roles in 
regulating/activating these pathways (Bowie and O'Neill, 2000; Kiss-Toth et al., 2006; Muzio 
et al., 1997; Yang et al., 1999; Zhang et al., 1999). Both TLR4 and IL-1R1 share similar 
pathway elements: both require MyD88, IL-1 receptor-associated kinase (IRAK), tumor 
necrosis factor (TNF) receptor-associated factor 6 (TRAF6), and NF-kB-inducing kinase (NIK) 
for activating transcription factor NF-kB (Muzio et al., 1997; Yang et al., 1999; Zhang et al., 
1999).  
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However, the difference between the IL-1R1 and TLR4 pathways is that TLR4 can recruit 
MyD88 directly but IL-1RAcP must be available in order to binding of IL-1RI receptor with 
MyD88 (Wesche et al., 1997). Released IL6 can then initiate the IL6 signal transduction 
pathway when it binds with its receptors. 
 
IL6 signal transduction (Figure 1.9 A and/or B) can occur through one of two distinct 
pathways including classic IL6 signalling (Heinrich et al., 2003; Ishihara and Hirano, 2002) or 
IL6 trans-signalling (Jones et al., 2005). In the classic IL6 signalling, IL6 signal transduction is 
induced through a complex containing IL-6R and gp130 altogether but binding of IL6 with 
sIL-6R and then interaction of this IL6-sIL-6R complex with gp130 is known as the IL6 trans-
signalling pathway which also triggers IL6 signal transduction. Binding of IL6-sIL-6R complex 
with the ubiquitously expressed gp130 on the cell surface, induces gp130 homodimerization 
and formation of a hexameric IL6-IL-6Ra-gp130 high-affinity complex (Boulanger et al., 
2003). This ligation induces three signalling pathways including Janus kinase/signal 
transducers and activators of transcription (JAK-STAT), extracellular signal regulated 
kinase1/2/mitogen-activated protein kinase (Erk1/2/MAPK) and phosphatidylinositol 3-
kinase (PI3K)/Akt pathways (Fischer and Hilfiker-Kleiner, 2007; Heinrich et al., 2003).  
 
The JAK/STAT3 cascades play important roles in cardiovascular disorders: according to 
(Brasier, 2010), the STAT pathway appears to be the main pathway associated with vascular 
inflammation. In the JAK/STAT3 pathway, a complex of IL6-IL-6Ra-gp130 leads to 
phosphorylation of JAK in the cytoplasm (Heinrich et al., 2003). The phosphorylated JAK in 
turn phosphorylates and activates the STAT3 transcription factor (Kurdi and Booz, 2007). 
After STAT3 is phosphorylated, it hetero-and/or homo-dimerizes and translocates into the 
nucleus where it binds to specific DNA sequences such as acute phase response elements 
and IL6 response elements and enhances transcription of target genes (Kurdi and Booz, 
2007; Vardam et al., 2007).  The activated STAT3 also triggers NF-kB and NF-IL6 transcription 
factors which are known to be involved in atherosclerosis and cardiovascular diseases 
(Brasier, 2010).  
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Figure 1.9. IL6 signalling pathway requires LPS-induced TLR signaling pathway (Panel A) and IL-1 
(Panel B) pathway. LPS binds with TLR receptor and IL-1 binds a complex of IL-1RI/ IL1RAP on the 
target cell surface, beginning similar pathways. In both pathways, Recruited MyD88 binds with IRAKs 
and this results in phosphorylation of IRAKs. Phosphorylated IRAK1 links with TRAF6 and then 
activates TAK1 which in turn activates IKKs and MAPK pathways. IKK family phosphorylates IκB 
proteins, resulting in   degradation of IκB proteins and the subsequent translocation of the 
transcription factor NFκB. MAPK pathway leads to induction of another transcription factor AP-1. 
These transcription factors together induce the expression of proinflammatory cytokines including 
IL6.IL6 is a cytokine that result in several cellular and physiological responses such as inflammation. 
Binding of IL6 with its receptors induce IL6 signal transduction through either classic IL6 pathway or 
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IL6 trans-signalling pathway. In this Figure, the classic IL6 pathway is shown. This pathway shows 
that interaction of IL6 with IL-6Rα and then binding with gp130 lead to activation of many different 
signalling pathways including JAK kinases. In the JAK pathway, the activated JAK kinase cause 
phosphorylation and stimulation STAT transcription factors (STAT3) that translocate to nucleus and 
binds with IL-6RE and CRE, activating transcription factors AP-1 and NF-IL6 that induce several 
inflammatory genes including IL6.    
1.7.3 Interleukin-6 gene 
The IL6 gene lies on chromosome 7p21 and has four introns and five exons as shown in the 
UCSC Genome Database. It contains three transcription start sites and at least one TATA 
sequences (Yasukawa et al., 1987). A conserved sequence is present at the 5’ promoter 
region and the majority of functional regulatory components of IL6 gene expression lie in 
this region (see Section 1.7.4) (Terry et al., 2000; Zhang et al., 2011). These functional 
elements play a central role in IL6 transcription, regulation and IL6 signal transduction.  
 
1.7.4 Interleukin-6 promoter 
IL6 transcription is regulated by a proximal promoter and an enhancer. The primary studies 
on the IL6 gene showed that its 5’ flanking region contains a number of regulatory elements 
(Ray et al., 1988) which might be modified via multiple inducible factors (Isshiki et al., 1990) 
including interleukin-1, tumor necrosis factor alpha (TNFα), platelet-derived growth factor 
(PDGF),  epidermal growth factor (EGF)  (Faggioli et al., 2004) and lipopolysaccharide (LPS) 
(Dendorfer et al., 1994). These regulatory elements in the IL6 promoter that may induce or 
repress the IL6 promoter activity and thus affect the level of  IL6 mRNA expression involve 
the NF-IL6 responsive element (RE), a member of the C/EBP (CCAAT/enhancer-binding 
protein) family, AP-1 RE (a specific DNA sequence that binds c-jun and c-fos heterodimers), 
NF-κB RE (Figure 1.10) (Akira et al., 1990; Faggioli et al., 2004), glucocorticoid receptor (GR) 
RE (Ray et al., 1990) and a multiple response element (MRE) (Ray et al., 1989). Some of 
these regulatory elements have been confirmed to be required for inducible and specific 
transcription regulation (Sehgal, 1992). It is useful to know that induction of IL6 gene 
expression depends on the kind of target regulatory element, signal pathway, inducible 
factor and interaction of these regulatory factors with some promoter polymorphisms as 
shown in Section 1.7.5. In our study, the transcription factors NF-κB, NF-IL6 and AP-1 are 
thought to be the main targets of IL-1 and LPS signal pathways for induction of IL6 and 
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hence vascular inflammation as shown in Section 1.7.2 . Several previous studies point out 
that NF-κB binding to the IL6 promoter is the main target of pro-inflammatory cytokines 
TNFα and IL1 in stimulating IL6 (Zhang et al., 1990). NF-IL6 and a 14bp palindromic sequence 
located at -150 are also responsible for activation of IL6 transcription (Isshiki et al., 1990). 
NF-IL6 and NF-kB may act synergistically for activation of transcription of inflammatory 
cytokines (Matsusaka et al., 1993).  Several studies carried out by electrophoretic mobility 
shift assays (EMSAs) have also indicated that NF-IL6 and the P65 subunit of NF-kB can 
immediately activate the IL6 gene in the murine embryonic carcinoma cell line P19 
(Armenante et al., 1999). Dendorfer et al. (1994) found that NF-κB and NF-IL6 are critical 
sites for induction of IL6 mRNA expression in a macrophage cell line induced by cAMP and 
LPS. A mutation in the NF-κB binding site reduces the activity of IL6 promoter by 60% in 
response to LPS (Frost et al., 2004; Son et al., 2008). TLR4 expression is important for NF-κB 
activity induced by LPS in C2C12 cells (Frost et al., 2004).  This means that this particular 
regulatory element is essential for inducibility by LPS.  
The IL6 promoter, which controls IL6 gene expression, is affected by additional factors such 
as density of chromatin and functional polymorphisms within or close to the IL6 promoter 
elements. Five DNaseІ hypersensitive sites (suggesting open chromatin), and a 
glucocorticoid receptor response element (GRE) have been identified in the IL6 promoter 
(Ray et al., 1990; Samuel et al., 2008). A glucocorticoid response element (GRE) contributes 
to down-regulation of IL6 promoter activity (Armenante et al., 1999). Armenante et al. 
(1999) suggest that the -1400 IL6 promoter region is involved in some repressive roles of the 
chromatin surrounding the IL6 gene. This means that IL6 gene expression may require 
chromatin structural remodelling which then facilitates binding of transcription factors to 
the appropriate regulatory elements (Armenante et al., 1999). The IL6 promoter contains 
single nucleotide polymorphisms that show evidence of association with susceptibility to a 
number of diseases including CAD and type 2 diabetes (T2D) (Section 1.7.5 following). 
1.7.5 The role of IL6 and IL-6R polymorphisms in CAD 
A number of polymorphisms in the IL6 gene promoter (Figure 1.10) contribute to increased 
risk of several inflammatory and/or autoimmune diseases including CAD. For example, the 
study carried out by Zhang et al., (2011) concluded that the C allele of the -572 SNP in the 
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IL6 promoter increased the risk of intracranial aneurysm (p<0.001) but -172 G allele was 
associated with higher CHD risk (p<0.05) in Chinese (Wei et al., 2006). Other studies 
(Kitamura et al., 2002; Pan et al., 2011) have shown that IL6-634 (also known as -572G/C SNP)  
G allele was found to be associated with increased plasma level of IL6 in Han Chinese 
population. The -174 G/C SNP (rs1800795) has been more commonly investigated and 
associated with several inflammatory diseases including CAD. The -174 C allele was found to 
contribute to increased CRP concentrations in hypertensive patients, whereas the G allele 
has been associated with significantly increased levels of CRP in type ΙΙ diabetes, but this 
was a very small study and so may not be reliable and therefore is likely to have been a false 
positive (Tuygun et al., 2009). Homozygosity for the -174 C allele has been also found to be 
associated with lacunar stroke (OR 3.22, 95% Cl, 1.12 to 9.09) (Chamorro et al., 2005). It is 
useful to know that the IL6 -597 A allele is usually associated with the -174 C allele in 
Caucasian populations, and the -572 C allele with the -174 G allele (i.e. the three SNPs are in 
strong linkage disequilibrium) (Kelberman et al., 2004). Moreover, Humphries et al., (2001) 
showed that -174 C allele was associated with increased risk of CHD in men (P=0·048) 
compared with the GG genotype and this influence was stronger in smokers even though 
the other risk factors such as age, body mass index, lipids and fibrinogen levels were taken 
into account (P=0·04). Jones and colleagues found also that IL6 plasma levels were higher in 
abdominal aortic aneurysm patients with the -174C allele (P=0.003) (Jones et al., 2001). 
Galimudi et al. (2014) found that -174 C allele was more frequent (64%) among Indian 
patients with CAD compared to controls and the authors also observed that -174 CC 
genotype resulted in increased  levels of IL6 compared to GC heterozygotes and GG 
homozygotes in CAD patients (P=0.01). Another case (n=402) and control (n=402) study 
carried by Wang et al. (2015) suggested that -174 CC genotype had a significantly higher 
frequency in CAD patients compared with controls. However, the association between 
circulating IL6 levels and this SNP is uncertain because some studies do not show this 
association, or show association of higher levels with opposite SNP alleles as discussed 
above (Samuel et al., 2008). Paradoxically, subjects with the -174 GG genotype had 11% 
greater intima-media wall thickness (IMT) (0.85 ± 0.17 versus 0.76 ± 0.16 mm; P= 0.03) 
(Rundek et al., 2002). This study suggested that the -174 G allele is considered as a high 
producer in vitro, resulting in increased risk of peripheral vascular disease, thrombotic 
events and intimal layer thickness of the carotid artery (Rios et al., 2010). Furthermore, 
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Elsaid et al. (2014) examined the effect of this SNP (IL6-174 G/C) among 108 Egyptian CAD 
patients and 143 healthy individuals and they found that the -174 G allele (GG and GC 
genotypes) were higher frequency in the patients with CAD compared to healthy people (P = 
< 0.0001). Similarly, in another study (Phulukdaree et al., 2013), it was also shown that -174 
G allele was significantly higher observed between Indian patients with CAD compared to 
controls (P=0.043). It is clear now that there are some factors that might be implicated in 
this kind of paradox such as ethnicity. In support of this suggestion, Liu et al., (2006) point 
out that -174 C allele is implicated in higher CVD risk in white patients but not in other 
ethnic groups. The study carried out by Rios et al., (2010) showed no relationship between 
CAD and the -174 G/C SNP in univariate analysis but -174 GG genotype was associated with 
significantly increased risk of CAD in African Brazilians (OR=2.037; P= 0.028) after 
adjustment for classical CAD risk factors.  Several groups were unable to show any 
relationship between this SNP and CAD in Caucasians (Lieb et al., 2004; Sie et al., 2008). 
These conflicting results may partly be explained by the fact that CAD is a multifactorial 
disease affected by age, gender, ethnicity and other genetic and environmental factors, and 
that the effect of a single IL6 SNP is small (Rios et al., 2010; Tuygun et al., 2009). It could, 
however, imply that the associations are not real, just chance results, but research in our 
laboratory and from others suggests that several polymorphisms may interact together to 
determine IL6 genetic regulation (Terry et al., 2000; Khwaja, 2004; Beeton, 2007; Chen et 
al., 2013).   
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Figure 1.10. A schematic representation of 5’ flanking region of the IL6. The proximal IL- 6 
promoter region shows six SNPs sites (-174, -278, -373, -572, -597,  and -6331) and trans-regulatory 
factors (GRE , AP-1 c-jun and c-fos binding region, MRE multiple, CRE  cAMP response element, NF-
IL6 and NF-kB complex binding). The TATA box and transcription start site are shown. Exons and 
introns are also shown. This Figure was constructed based on Terry et al., 2000; Smith et al., 2008 
and Jeon et al., 2010.    
 
There are some differences in the reported effects of IL6 promoter polymorphisms and/or 
haplotypes on IL6 transcriptional activity, possibly explained by methodological differences; 
however several studies have shown that some promoter polymorphisms and/or haplotypes 
play important roles in increasing IL6 transcription activity through their interaction with 
promoter or enhancer elements. For example, my supervisor’s group investigated eight 
haplotypes at four polymorphic sites, three SNPs (-597G/A, -572G/C, -174 GC) and a 
complex polymorphism involving a variable number of As and Ts (-373 AnTn) in the IL6 
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promoter (Terry et al., 2000). They found that the GG9/11G haplotype increased IL6 
expression in response to IL-1
significantly increased expression is not a consequence of -174 G allele alone because the 
other -174 G-containing haplotypes did not show the same effect (Terry et al., 2000). This 
means that the combination of different alleles for these four different polymorphisms is 
responsible for this increase. In contrast, the AG8/12G haplotype resulted in lower IL6 
expression compared with AG8/12C.  The other finding in this study, that constructs 
containing both -174 G/C  alleles were stimulated by IL-1 (P<0.0000002) in the HeLa cell-line 
but neither in the ECV304 cell-line, shows that regulation of IL6 transcription may differ in 
different cell types, due to cell type-specific receptor expression, transcription factor 
expression and/or signalling pathways. The overall conclusion of this study was that the 
differences in the level of IL6 transcription may be associated with specific IL6 promoter 
haplotypes and that it was not due to only one of the constituent polymorphisms. Another 
group, (Smith et al., 2008), showed that TT genotype for IL6-6331C/T SNP was significantly 
associated with increased IL6 serum levels in three different cohorts studies: a UK cohort of 
patients who underwent coronary artery bypass grafting surgery (CABG) (Brull et al., 2001); 
a cohort of patients who received intensive periodontal therapy (IPT) (D'Aiuto et al., 2004; 
D'Aiuto et al., 2005; D'Aiuto et al., 2006; Tonetti et al., 2007); and the control population 
from a European case-control study of myocardial infarction (HIFMECH) (Juhan-Vague et al., 
2002). IL6-6331T/C shows strong negative linkage disequilibrium with -174G/C (D' = -0.97).  
Smith et al. found that CGG haplotype derived from three different IL6 promoter SNPs (-
6331C/T, -572G/C and -174G/C respectively) was associated with a greater reduction in IL6 
level compared with TGG in these three cohorts (P=0.01; P=0.002 and P=0.07 respectively). 
In that study, luciferase reporter assays were carried out using -6331C/T and -174C/G 
constructs to determine the effect of the alleles on IL6 mRNA expression in two different 
cell lines (HeLa and Huh7) stimulated with/without IL-1β. The results showed that the TG 
haplotype derived from two SNPs (IL6-6331C/T and -174G/C) increased the IL6 expression in 
both HeLa and Huh7 cell lines stimulated with IL-1β (P = 0.013 and P = 0.01, respectively). 
Similarly, TC haplotype increased the IL6 expression in both stimulated cell lines (P = 0.0014 
and P =0.001 respectively), suggesting that in fact it was the -6331T allele that was leading 
to the increase, since the constructs differed at the -174 SNP site. Moreover, EMSAs were 
performed to assess the effect of IL6-6331C/T alleles on binding of the transcription factor 
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Oct-1, whose binding site contains this SNP. The Oct-1 transcription factor is known to have 
a crucial role in regulation of housekeeping genes and other genes that encode cytokines 
such as TNF-α (Hohjoh and Tokunaga, 2001), IL-2 (Ullman et al., 1991), IL-3 (Kaushansky et 
al., 1994) and IL-8 (Wu et al., 1997). Smith et al. showed that increased IL6 gene expression 
is associated with binding of Oct-1 preferentially to the IL6 -6331T allele compared with the 
C allele (Figure 1.10).   
 
The Smith et al. study results were not entirely consistent with Chen et al., (2013) who 
tested the role of IL6 promoter haplotypes derived from two putative functional IL6 
promoter SNPs (-6331T/C and -572C/G) on increased risk of lung cancer in the Chinese 
population and also to determine the effect of these haplotypes on the transcriptional 
activity of IL6 promoter in two different cell lines (the human lung cancer cell line A549 and 
the human bronchial epithelial cell line HBE) stimulated by IL-1 using the luciferase reporter 
gene assay. Chen et al. reported that CC haplotype (-6331C and -572C) is associated with 
increased risk of lung cancer in the Chinese population (OR, 1.56 (95%CI, 1.04-2.34) and 1.51 
(95%, CI, 1.03-2.22), respectively). They found that reporter gene expression determined by 
the C allele or the CC haplotype for both IL6 -6331C/T and -572C/G was higher (1.44- and 
1.35-fold higher, respectively), compared with the respective T and G alleles in both cell 
lines, with or without IL-1. Therefore, these results confirmed the biological importance of 
these SNPs on IL6 promoter activity, although there are clearly some cell type specific 
differences between the studies because Chen found the -6331 C allele to be associated 
with increased IL6 promoter function in lung-derived cell lines, whereas Smith found 
increased expression from the -6331 T allele through Oct 1 binding in HeLa (epitheliod cervix 
carcinoma) and Huh7 (liver carcinoma) cell lines (Chen et al., 2013; Smith et al., 2008). A 
study carried out by Jeon et al.(2010) has shown that IL6-278 C allele enhanced the IL6 
promoter activity compared with A allele in Hep3B and HeLa cell lines (P=0.001). This SNP 
may affect the IL6 expression because it is in the binding site for the transcription factor AP-
1. 
 
It is known that a particular polymorphism can affect IL6 promoter activity if it is in or near 
the binding site for a transcription factor.  If the SNP is not in or near the transcription factor 
binding site it is less likely to have any effect. The important finding emerging from several 
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studies, including from this laboratory, is that a single SNP alone may not be sufficient to 
affect IL6 mRNA expression; a particular combination (i.e. haplotype) of these SNPs may be 
required for the full in vivo effect on IL6 levels. This is at least in part because data from our 
laboratory suggest that the combination of SNPs could be affecting IL6 chromatin 
modification (Beeton, 2007).  
Our laboratory has shown changes in IL6 gene expression in monocytic and macrophage-like 
THP-1 cells treated with inflammatory mediators. For example, IL6 mRNA expression 
showed a significant increase in both cell types stimulated with LPS for 24 hours. There was 
also an increase in IL6 gene expression in both differentiated and non-differentiated cells 
induced by IL1β treatment for 16 hours. Under all conditions, differentiated THP-1s 
consistently showed more open chromatin, and this was significant for IL-1β stimulation 
(Beeton, 2007). 
In the case of the the IL-6 receptor (gp80, CD126), several IL-6R SNPs have been identified. 
For example, Kim et al., (2003) have discovered seven novel IL-6R polymorphisms from 300 
healthy Korean volunteers. These SNPs include one SNP in promoter region (-183G>A), one 
synonymous SNP in exon 2 (24013G>A: Ala31Ala), one non-synonymous SNP in exon 9 
(48892A>C: Asp358Ala) and four in introns (29753A>C, 42700T>C, 48869T>A and 
59818C>T). All of these polymorphisms are in linkage disequilibrium except -183G>A (Kim et 
al., 2003). Most of the studies did not elucidate role of these polymorphisms or other IL-6R 
SNPs on risk of disease.  Several groups have shown association of the IL-6R SNP rs2228145 
(formerly known as rs8192284) Asp358Ala that results in an aspartic acid to alanine 
substitution at the proteolytic cleavage site (Gln357/Asp358),  affects production of sIL-6R 
generated by shedding of the membrane-bound form (Galicia et al., 2004; Marinou et al., 
2010; Rodriguez-Rodriguez et al., 2011). For example, the rs2228145 C (Ala) allele was 
associated with higher sIL-6R compared with AA homozygous individuals in the Japanese 
population, suggesting this sequence variation strongly affects the serum levels of sIL-6R 
(Galicia et al., 2004). Therefore, the carriers of C allele are more likely to have CAD risk than 
A allele carriers.  Another study has shown that the minor allele (C allele) of rs7529229 C/T 
SNP that shows strong LD with rs2228145 is also associated with increased plasma levels of 
IL6 (P=8·41×10−68) and Sil-6R (2·69×10−59) (Hingorani and Casas, 2012). In another study, 
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carriers of rs2228145 C allele (358Ala) also showed increased plasma concentrations of both 
IL6 and sIL-6R (both p<10−13) (Sarwar et al., 2012). It is clear now that the role of this IL-6R 
SNP in CHD has recently been shown to be much less controversial than the IL6 associations 
and the data now strongly implicate the IL-6R pathways in risk of CHD (Hingorani and Casas, 
2012; Sarwar et al., 2012).  
1.7.6 The role of IL6 polymorphisms in inflammatory diseases 
A number of studies has been shown that IL6 alleles/ haplotypes play an important role in 
increasing the risk of several inflammatory diseases. Because of a large number of studies,  a 
summary of key findings for some of these studies is given in Table 1.3.  
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Table 1.3. List of key findings of IL6 alleles/genotype/haplotype association with several inflammatory diseases.  
Study description Number of 
participants 
Population group IL6 SNP Il6 alleles/genotype/haplotype association Reference 
Endothelial function 
in healthy adults  
248 UK  -174G/C -174 CC induce endothelial activation in 
smokers  
Brull et al., 2002  
Stroke  48 German  -597G/A,572G/C,373An/Tn, -
174G/C 
AG8/12C haplotype associated with decreased 
serum levels of IL6 in stroke patients  
Acalovschi et al., 
2003 
Heat shock protein 
hsp60 in healthy 
male blood donors  
176 Finish  -174G/C -174 C allele associated with lower level of anti-
hsp60 and anti-hsp65 antibodies  
Pandey et al., 2004 
Coronary artery 
bypass graft surgery  
132 UK Caucasian  -373 AnTn Increased post-operative IL6 levels with -373 
9A/11T genotype 
Kelberman et al., 
2004 
Deep vessel lacunar 
stroke  
89 Spanish  -174G/C  -174 CC in patients  Chamorro et al., 
2005 
Renal artery 
occlusion  
182  Austrian  -174G/C  Lower frequency of -174 C allele in patients  Weger et al., 2005  
Peritoneal dialysis 
(PD) 
398 patients  Dutch -174G/C -174 CC was associated with an increased 
mortality risk in PD patients 
Verduijn et al., 
2012 
Alzheimer's disease 
(AD) 
3101 cases and 3860 
controls 
Europeans and non-
Europeans 
-174G/C -174 CC could decrease the risk of AD Dai et al., 2012 
Systemic sclerosis 
(SSc) 
2749 cases and 3189 
controls 
Europeans rs2069827, rs1800795 and 
rs2069840 
GGC haplotype associated with SSc Cénit et al., 2012 
intracranial 
aneurysms (IAs) 
220 patients and 220 
control  
Chinese -572G/C -572GG genotype was associated with a higher 
risk of IA 
Liu et al., 2012 
acute myocardial 
infarction (AMI) 
102 patients and 108 
controls 
Brazilian  -174G/C -174CC had higher serum triglycerides, VLDL 
cholesterol, glucose, hyperglycemia and 
hypertriglyceridemia 
Lima-Neto et al., 
2013 
Atrial fibrillation (AF) 31 patients and 45 
controls  
Han Chinese -634C/G -634 G allele had a 2.79-fold increased risk of 
thrombus or severe spontaneous echocontrast 
(SEC) 
Deng et al., 2013 
bone mineral density 
(BMD) 
11957 subjects Chinese -634C/G -634GG resulted in a significantly lower mean 
BMD at any skeletal site examined 
Wang et al., 2013 
breast cancer patients = 182; 
controls = 236 
North Indians -174G/C -174 C allele had a protective role associated 
with lower expression of IL6 
Joshi et al., 2014 
pneumonia-induced 
sepsis 
277 patients  Chinese  -174G/C -174 C allele had a 2.42 fold higher risk for 
septic shock 
Feng et al., 2015 
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In conclusion, there is considerable, although somewhat controversial, evidence for the 
association of IL6 SNPs with CAD, there is now very good evidence for the role of IL-6R and 
the rs2228145 SNP in the disease, and some evidence that SelS and its SNPs are also 
implicated in CAD, possibly through an influence on IL6 levels. 
 
1.8. Hypothesis, aims and objectives 
The hypothesis is that SelS polymorphisms are associated with the pathogenesis of CAD 
through the role of SelS in increasing the levels of IL6 and the soluble IL-6 receptor (sIL-6R) 
and hence increased IL6 signal transduction. Furthermore, SelS may have allele-specific 
effects on IL6 signal transduction mediated through IL6 and sIL-6R polymorphisms.  
 
Aims:  
To investigate the molecular mechanisms underlying the reported association of IL6 and 
SelS genetic variation with increased risk of CAD and related phenotypes.  
 
Objectives: 
1) Investigate IL6 and SelS genotype-specific functional differences in peripheral blood 
derived macrophages from healthy volunteers   
2)  Characterize these differences by a variety of techniques including QPCR, western 
blotting and flow cytometry.
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Chapter 2. Materials and Methods 
2.1 List of Material suppliers   
Material suppliers used in the methodology are listed below unless stated in the text. 
 
Material Supplier 
1× TruPAGE TEA-Tricine SDS Running 
buffer 
Sigma-Aldrich, UK 
3,3’,5,5’–Tetramethylbenzidine; TMB Sigma-Aldrich, UK 
4-12% TruPAGETM precast gradient gels Sigma-Aldrich, UK   
Agarose gel Life Technologies Ltd,UK 
Bovine serum albumin (BSA) Thermo Scientific, UK 
Bromophenol blue Sigma-Aldrich, UK 
Chloroform Sigma-Aldrich, UK 
Citrate phosphate buffer Sigma-Aldrich, UK 
Colorimetric bicinchoninic acid assay (BCA) Thermo Scientific, UK 
DNase1 Promega, UK 
EDTA Sigma-Aldrich, UK 
Ethanol Sigma-Aldrich, UK 
Florescence Activated Cell Scanning (FACs) 
flow buffer  
BD Biosciences, UK 
Foetal bovine serum (FBS)   Invitrogen, UK 
Glycerol Sigma-Aldrich, UK 
Histopaque-1077 Sigma-Aldrich, UK 
Interleukin-1β (IL-1β) R & D System, UK 
Supplied as 5µg lyophilised. Add 5ml 
sterile PBS/0.1% BSA sterile filtered. 
Divided into aliquots and stored at -20°C at 
1ng/µl. Use at 2.5ng/ml medium in the 
well 
Isopropanol Sigma-Aldrich, UK 
Lipopolysaccharide (LPS) Sigma-Aldrich,UK 
Strain 0127:B8 
Supplied as 1mg. 
Reconstitute with sterile PBS. 
Divided into aliquots and stored at -20°C at 
1mg/ml. Use at 100ng/ml medium in the 
well 
Methanol Sigma-Aldrich, UK 
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Nuclease free water Amresco ,UK 
NuPAGE transfer buffer Life Technologies Ltd,UK 
 Paraformaldehyde (PFA) Thermo Scientific, UK 
Penicillin/Streptomycin Invitrogen, UK 
Phorbol myristate acetate (PMA)  Sigma-Aldrich, UK 
Phosphate Buffered Saline (PBS) OXOID, Basingstoke, UK 
Polyvinylidene difluoride (PVDF) 
membrane 
Bio-Rad, UK 
Protease inhibor Thermo Scientific, UK 
QuantiTectSybr Green RT-PCR kit Qiagen, UK 
Radioimmunoprecipitation assay (RIPA) 
buffer 
Thermo Scientific, UK 
RPMI-1640 with L-Glutamine medium Invitrogen Gibco, UK 
Sodium azide Thermo Scientific, UK 
sodium chloride (NaCl) Fisher Scientific, UK 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, UK 
Streptavidin-horseradish peroxidase Invitrogen, UK 
 Tris base Calbiochem, UK 
Tris HCl Sigma-Aldrich, UK 
Triton-X100 Sigma-Aldrich, UK 
TRIzol Invitrogen, UK 
Trypan blue Invitrogen, UK 
β-mercaptoethanol Sigma-Aldrich, UK 
 
2.2 Ethics and recruitment of volunteers 
We received favourable opinions from the NHS South West Surrey Local Research Ethics 
committee (04/Q1909/19) and the Advisory Committee on Ethics of the University of Surrey 
(EC/2004/58/SBMS) for collection of peripheral blood samples from ‘healthy’ volunteers 
working or studying at the University of Surrey or the Royal Surrey County Hospital. 
Additional blood collection from ‘healthy’ volunteers in the School of Biosciences and 
Medicine was covered by the School’s generic ethics approval. Written informed consent 
was obtained in all cases.  A total of forty three volunteers were recruited.  Several ‘blood 
cones’ (white cells derived from donated blood) were obtained from the National Health 
Service ‘Blood and Transplant (NHSBT) service to complete the study. 
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2.3 Experimental design 
Volunteers donated 5 ml of EDTA-anticoagulated blood, DNA was extracted and volunteers 
were genotyped for selected IL6, IL-6R and SelS single nucleotide polymorphisms (SNPs).  
Volunteers of selected genotypes were recalled to donate a further 50 ml of EDTA-
anticoagulated blood and peripheral blood mononuclear cells (PBMCs) were isolated, 
cultured in vitro to differentiate them into macrophages, and treated with interleukin-1β (IL-
1β) or lipopolysaccharide (LPS) to mimic an inflammatory challenge. PBMCs were also 
extracted from the ‘blood cones’ purchased from NHSBT. The phenotype of the cells was 
examined by flow cytometry. RNA was extracted from cells and MLN51 (housekeeping 
gene), IL6 and SelS (and in some cases BiP and CHOP) mRNA expression was quantitated. 
Cellular proteins were extracted, quantified, and analysed by Western blotting. Cell culture 
supernatants were assayed for protein/cytokine production. Phenotype and gene 
expression (mRNA and protein) were examined by IL6 and SelS genotype and haplotype. 
2.4 Genomic DNA extraction 
Approximately a half of genomic DNA samples were extracted previously from the 
leukocytes of healthy volunteers by Beeton (2007). Where the DNA had been used up, it 
was re- extracted from either a saliva sample or from the buffy coat of those volunteers 
stored at -80OC, according to manufacturer’s instructions (QIAGEN Kit). The other genomic 
DNA samples were extracted from either EDTA peripheral blood or buffy coat of students or 
purchased human blood cones. The quantity and quality of the extracted DNA were 
assessed by using NanoDrop Spectrophotometry and 2% agarose gel electrophoresis. The 
extracted DNA was then diluted to 10ng/l using Nuclease free water and stored at -20OC or 
4OC prior to genotyping.     
2.5 selection of polymorphisms for IL6, IL-6R and Selenoprotein S genes 
The selection of IL6, IL-6R and SelS polymorphisms was based on evidence described in the 
Introduction. These SNPs include IL6-6331 T/C (rs10499563), IL6-597 G/A (rs1800797), IL6-
572 G/C (rs1800796), IL-6R A/C (rs8192284), SelS-1500 A/C (rs8025174), SelS+3705 G/A 
(rs4965814), SelS+5227 C/T (rs4965373), and SelS+9000 C/G (rs7178239).  
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2.6 Genotyping of IL6, IL-6R and Selenoprotein S polymorphisms using 
TaqMan assay   
The individuals were genotyped for the above polymorphisms using the TaqMan assay. 
These SNPs were identified on dbSNP    (http://www.ncbi.nlm.nih.gov/projects/SNP/).  
 
A custom TaqMan SNP genotyping assay was used to genotype the DNA samples using the 
ABI Prism 7500 real time instrument (Applied Biosystems) according to the manufacturer’s 
instructions. The primer and probe sequences were unavailable. The IL6 primers and 
TaqMan Universal PCR master mix were purchased from Life Technologies Limited, Paisley. 
The final volume of each PCR reaction was 25µl consisting of 12.5µl of 2× TaqMan Universal 
PCR Master Mix, 1.25µl of 20× SNP Genotyping assay mix, 9.25µl of DNase-free water and 
20ng of DNA (10ng/µl). The PCR conditions were 50°C for 2 minutes, followed by 95 °C for 
10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for one minute. The plate was sealed, 
centrifuged for 3 minutes at 1238 RCF at RT and placed in QPCR machine. At least two 
negative controls were used in 96-well plate to ensure the genotyping quality. 
 
The program PHASE v2.1 (Stephens et al 2001; Stephens & Donnelly 2003) was used to 
reconstruct haplotypes of IL6and SelS.  
 
2.7 Ex vivo culture of primary monocyte-derived macrophages 
2.7.1 Isolation of mononuclear cells from whole blood 
Peripheral blood mononuclear cells (PBMCs) were isolated from EDTA-anticoagulated whole 
blood or ‘blood cones’ by density gradient centrifugation using Histopaque-1077. The first 
step was dilution of whole blood and/or leucocyte ‘cones’ in a 1:1 ratio with sterile pre-
warmed (37°C) PBS. The diluted blood was then layered gently onto an equal volume of 
Histopaque®-1077 solution containing polysucrose and diatrizoate. Centrifugation of 
Layered blood was then performed at 400g for 30 minutes at room temperature (RT) in a 
swing-out rotor without brakes, resulting in rapid sedimentation of red blood cells and 
granulocytes to the bottom of centrifuge tubes. PBMCs were found at the interface 
between Histopaque®-1077 and plasma. They were collected using a sterile plastic pipette 
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into a fresh 50ml centrifuge tube. The tube was then filled to 50 ml with sterile warmed PBS, 
mixed gently by inversion and then the PBMCs were centrifuged at 250g for 10 minutes at 
RT with break to remove the excess of Histopaque and platelets, followed by washing the 
cell pellet once more with warmed PBS before assessment of cell viability and culture. 
 
2.7.2 Ex vivo primary monocyte-derived macrophages (MoMΦ) culture 
The PBMCs were then suspended in pre-warmed (37°C) serum-free RPMI-1640 medium 
with Glutamax and 1% penicillin/streptomycin (5000 U/ml penicillin, 5000 µg/ml 
streptomycin). The viable PBMCs were counted using a haemocytometer and trypan blue 
and then seeded at two different densities (2 × 106 cells/5ml/well and 4 × 106 cells/5 
ml/well) in 6-well plates in in pre-warmed (37°C) serum-free Invitrogen Gibco RPMI 1640 
Glutamax medium with 1% penicillin/streptomycin. Culture of isolated PBMCs cells at two 
different densities was to optimize the cell culture model. They were then incubated for two 
hours in 5% humidified CO2 at 37OC to allow adherence.  
 
After two hours of incubation, the adherent cells were checked under an inverted 
microscope, and the medium containing non-adherent lymphocytes was then pipetted off 
gently, discarded and replaced with RPMI-1640 completed medium was supplemented with 
10% FBS and 1% penicillin/streptomycin. 
 
The monocyte-derived macrophages were then incubated for at least five days because 
PBMCs need that time period to differentiate into macrophages (Ylisastigui et al. 1998 and 
Zhou & Tedder 1996). The medium was changed daily for four days.  
 
2.7.3 Stimulation of monocyte-derived macrophages 
The stimulation of monocyte-derived macrophages was then carried out in triplicate using 
either IL-1β (2.5ng/ml) or LPS (100ng/ml) for 8 or 12 or 24 hours at 37 °C, 5% CO2 in a 
humidified atmosphere.  
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2.8 Preparation of samples for flow cytometry analysis  
Flow cytometry was used to quantify the cell-surface expression of two differentiation 
markers (CD14 and CD11c) and IL-6R (CD126). 
 
MOMOs were  scraped and cells collected in 50ml tubes, followed by centrifugation at 300g 
for 5 minutes at 4°C. Cell washing (3X) was then performed using cold Florescence Activated 
Cell Scanning (FACS) buffer (PBS pH7.4 containing 1.0% BSA and 0.1% sodium azide) and 
cells were then resuspended in 350µl of cold FACS buffer.  The cells were stained with 
mouse anti-human CD14-PE, CD11c-APC or CD126 antibodies. These antibodies and their 
respective isotype controls were added to 96 well round bottom plate at particular 
concentrations as shown in Table 2.1. The isotype control for each marker was used to 
distinguish specific antibody staining from non-specific binding. The next step was addition 
of 50µl of cell suspension to each antibody.  The cells were then incubated at 4oC for one 
hour in dark, washed twice with cold FACS buffer and centrifuged. The cells were 
resuspended in 200µl of 2% paraformaldehyde (PFA). This mixture was transferred to 
labelled FACS tubes containing 300µl of ‘FACS flow buffer’ (BD Biosciences). The cells were 
then kept at 4°C prior to their analysis by BD FACS Canto flow cytometry (BD Biosciences, 
UK). The analysis of data was by BD FACSDiva software, version 5.0.3. A negative control 
(unstained cells) was used for each staining.  
 
The fluorescence of positive cells was measured based on mean fluorescence intensity 
(MFI). The percentage (%) of cells positively expressing each marker was calculated as % of 
cells bound to target antibody (labelled with specific fluorochrome) minus % of cells bound 
to fluorescently labelled isotype control antibody.  
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Table 2.1   List of fluorescently labelled antibodies with the concentrations used for cell-surface staining 
Antibody Host 
species 
Target 
species 
Isotype control Concentration 
(µg/ml) 
µg/test Conjugate Supplier 
CD14 Mouse Human IgG2b-PE 
(50µg/ml) 
0.125µg/test 
12.5µg/ml 0.125µg PE BD Pharmingen, 
UK 
CD11c Mouse Human IgG1-APC 
(50µg/ml) 
0.25µg/test 
50µg/ml 0.25µg APC BD Pharmingen, 
UK 
CD126 Mouse Human IgG1-PE 
(25µg/ml) 
0.25µg/test 
50µg/ml 0.25µg PE BD Pharmingen, 
UK 
 
PE=Phycoerythrin; APC=Allophycocyanin 
Mouse IgG1-APC isotype control (BD Pharmingen, UK) 
Mouse IgG2b-PE, isotype control (BD Pharmingen, UK) 
Mouse IgG1-PE, isotype control (BD Pharmingen, UK) 
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2.9 Culture, differentiation and stimulation of the THP-1 cell line  
The human monocytic leukemia cell line THP-1  (Tsuchiya et al., 1980) was used to optimize 
the model system prior to use of primary blood monocyte/macrophages. 
 
2.9.1 Culture of THP-1 cell line 
THP-1 cells were cultured in suspension at 37°C using pre-warmed (37°C) Invitrogen Gibco 
RPMI 1640 Glutamax medium supplemented with 1% penicillin/streptomycin and 10% FBS. 
The source of THP-1 stocks used in this study was originally ATCC but these were brought 
from Wellcome Trust Centre for Human Genetics, University of Oxford, by Dr Green. The 
culture conditions were 5% CO2 in a humidified atmosphere at 37°C. The cells were counted 
using a haemocytometer (diluting the cells 1:10 in complete RPMI) and their viability was 
assessed using trypan blue. The cells were checked daily under the microscope to ensure 
that they were still healthy. The cells were passaged when they reach approximately 85-95% 
confluence to prevent contact inhibition. The passage was usually carried out at a 1:3 ratio of 
the original culture. 
 
2.9.2 Differentiation and stimulation of THP-1 cells 
The differentiation of THP-1 monocytic cells to macrophages was done by using phorbol 
myristate acetate (PMA) at a final concentration of 10 nM, for 72 hours (Tsuchiya et al., 
1982). Then, cells were centrifuged at 125xg for 5 minutes at RT, forming a pellet. The cells 
were then washed with 50 ml phosphate-buffered saline (PBS) and counted using a 
haemocytometer. The cells were then suspended in complete RPMI media. This step was 
followed by plating the cells at the density of 4 × 105 cells/ml in 6-well plates; each well 
contained 5 ml of suspension cells (2 × 106 cells/ well). Cells were either treated or not with 
PMA at 37 °C for 72 hours.  
 
The undifferentiated cells (monocytic cells, in suspension) and differentiated macrophage-
like THP-1 cells (adherent, dTHP-1) were stimulated with either IL-1β (2.5ng/ml) or LPS 
(100ng/ml) in triplicate for 24 hours at 37 °C, 5% CO2 in a humidified atmosphere as 
described in Section 2.7.3. 
48 
 
2.10 Extraction of RNA 
After incubation of THP-1 and dTHP-1 cells or PBMCs-derived macrophages, they were lysed 
using TRIzol at a ratio of 1ml/10 cm2. Before adding the TRizol, the cell culture supernatants 
from MoMΦs (unstimulated, IL-1β-induced and LPS-induced MoMΦs) were kept at -80C for 
subsequent use for ELISA and cytometric bead array (CBA). TRIzol is a mono-phasic 
compound of phenol and guanidine isothiocyanate. It is used for extraction of RNA from 
cells by disrupting their membranes, and dissolving the cellular components, whilst 
maintaining the integrity of RNA. Total RNA was extracted from the lysate according to the 
manufacturer’s protocol. Briefly, the following steps were performed: chloroform phase 
separation, precipitation of RNA by isopropanol and RNA wash with 75% ethanol in 
Diethylpyrocarbonate (DEPC) treated water. Twenty two microliters of nuclease free water 
were then added to re-suspend the RNA.  
The NanoDrop ND 1000 spectrophotometer (Agilent).was used to check on the quantity and 
quality of RNA.  The ratio of optical density at wavelengths 260 and 280 (260/280 ratio) was 
used to determine the quality of RNA. A ratio of 1.8 to 2 indicates a good quality of RNA. 
The 260/230 ratio is another measure of nucleic acid purity. It should range between 1.8 
and 2.2. If the ratio is below 1.8, this means that the nucleic acid is contaminated with some 
organic materials such as phenol. To further ensure that the RNA integrity, total RNA was 
resolved in a 2% agarose gel in running buffer (1X Tris-borate-EDTA (TBE)) at 120 volts for 40 
minutes. RNA was then stored at -80oC until subsequent use.  
 
2.11 Quantitative PCR (QPCR) 
2.11.1 Primer design 
QPCR primer sequences for SelS, IL6, IL-6R, BiP, CHOP and MLN-51 genes were obtained 
from different sources. The housekeeping gene metastatic lymph node 51 (MLN-51) primers 
were designed previously by Beeton (2007). SelS primers were designed using Primer3 
software, and IL6 primer pairs were obtained from Primer-bank 
(http://pga.mgh.harvard.edu/primerbank/). IL-6R (gp80) primers were validated primers 
from QIAGEN.  BiP and CHOP primers were validated primers from Sigma Aldrich,UK.  
Primers sequences are as follows:  
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IL6_LH    5’-ACTCACCTCTTCAGAACGAATTG-3’ 
IL6_RH   5’-CCATCTTTGGAAGGTTCAGGTTG-3’ 
 
MLN-51_LH 5’-CAA GAG TGC TGA GGA GTC GG-3’ 
MLN-51_RH 5’-TCA TTA GCT TCT GAT TTC AG-3’ 
 
SelS_LH 5’-ATC GTC TTC AGC TGC ATC CT-3’ 
SelS_RH 5’-CTT GCA TTT TCA GTC GAG CA-3’ 
 
IL-6R_LH 5’-CAT TGC AT TGTTCT GAG GTT-3’ 
IL-6R_RH 5’-AGT AGT CTG TAT TGC TGA TGT-3’ 
 
BiP_LH  5’-CATCACGCCGTCCTATGTCG-3’ 
BiP_RH  5’-CGTCAAAGACCGTGTTCTCG-3’ 
 
CHOP_LH  5’-GAACGGCTCAAGCAGGAAATC-3’ 
CHOP_RH 5’-TTCACCATTCGGTCAATCAGAG-3’ 
 
2.11.2 QPCR method 
DNase1 treatment was used to remove any DNA contamination from the extracted RNA 
prior to performing QPCR. It was carried out according to the manufacturer’s instruction. 
The RNA samples were then diluted in nuclease free water at the concentrations of 10ng/ul 
and stored as aliquots at -80OC until subsequent QPCR. One step Sybr green RT-PCR protocol 
(QuantiTectSybr Green RT-PCR kit) was carried out to measure SelS, IL6, IL-6R, BiP, CHOP 
and MLN-51 mRNA expression in THP-1/dTHP-1 and primary monocyte-derived macrophage 
cells using the ABI Prism 7500 real time PCR instrument (Applied Biosystems).  Normalised 
SelS, IL6, IL-6R, BiP and CHOP mRNA expression was calculated as a ratio of each gene 
divided by the housekeeping gene MLN-51.  Housekeeping genes such as MLN-51 have a 
constant expression level in the cell or tissue of interest, even when treated with 
cytokines/LPS (Beeton, 2007), and are therefore appropriate as controls to normalize mRNA 
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expression. The fold induction of each target gene was calculated as the ratio of normalized 
mRNA expression of that gene (e.g. IL6/MLN51) to an untreated normalised control sample.  
Each RT-PCR reaction contained 30 ng/3µl of DNase-treated RNA plus 9.5 µl of QuantiTect 
Sybr Green RT-PCR kit master mix in a total volume of 12.5 µl.  The QPCR plate was sealed 
with film, centrifuged for 3 minutes at 1238 RCF at RT and placed in the QPCR machine. Each 
assay was performed in duplicate and a non-template control (NTC) was used for each 
QPCR. The cycling parameters were 50 oC for 30 minutes ( reverse transcriptase-mediated 
cDNA production), 95 oC for 15 minutes (activation of Taq polymerase), 95 oC for 15 seconds 
(denaturation of cDNA) and 58 oC for 1 minute  (primer annealing; template extension) for 
40 cycles. A melt curve was generated for each reaction to check the specificity. 
 
Total RNA samples with specific concentrations (100 ng/µl, 10ng/µl, 1.0 ng/µl, 0.1 ng/µl and 
0.01 ng/µl) were prepared from macrophage-like THP-1 stimulated with LPS. These samples 
were used to generate standard curves for SelS, IL6, IL-6R, BiP, CHOP and MLN-51 genes. 
These standard curves were then used to determine the SelS, IL6, IL-6R, BiP, CHOP and 
MLN-51 mRNA expression levels in THP-1 and primary cells. 
 
2.12 Characterisation of SelS, IL6 and IL-6R mRNA expression in 
monocyte-derived macrophages  
Messenger RNA was obtained from monocyte-derived macrophages (MoMΦ) from a total 
of fifteen individuals of different genotype/haplotype. Nine of these donors were recalled 
from Surrey University staff or students and the other six were ‘blood cones’ purchased 
from NHSBT. Isolation, culture and stimulation of PBMCs were described in Section 2.7. 
Extraction of RNA and measurement of IL6, IL-6R and SelS mRNA expression by QPCR were 
described in Sections 2.10 and 2.11.2 respectively.   
 
2.13 BiP and CHOP mRNA expression in MoMΦ 
Because BiP and CHOP play an important role in ER stress associated with SelS (see 
introduction), QPCR was also used to detect mRNA expression of BiP and CHOP in MoMΦ of 
recruited individuals.  
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2.14 Detection of SelS protein expression by Western blotting (WB) 
assays 
SelS protein expression was assessed in stimulated MoMΦ by Western blotting. Four steps 
were performed to produce a Western blot. These steps include, protein extraction, 
quantitation of proteins by protein assay, sample preparation and protein denaturation for 
gel electrophoresis and transfer of proteins and staining (Western blotting).  
 
2.14.1 Protein extraction  
After the culture and treatment of cells as in Section 2.3, the 6-well plates were taken from 
the incubator and put on ice to inhibit protein degradation and dephosphosphrylation by 
endogenous proteases and phosphatases respectively. The supernatants from each well 
were then stored at -80C for subsequent use. Cells were washed twice using 2 ml of cold 
PBS and then whole cells were lysed using 200 µL of cold radioimmuno-precipitation assay 
(RIPA) lysis buffer ( 10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.1% sodium dodecyl sulfate 
(SDS); 1% Triton-X100; 1% Sodium deoxycholate; 1 mM NaF; 5 mM EDTA; 1 mM sodium 
orthovanadate; protease inhibitor cocktail) per well (0.5ml of Lysis buffer/5 × 106 cells) . 
Residual cells were scraped off the wells, and lysates collected into 1.5 ml Eppendorf tubes. 
The cell lysates were then centrifuged at 25000xg for 15 minutes at 4°C. The supernatants 
were carefully transferred into fresh 1.5 ml Eppendorf tubes and the pellets discarded. The 
cell lysate samples were stored at -80° C for later use or were kept on ice for protein 
quantification.  
 
2.14.2 Protein assay 
Protein concentrations were determined using the colourimetric bicinchoninic acid assay 
(BCA) assay. The BCA protein assay depends on reduction of Cu+2 to Cu+ by proteins in an 
alkaline environment (Smith et al, 1985).  Two reactions are essential to determine the 
protein concentrations by this assay. First, the protein peptide bonds reduce copper (Cu+2) 
ions from the cupric sulfate to compose cuprous cation (Cu+). Secondly, Cu+ reacts with 
BCA, forming a complex two molecules of bicinchoninic acid chelate with each Cu+ ion (BCA 
CU+)  and as a result of that a purple-colored is produced that strongly absorbs light at a 
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wavelength of 540-562 nm. The formed purple coloured occurs at temperatures between 37 
and 60°C. The quantity of purple colour produced (BCA-Cu+ complex) or reduced Cu+2 is 
proportional to the amount of protein present in the solution. 
 
Protein concentrations were determined using bovine serum albumin (BSA) as the protein 
reference standard. BSA was diluted in RIPA buffer to make a dilution series of known 
protein concentration (0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4 and 1.6 mg/ml) that were used to 
produce standard curves. Unknown and standard samples (10 µL) were added in duplicate 
into a 96-well plate. The first duplicate wells were used as a blank and contained only RIPA 
buffer. This was followed by adding 200 µL of a mixture of BCA assay kit at the ratio of 1:50, 
to each well, sealing the plate and gently mixing for few seconds on a plate shaker. The 
samples were incubated for 30 minutes at 37°C in the dark. The plate was then sealed and 
cooled to RT, allowing the purple colour to develop in the wells. A spectrophotometer 
(Victor3 Wallac multilabel counter; Perkin. Elmer) was then used to measure the 
concentration of protein samples at 540 nm within approximately a minute. The standard 
curve was produced by plotting the amount of each BSA standard sample versus its known 
concentration in µg/ml allowing determination of unknown sample concentrations. 
Standard curves were acceptable if the best-fit (R2) was at least 0.98. 
 
2.14.3 Sample preparation and protein denaturation for gel electrophoresis 
After determination of total protein in each sample by the BCA assay, the samples were 
prepared for gel electrophoresis by mixing 16µg of protein extract with 5× SDS (10% SDS, 
50% glycerol, 0.025% bromophenol blue, 250 mM Tris HCl pH 6.8) and 10% of β-
mercaptoethanol in a total volume of 35µl.  β-mercaptoethanol reduces disulphide bridges 
in proteins, allowing the proteins to adopt the random coil configuration necessary for 
separation by size. This mixture was then heated at 95C for 5 minutes, allowing protein 
denaturation and SDS binding. The use of SDS maintains the proteins in their 
unfolded/denatures state, allowing better size separation and antibody access. SDS is an 
anionic detergent that gives a negative charge to a polypeptide in proportion to its length. 
Glycerol is used to make the buffer heavy to allow it to sink down into the well. 
Bromophenol blue is a tracking dye to monitor the progress of electrophoretic protein 
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migration. The prepared samples were load into 4-12% TruPAGETM precast gradient gels and 
gels were subjected to electrophoresis at 120 volts  for 1.5 hours at 4°C using cold 1× 
TruPAGE TEA-Tricine SDS Running buffer. The Thermo Scientific pre-stained protein ladder 
(ranging from 10 kDa to 170 kDa) was used to determine relative protein molecular weight.  
 
2.14.4 Transfer of proteins and staining (Western blotting). 
After electrophoresis, the separated molecules were blotted/transferred from the 
electrophoresis gel onto a polyvinylidene difluoride (PVDF) membrane using a wet transfer 
system. The membrane was activated by methanol for one minute and then the gel and 
membrane were sandwiched between wet sponges and some filter papers (Bio-rad, UK). 
This sandwich was clamped strongly together to avoid any bubbles between the membrane 
and gel. Physically, the negatively charged proteins migrate towards the positively charged 
electrode but the membrane prevents that, allowing the proteins to stick onto the 
membrane. The transfer apparatus was placed in the tank, filled with cold 1x NuPAGE 
transfer buffer and 30 volts were applied across the apparatus for 1.5 hours at 4°C.  
Following transfer, the membrane was blocked to prevent non-specific binding of antibodies 
in 5% non-fat dried milk dissolved in 1x Tris-buffered saline (TBS) containing 0.05% Tween (1X 
TBS-T), at RT for one hour on a shaker. The membrane was then incubated with anti-SelS 
rabbit polyclonal (Cell Signalling Technology, USA) primary antibody at 1:1000 dilution in 5% 
non-fat dried milk/TBS-T at 4°C overnight under continuous rotation. The membrane was 
then washed three times using 1x TBS-T (5 minutes per wash on a shaker at RT). Goat anti-
rabbit secondary antibody labelled with LI-COR flourophore IRDye 800CW was then 
prepared (1:5000 dilution) in 5% non-fat dried milk/TBS-T and the tube was wrapped in foil 
to prevent exposure to light, followed by incubation of the membrane with secondary 
antibody for one hour at RT under continuous rotation. The membrane was then washed 
twice using 1x TBS-T and once with 1x TBS (5 minutes per wash on shaker at RT). SelS 
protein was visualized and quantified using the Odyssey CLx system (LI-COR).  
The membrane was first re-blocked and then re-probed (as above) with a mouse 
monoclonal antibody against human -β-actin (Santa Cruz) (1:1000) and an anti-mouse 
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secondary antibody (Li-COR). Beta-actin protein was used as housekeeping gene to 
normalise SelS protein.  
 
2.15 Detection of TNF-α by Enzyme-Linked Immunosorbent Assay 
(ELISA) 
A sandwich, enzyme-linked immunosorbent assay (ELISA) was used to detect the 
concentration of tumour necrosis factor (TNFα) in supernatants of cultured PBMCs. The first 
three wells of 96 well flat bottom plate (VWR, UK) were incubated with 0.1M disodium 
hydrogen phosphate (Na2HPO4) buffer, pH9.0, to detect non-specific binding. The rest of 
wells were coated with 50µl of monoclonal mouse anti-human TNFα (BD Pharmingen™, UK) 
at 0.25μg/ml diluted in 0.1M disodium hydrogen phosphate buffer by incubation overnight 
at 4°C. Washing (x4) the plates was then carried out using PBS containing 0.05% Tween®20 
(PBS-T). This step was followed by blocking all the wells with 200 µl/well of PBS containing 
2% BSA (PBS-BSA), followed by incubation for one hour at RT. A serial dilution (from 
20ng/ml to 10pg/ml) of the TNF-α standard [Second World Health Organisation 
International Standard for human TNF (National Institute for Biological Standards and 
Control)] was prepared using complete RPMI medium. After incubation, the plate was 
washed (x4) with PBS-T and then 50 µl standard and unknown samples were added to the 
wells in triplicate. The plate was incubated for 2 hours at RT, followed by washing (x4) with 
PBS-T (0.05%). Biotinylated mouse anti-human-TNF-α (BD Pharmingen™, UK) (50 µl) was 
then added to each well at 1μg/ml, diluted in PBS-BSA (2%), following by incubation for one 
hour at RT. The plate was then washed (x5) with PBS-T (0.05%), followed by addition of 50 
µl/well of streptavidin-horseradish peroxidase conjugate at 0.5μg/ml, diluted in PBS-BSA 
(2% ) and incubation for 30 minutes at RT. The plate was washed x3 with PBS-T (0.05%), x3 
with PBS and x1 with citrate phosphate buffer (0.05M, pH5.0). Fifty microlitres of substrate 
solution (3,3’,5,5’–tetramethylbenzidine; TMB) was added per well to develop the plate. The 
TMB substrate was prepared by dissolving one tablet of TMB in 10ml of 0.05M citrate 
phosphate buffer and 2μl of 50% hydrogen peroxide. The plate was incubated for 20-30 
minutes at RT in the dark and then the reaction was stopped by adding 12.5μl of 2M 
sulphuric acid to each well prior to reading the plate at 450nm using a Wallac plate reader. 
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2.16 Inflammatory cytokines detection by Cytometric Bead Array (CBA)  
CBA is a flow cytometry application that allows users to measure multiple proteins 
simultaneously. The BD CBA system uses the broad dynamic range of fluorescence detection 
offered by flow cytometry and antibody-coated beads to efficiently capture analytes. Each 
bead in the array has a unique fluorescence intensity so that beads can be mixed and run 
simultaneously in a single tube. This method significantly reduces sample requirements and 
time to results in comparison with traditional ELISA and Western blot techniques. 
 
Six human inflammatory cytokines (IL-8, IL-1β, IL6, IL-10, TNF and IL- 12p70) were detected 
in supernatants of cultured PBMCs according to manufacturer’s instructions (BD 
Biosciences, UK). The principle of CBA involves, briefly, incubation of capture beads coated 
with specific antibodies and a detector reagent, using standards and unknown samples. 
When capture beads coated with specific antibodies for the above human inflammatory 
cytokines and detector reagent which is a mixture of Phycoerythrin (PE)-conjugated 
antibodies are incubated with unknown samples, the sandwich complexes will be formed. 
The fluorescence of beads and detector can then be detected by flow cytometry.  
 
2.17 Statistical analysis  
All statistical calculations were carried out using GraphPad Prism 6. Significant differences 
were considered to have a P value (two-sided) <0.05. Nonparametric Mann-whitney tests 
were used in most cases because of small numbers. The genotype distribution of all IL6 and 
SelS SNPs were tested for Hardy-Weinberg equilibrium. 
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Chapter 3:  Validation of PBMC-derived macrophage cell culture 
model system 
  
3.1 Validation of the cell differentiation status 
3.1.1 PBMC-derived monocyte and macrophage morphology 
Differentiation of PBMCs-monocyte to monocyte-derived macrophages can be observed by 
light microscopy. Monocytes and macrophages are round or spindle shaped, respectively 
(Figure 3.1). PBMCs were isolated and cultured at a density of 2 × 106 cells/5ml/well in 
triplicate in 6-well plates as described in Section 2.7.  The monocyte-derived macrophages 
were then incubated for at least 5 days because PBMCs need that period in which to 
differentiate into macrophages (Ylisastigui et al. 1998 and Zhou & Tedder 1996). However, 
morphology changes could be due to other factors such as enzymatic or physical agents, 
rather than actual differentiation. Therefore, the expression of cell surface marker proteins 
such as CD11c and CD14 will provide a molecular indicator of the differentiation status of 
the cells.  
 
Figure 3.1 Morphology of untreated monocyte and monocyte-derived macrophages cells 
cultured for 6 days under light microscopy. (A) represents the monocyte cells  (B) shows 
monocyte-derived macrophages (arrow). Magnification ×200.  
 
A 
B 
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3.1.2 Flow cytometry analysis of CD11c and CD14 expression on PBMCs-
derived macrophages  
Flow cytometry was used to assess the surface expression of the macrophage 
differentiation-specific markers CD14 and CD11c by untreated PBMC-derived macrophages. 
PBMCs were isolated and cultured at a density of 2 × 106 cells/5ml/well in triplicate for 6 
days in 6-well plates. They were then harvested and stained using the target antibodies 
(mouse anti-human CD11c antibody conjugated to APC and anti-CD14 conjugated to PE) and 
their isotype controls (mouse IgG1-APC and IgG2A-PE, respectively) as described in Section 
2.8 
 
3.1.3 Gating strategy  
For flow cytometry analysis, the relevant populations of cells were gated according to 
forward scatter (FSC) and side scatter (SSC) dot plots that show size and granularity, 
respectively, of the monocyte derived macrophages (Figure 3.2). Contour plots were used 
occasionally along with dots plots to exclude dead cells and to provide more accurate data 
representation compared to dot plots (Figure 3.3 Panel B).  
 
Live cells with the desired marker were selected by gating for CD11c-APC and CD14 positive 
cells using matched isotype controls. The fluorescence of positive cells was measured based 
on mean fluorescence intensity (MFI). The percentage (%) of cells positively expressing each 
marker was calculated as % of cells bound to target antibody (labelled with specific 
fluorochrome) minus % of cells bound to fluorescently labelled isotype control antibody.   
 
3.1.4 CD11c and CD14 marker expression 
Cells expressing CD11c and CD14 were selected to distinguish between monocyte and 
monocyte-derived macrophage cells. CD11c is a macrophage cell marker that is abundant in 
monocyte-derived macrophage cells (Pilling et al., 2009), but is not expressed on monocytic 
cells (Prieto el al., 1994). In contrast, CD14 is an abundantly expressed protein on monocytic 
cells but is expressed at low level on macrophages (Schwende et al, 1996). The example for 
gating strategy in Figure 3.2 shows the expression of CD11c and CD14 markers on the cell 
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surface of untreated PBMCs cultured at 2 × 106 cells/5ml/well for 6 days. Selected live cells 
and matched isotype controls for CD14 and CD11c (Figure 3.2 A, B and D respectively) were 
used to gate the positive expression of these both markers. According to these data 
(repeated more than three times), PBMC-derived macrophage cells showed low expression 
of CD14 (26.1%) and high expression of CD11c (91.1%). This means that most of monocytes 
differentiated to monocyte-derived macrophages, validating our differentiation model.  
 
 
 
Figure 3.2 Flow Cytometric analysis of PBMC-derived macrophages stained for 
macrophage markers CD11c and CD14. Representative dot plot of 2 x 106 PBMC-derived 
macrophage cells/ well cultured for 6 days were selected based on forward scatter (size) on the x-
axis and side scatter (granularity) on the Y-axis). (A) is unstained cells; (B) IgG2A labelled with 
phycoeythrin (PE) isotype control for anti-CD14-PE; (C) Anti-CD14-PE; (D) IgG1 labelled with 
Allophycocyanin (APC) isotype control for CD11c; (E) anti-CD11c-APC. CD14+ (C) and CD11c+ (E) cells 
were selected using the matched IgG2A-PE and IgG1-APC isotype controls (B and D) respectively. 
Cells fluorescing positive for CD14-PE and CD11c-APC (C-B= % CD14+ ; E-D= % CD11c+) were used to 
4.2% 30.3% 
2.2% 93.3% 
A 
B C 
D E 
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analyse a range of cell surface markers detected by PE or APC-conjugated antibodies and their 
relevant isotype controls.    
3.2  Optimisation of cell culture density and duration 
Further optimisation was performed to optimise the cell culture density and duration. 
PBMCs-derived macrophages was cultured at two different densities (2 × 106 cells/5ml/well 
and 4 × 106 cells/4ml/well) for 6 or 8 days. They were stained with CD14 and CD11c 
antibodies matched with their isotype controls prior to flow cytometry analysis. The data 
were gated for CD14+ and CD11c+ expression as described in Section 3.1.3. Table 3.1 shows a 
summary of the flow cytometry data. CD14 expression on the cells was consistently ‘low’ at 
both densities cultured for either 6 days (26.1% and 26.1%) or 8 days (26.1% and 21.5%). 
Similarly, expression of CD11c was consistently ‘high’ at both densities cultured for 6 (91.1 % 
and 93.9 % respectively) or 8 days (84.2% and 77.5% respectively). This shows that the cells 
had the phenotype ‘CD14 lo, CD11c hi’, which is characteristic of macrophages, confirming 
that differentiation of the PBMCs had occurred. 
 
Table 3.1 CD14 and CD11c marker expression on PBMC-derived macrophages cultured for 
6 or 8 days at two different cell densities.  
markers 6 days 8 days 
 2 x 106 cells/well 4 x 106 cells/well 2 x 106 cells/well 4 x 106 cells/well 
CD14+ 26.1% 26.1% 33.8% 21.5% 
CD11c+ 91.1 % 93.9% 84.2% 77.5% 
 
 
 
After optimisation of differentiation time and cell culture density, the effect of duration of 
stimulation by LPS and IL-1β on the differentiation state of macrophage-like PBMCs was 
assessed by flow cytometry analysis of cell surface markers (CD14 and CD11c). PBMCs were 
isolated, cultured at 2 x 106 cells/well, stimulated using either IL-1β (2.5ng/ml) or LPS 
(100ng/ml) for 8, 12 or 24 hours in triplicate, staining with CD14 and CD11c and isotype 
control antibodies and flow cytometry analysis as described in Section 2.8. The graph in 
Figure 3.3 shows an example of positive expression of the differentiation-specific markers 
CD14 and CD11c by untreated PBMC-derived macrophages which was used as a control for 
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PBMC-derived macrophages treated with IL-1β or LPS for 8 hours. The rest of the results are 
summarized in Table 3.2. The relevant population of cells were gated according to FSC/SSC 
as described in Section 3.1.3. Table 3.2 shows that neither IL-1β nor LPS stimulation for any 
duration influenced expression of CD11c or CD14 i.e. differentiation state. There was no 
significant difference in CD11c or CD14 expression on untreated or treated monocyte-
derived macrophages by IL-1β or LPS for 8 hours (3.1%, 7.1% and 6.1% for CD14+  
respectively; 87.2%, 84.8% and  82.5% for CD11c+ respectively), and similar results were 
apparent for both markers treated for 12 or 24 hours. There was no difference in marker 
expression among the three treatment durations. Therefore, culture of PBMCs at 2 x 106 
cells/well for 8 days, followed by inflammatory stimulation for 8 hours, was adopted for 
subsequent experiments to detect the expression of IL6 and SelS and other genes.   
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Figure 3.3 Example of flow cytometric analysis of PBMC-derived macrophages stained for 
macrophage markers CD11c and CD14.  2 x 106 PBMC-derived macrophage cells/ well cultured 
for 8 days. The relevant population of cells were gated according to FSC/SSC. (A) is unstained cells; 
(B) Contour plots were used alongside their respective dot plots to exclude dead cells and debris and 
to gate for the PBMC-derived macrophage population. (C and E) are IgG2A-PE and IgG1-APC isotype 
controls for CD14 and CD11c positive expression respectively. (D and F) show  CD14+ and CD11c+ 
expression.  The amount of positive cells for CD14 or CD11c were calculated by subtracting the 
percentage of cells bound to the isotype control antibody from the percentage of positive cells for 
target antibodies.   
 
 
 
Table 3.2 CD14 and CD11c marker expression on stimulated PBMC-derived macrophages. 
2 x 106  cells/ well cultured for 8 days were treated using either LPS or IL-1β for 8 or 12 or 24 hours. 
Treatment 
time point 
8 hours 12 hours 24 hours 
Treatment Control IL1β LPS Control IL1β LPS Control IL1β LPS 
CD14+ 3.1% 7.1% 6.1% 1.8% 2.5% 1.5% 3.9% 3.1% 2.3% 
CD11c+ 87.2% 84.8% 82.5% 86.2% 82.3% 87% 85.6% 89.4% 93.7% 
1.3
% 
4.4
% 
1.0% 88.2% 
A B 
C D 
E F 
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3.3 Conclusion 
Optimisation of the PBMC-derived macrophage cell culture system was carried out through 
three different experiments. The first was to confirm the differentiation state using CD14 
and CD11c cell surface markers and I found that CD11c expression, which is a marker 
associated with the macrophage differentiation state, was higher compared with a marker 
of monocyte differentiation state, CD14, consistent with the morphology of the cells and 
confirming that they were indeed macrophage-like. The second experiment was to test the 
optimal cell culture density and duration, and the results showed that neither 
differentiation marker was affected by either of these factors. Finally, there was no effect of 
inflammatory stimulation (LPS or IL-1β) duration (8, 12 or 24 hours) on differentiation 
marker expression. Therefore, the differentiation protocol for producing PBMC-derived 
macrophages from blood/blood cones was validated, and the lowest cell density and the 
shortest incubation times were chosen as optimal for the remaining experiments.  
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Chapter 4: SelS genotype/haplotype-specific functional differences 
in primary monocyte-derived macrophages of healthy 
volunteers  
4.1 SelS genotype/haplotype determination 
 
DNA samples from healthy volunteers who gave written informed consent (see Appendix IV 
for consent forms) were isolated from either EDTA-anticoagulated peripheral blood or buffy 
coat or saliva samples. Forty three volunteers were genotyped for selected SelS SNPs using 
the TaqMan assay.  A summary of the results is given in Table 4.1, and the individual results 
in Table 4.3. Genotype frequencies were in Hardy–Weinberg equilibrium. 
 
The program PHASE v2.1 (Stephens et al 2001; Stephens & Donnelly 2003) was used to 
reconstruct SelS haplotypes (performed by Dr Fiona Green). The eight most common 
haplotypes that could be reconstructed by the programme with maximum confidence are 
shown in Table 4.2, together with their codes that are used in Table 4.3. The letters given in 
Table 2 show the base for each SNP allele in a left to right direction on the page, 
representing the SNPs from 5’ to 3’ on the chromosome: SelS-1500 A/C (rs8025174),  
SelS+3705 G/A (rs4965814), SelS+5227 C/T (rs4965373), SelS+9000 C/G (rs7178239). The 
haplotypes of each individual volunteer are given in Table 4.3. Fifteen of these volunteers 
donated sufficient blood for separation of PBMCs and subsequent differentiation and 
inflammatory stimulation. 
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Table 4.1 Summary of genotypes and rare allele frequencies for four SelS polymorphisms.  
SNP Genotype 
(Number of 
subjects) 
Genotype 
(Number of 
subjects) 
Genotype 
(Number of 
subjects) 
Rare allele 
frequency 
SelS-1500 A/C 
rs8025174  
CC (13) CA (24) AA (6) 0.42 
SelS+3705 G/A  
rs4965814 
 AA (23) GA (17)  GG (3)  0.27 
SelS+5227 C/T 
rs4965373 
CC (19) TC (22) TT (2) 0.30 
 SelS+9000 C/G 
rs7178239 
CC (25) GC (13) GG (3) 0.23 
 
 
 
           Table 4.2 Common SelS haplotypes, their codes and frequencie. Each  haplotype 
           was derived from four SelS SNPs ( SelS-1500 A/C (rs8025174), SelS+3705 G/A  
           (rs4965814), SelS+5227 C/T (rs4965373), and SelS+9000 C/G (rs7178239)). 
 
 
 
 
 
 
 
  
 
 
  
Haplotype Code Haplotype frequency 
CGCG 1 0.118 
CATG 2 0.237 
CACC 3 0.212 
AGCG 4 0.096 
AGCC 5 0.044 
AATC 6 0.058 
AACG 7 0.007 
AACC 8 0.211 
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Table 4.3. SelS genotypes and haplotype of individual healthy volunteers. Forty three healthy 
volunteers were genotyped for four SelS SNPs using the TaqMan assay. Haplotypes were reconstructed using 
the programme PHASE, and are coded as in Table 4.2. Volunteers highlighted in green were recalled for further 
blood donation for culture of primary monocyte-derived macrophages.  
Common name SelS-1500 A/C SelS+3705 G/A SelS+5227 C/T SelS+9000 C/G 
SelS haplotype 
SNP ID rs8025174 rs4965814 rs4965373 rs7178239 
Index No.         
1 CC GA TC GC 1 2 
2 AC GG CC GG 1 4 
3 CC GA CC GC 1 3 
4 AC AA TC CC 2 8 
5 CC AA TT CC 2 2 
6 AC AA CC CC 3 8 
7 AC AA CC CC 3 8 
8 AC AA TT CC 2 6 
9 CC GA TC GC 1 2 
10 CC GG CC GG 1 1 
11 AC AA TC CC 2 8 
12 CC AA TC CC 2 3 
13 AC AA TC CC 2 8 
14 CC AA TC CC 2 3 
15 CC AA TC CC 2 3 
16 AC GA CC GC 1 8 
17 AC AA TC CC 2 8 
18 AA GA TC GC 4 6 
19 AC AA TC CC 2 8 
20 AC GG CC GG 1 4 
21 AA GA CC CC 5 8 
22 AC GA CC GC 1 8 
23 CC AA TC CC 2 3 
24 AA GA CC GC 4 8 
25 AC GA CC CC 3 5 
26 CC AA CC CC 3 3 
27 AC AA CC CC 3 8 
28 AA AA CC CC 8 8 
29 CC AA CC CC 3 3 
30 AA GA CC GC 4 8 
31 AC AA TC CC 2 8 
32 CC GA TC GC 1 2 
33 CC AA TC CC 2 3 
34 AC GA TC GC 2 4 
35 AC AA CC ? 3 8 
36 AC GA TC ? 2 4 
37 AC AA TC GC 2 7 
38 AC GA CC GC 1 8 
39 AC GA TC GC 2 4 
40 AA AA CC CC 8 8 
41 AC AA TC CC 2 8 
42 AC GA TC CC 2 5 
43 AC GA TC CC        25 
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4.2 Optimization of QPCR 
4.2.1 THP-1 cells    
The THP-1 human monocytoid cell line was used to optimize the SelS mRNA QPCR and also 
to measure relative SelS mRNA expression in undifferentiated/differentiated THP-1 cells. 
THP-1 cells (monocytic) were cultured in suspension at a density of 2.0 × 106 cells per well. 
The monocytic cells were differentiated to macrophage-like THP-1 (dTHP-1) cells as 
adherent monolayer cells using phorbol myristate acetate (PMA) at a final concentration of 
10 nM for 72 hours and then stimulated with either IL-1β (2.5 ng/ml) or  LPS (100 ng/ml) for 
24 hours.  Cells were harvested after the incubation using TRIzol to lyse them and total RNA 
was extracted as described in Section 2.7.  
 
SelS mRNA expression was measured in undifferentiated and differentiated THP-1 cells 
using a one-step Sybr green RT-PCR protocol (QuantiTectSybr Green RT-PCR kit, Qiagen) and 
ABI Prism 7500 real time PCR instrument (Applied Biosystems).  The mRNA expression of 
SelS was normalized to the expression of the housekeeping gene MLN-51 which is expressed 
constantly in most cell lines and primary cells and has previously been shown to be 
unresponsive to both IL-1β and LPS treatments (Beeton, 2007). Standard curves produced 
from known serially diluted RNA samples were created for SelS and MLN-51 in order to 
enable measurement of relative SelS expression in THP-1 and dTHP-1 cells, and 
subsequently in the PBMCs. 
4.2.2 Standard curves 
Serially diluted RNA samples used to produce standard curves of SelS and MLN-51 (Figure 
4.1) were prepared from dTHP-1 cells treated with LPS. The standard RNA samples with 
known nanogram (ng) amounts (100, 10, 1.0, 0.1 and 0.01) were plotted against the 
threshold cycle (ct) values that are derived from amplification curves. A linear regression 
equation (y = mx + b) was used to derive the RNA quantities of unknown samples relative to 
the standards. In the equation, m represents the slope and b is the point where the line 
intercepts the y-axis. The r2 values were also derived to determine the ‘best fit’, and 
standard curves with r2 values lower than 0.97 were rejected. Melt-curves were routinely 
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examined to check for a single PCR product and a non-template control (NTC) was included 
in each QPCR plate to show any contamination.   
 
Initial experiments revealed maximal expression of IL6 in dTHP-1 cells treated with LPS (data 
not shown), and adequate expression of MLN51 and SelS, so this condition was selected to 
generate standard curves for all QPCR experiments in human primary cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Examples of standard curves for MLN-51 and SelS. Standard curves for SelS gene 
expression were obtained from known quantities of total RNA (100, 10, 1.0, 0.1 and 0.01) extracted 
from dTHP-1 cells stimulated with LPS. These known amounts of RNA were plotted against the cycle 
threshold (ct) values, producing the regression equation y= mx + b that was utilized to determine the 
amount of mRNA expression in vitro for SelS gene. The r2 values were also derived to determine the 
‘best fit’. 
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4.2.3 Dissociation plot 
A melt curve or dissociation protocol was carried out for each QPCR assay to check that a 
single product was produced during amplification. The temperature in each sample was 
increased from 58 °C to 95 °C. A specific product was detected and dissociated at 83 °C for 
SelS as shown in Figure 4.2.  
 
 
Figure 4.2 Dissociation plot of Selenoprotein S (SelS) mRNA in duplicate samples. The 
dissociation or melt curve analysis was used to determine the melting temperature (Tm) of a PCR 
product and is the derivative of raw fluorescence data. The Tm of SelS is 83ºC as shown in duplicate 
wells (The two lines are very close together). The temperature is plotted against unit of SYBR Green 
fluorescence. The Tm was calculated by the ABI Prism 7500 software.  
 
 
 
4.2.4 MLN-51 housekeeping gene in THP-1 cells 
A housekeeping gene such as MLN-51 is usually expressed ubiquitously in most cell lines and 
primary cells. It has been shown that the expression of this housekeeping gene in different 
types of cell lines and primary cells does not vary with differentiation state of cells or 
69 
 
cytokine stimulation (Beeton, 2007). This was investigated in the present study to confirm 
that MLN-51 can be used as a housekeeping gene. It was found that there was no significant 
difference between unstimulated monocytic and macrophage-like THP1 (P=0.4) as shown in 
Figure 4.3. No significant difference was observed in the level of MLN-51 gene expression 
between THP-1 and THP-1 treated with IL-1β and LPS respectively (P=0.2 and P=0.2). 
Similarly, the macrophage-like THP1 cells stimulated with IL-1β showed no significance 
difference (P=1.0) when compared to dTHP1. The effect of LPS on the level of MLN-51 
mRNA expression in dTHP-1 was also found to be not statistically significant (P=0.1). 
 
 
  
Figure 4.3 MLN-51 expression in monocytic and in differentiated THP-1 cells stimulated 
with either 2.5 ng/ml IL-1β or 100 ng/ml LPS in vitro for 24 hours in triplicate. Expression of 
the housekeeping gene MLN-51 was calculated in undifferentiated and differentiated cells using 
QPCR. Each QPCR assay was performed in duplicate. Values are presented as Mean ± SD. The data 
are representative of 3 independent biological repeats (n=3). 
 
 
4.2.5 Expression of SelS mRNA in THP-1 cells   
There was no significant difference in SelS mRNA expression between THP-1 or dTHP-1 cells, 
or following treatment with either IL-1β or LPS (Figure 4.4).  
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Figure 4.4 Normalized SelS mRNA expression in monocytic and in differentiated THP-1 
cells stimulated with either 2.5 ng/ml IL-1β or 100 ng/ml LPS in vitro for 24 hours in 
triplicate. The expression of the SelS gene in THP1 and dTHP-1 cells was established by QPCR 
analysis. Each QPCR assay was performed in duplicate. The levels of SelS mRNA expression were 
normalized to housekeeping gene MLN-51. Data given are presented as Mean ± SD. The data are 
representative of 3 independent biological repeats (n= 3). 
 
 
 
4.3 SelS mRNA expression in stimulated primary monocyte-derived 
macrophages (PBMCs) 
4.3.1 Normalisation of SelS mRNA expression  
After optimisation of SelS mRNA expression using the housekeeping gene MLN51 by QPCR 
in THP-1 and dTHP-1 cells, it was important to check that the normalisation protocol was 
also valid for the PBMCs. Gene normalisation means how measured mRNA levels correlate 
from a single experiment to another one (i.e. measurement error), which can affect 
significance estimates. The purpose of normalization is to account for experimental 
variabilities in all stages of experimental procedures starting from cell culture to 
measurement of gene expression by QPCR (Edmunds et al., 2014). This approach depends 
on an essential biological assumption that MLN-51 mRNA expression remains unchanged 
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under any condition in all experiments. If so, this can be used as a biological internal 
standard to correct the variability of target gene expression and this will lead to a reliable 
quantification of SelS mRNA expression.  
 
SelS mRNA expression was therefore analysed by QPCR in treated PBMC-derived 
macrophages extracted from whole blood of fifteen individuals. PBMCs were cultured at a 
density of 2 × 106 cell per well and then RNA was isolated from stimulated primary 
monocyte-derived macrophages at 8 days + 8 hours stimulation (Sections 2.3.2, 2.3.3 and 
2.8). The percentage of macrophage phenotype was determined (CD14 vs CD11c) at 8 days 
of primary PBMCs cell culture prior to stimulation as outlined in Chapter 3.  The relative SelS 
mRNA expression was then measured by QPCR. The graphs in Figure 4.5 show high SDs in 
the expression of MLN51 and SelS (and in their fold induction) under each treatment, which 
suggests that there was a large inter-well variation probably caused by inaccuracies in the 
seeded cell numbers. However, after normalisation of SelS expression to MLN51, the SDs 
are reduced, showing that the variability has been corrected, prior to analysis.  
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Figure 4.5 Normalisation of SelS mRNA expression. PBMCs extracted from whole blood fifteen 
individuals were cultured at a density of 2 × 106 cell/well and then stimulated in triplicate using 
either LPS or IL-1β for 8 hours. SelS mRNA expression was determined using QPCR and each QPCR 
assay was performed in duplicate. The values were expressed as mean ± SD. There were no 
significant differences. Mann-whitney was used to analyse the data.  
 
 
4.3.2 Expression of SelS mRNA in stimulated PBMCs-derived macrophages 
based on SelS haplotype  
IL-1β-and LPS-induced relative SelS mRNA expression was then analysed in terms of SelS 
SNP haplotype of fifteen individuals. The haplotypes of those volunteers were shown in 
Table 4.3, coded as shown in Table 4.2 and explained in Section 4.1. The individuals were 
assigned as possessing at least one copy (+) of each haplotype or none (-).  According to the 
data in Figure 4.6, there was no significant difference in the SelS mRNA from each haplotype 
either unstimulated (control) or stimulated with IL-1β or LPS (Figure 4.6 A to E). However, 
SelS mRNA from individuals with the +CATG haplotype was significantly induced by LPS 
(P=0.015; Figure 4.6 B), whereas that from the –CATG haplotype was not. There were no 
other significant difference in SelS mRNA expression. 
C
o
n
tr
o
l
IL
-1

L
P
S
0
1 0
2 0
3 0
4 0
T re a tm e n t
M
L
N
5
1
 m
R
N
A
 e
x
p
r
e
s
s
io
n
C
o
n
tr
o
l
IL
-1

L
P
S
0
1 0
2 0
3 0
4 0
T re a tm e n t
S
e
lS
 m
R
N
A
 e
x
p
r
e
s
s
io
n
C
o
n
tr
o
l
IL
-1

L
P
S
0
2
4
6
8
1 0
T re a tm e n t
N
o
r
m
a
li
s
e
d
 S
e
lS
m
R
N
A
 e
x
p
r
e
s
s
io
n
IL
-1

L
P
S
0
1
2
3
T re a tm e n t
M
L
N
5
1
 f
o
ld
 i
n
d
u
c
ti
o
n
IL
-1

L
P
S
0
1
2
3
T re a tm e n t
S
e
lS
 m
R
N
A
 f
o
ld
 i
n
d
u
c
ti
o
n
IL
-1

L
P
S
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
T re a tm e n t
N
o
r
m
a
li
s
e
d
 S
e
lS
m
R
N
A
 f
o
ld
 i
n
d
u
c
ti
o
n
73 
 
 
Figure 4.6 Normalised SelS mRNA expression in LPS- and IL-1β-induced monocyte-derived 
macrophages by SelS haplotypes. PBMCs-derived macrophages were stimulated for 8 hours in 
triplicate.  SelS mRNA expression was determined using QPCR and each QPCR assay was performed 
in duplicate. *P<0.05. 
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The fold change in SelS mRNA expression was also assessed in IL-1β- and LPS-induced 
monocyte-derived macrophages. It was calculated as the ratio of normalized SelS mRNA 
expression (SelS/MLN51) to an untreated control sample. There was no significant 
difference in SelS mRNA expression induction by either LPS- and IL-1β for all the haplotype 
groups (Figure 4.7 A to E).  
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Figure 4.7 Induction of SelS mRNA expression in IL-1β- and LPS-induced monocyte-derived 
macrophages by SelS haplotypes. The cells were treated for 8 hours in triplicate. SelS mRNA 
expression was determined using QPCR and each QPCR assay was performed in duplicate. There 
were no significant differences. 
-C
G
C
G
-I
L
1

+
C
G
C
G
-I
L
1

-C
G
C
G
-L
P
S
+
C
G
C
G
-L
P
S
0
1
2
3
4
S e lS  h a p lo ty p e /T re a tm e n t
R
e
la
ti
v
e
 S
e
lS
m
R
N
A
 f
o
ld
 i
n
d
u
c
ti
o
n
-C
A
T
G
-I
L
1

+
C
A
T
G
-I
L
1

-C
A
T
G
-L
P
S
+
C
A
T
G
-L
P
S
0
1
2
3
4
S e lS  h a p lo ty p e /T re a tm e n t
R
e
la
ti
v
e
 S
e
lS
m
R
N
A
 f
o
ld
 i
n
d
u
c
ti
o
n
-A
G
C
G
-I
L
1

+
A
G
C
G
-I
L
1

-A
G
C
G
-L
P
S
+
A
G
C
G
-L
P
S
0
1
2
3
4
S e lS  h a p lo ty p e /T re a tm e n t
R
e
la
ti
v
e
 S
e
lS
m
R
N
A
 f
o
ld
 i
n
d
u
c
ti
o
n
-A
G
C
C
-I
L
1

+
A
G
C
C
-I
L
1

-A
G
C
C
-L
P
S
+
A
G
C
C
-L
P
S
0
1
2
3
4
S e lS  h a p lo ty p e /T re a tm e n t
R
e
la
ti
v
e
 S
e
lS
m
R
N
A
 f
o
ld
 i
n
d
u
c
ti
o
n
-A
A
C
C
-I
L
1

+
A
A
C
C
-I
L
1

-A
A
C
C
-L
P
S
+
A
A
C
C
-L
P
S
0
1
2
3
4
S e lS  h a p lo ty p e /T re a tm e n t
R
e
la
iv
e
 S
e
lS
m
R
N
A
 f
o
ld
 i
n
d
u
c
ti
o
n
A
E
DC
B
76 
 
4.3.3 Expression of SelS mRNA in PBMC-derived macrophages based on SelS 
genotype 
Further analysis was carried out to test whether there were any SelS genotype effects on 
SelS mRNA expression that were masked by haplotype analysis. The genotypes for the SelS 
SNPs of the 15 individuals were shown in Table 4.3. Monocyte-derived macrophages were 
stimulated using either LPS or IL-1β for 8 hours prior to determining the SelS mRNA 
expression by one step SYBR green QPCR. Our model to find out the effect of SelS genotype 
on SelS fold change (Figure 4.8) was tested as common homozygous versus heterozygous + 
rare homozygous for each SelS SNP. The only significant difference concerned the SelS -1500 
SNP: there was no significant difference between the two genotype groups on IL-1β 
stimulation (P=0.7), but there was on LPS stimulation (P=0.004; Figure 4.8), with the +C 
group showing stronger LPS induction than the AA group.  
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Figure 4.8 Induction of SelS mRNA expression in IL-1β- and LPS-induced monocyte-derived 
macrophages by SelS genotypes. The monocyte-derived macrophages was treated in triplicate 
with either IL-1β or LPS for 8 hours. SelS mRNA expression was determined using QPCR and each 
QPCR assay was performed in duplicate. **P=0.0044 only for SelS-1500 treated by LPS. Mean ± SD  
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4.4 SelS protein expression in stimulated PBMCs-derived macrophages 
4.4.1 Normalisation of SelS protein expression  
After assessment of SelS mRNA expression, SelS protein expression was also measured in monocyte-
derived macrophages using a western blotting assay. Eleven individuals were available for this 
experiment. PBMC extraction, culture at density 2 × 106 cells/5ml/well in 6 well plates and 
stimulation in triplicate using either LPS or IL-1β for 8 hours were as described in Sections 2.7. 
Harvesting and lysis of the cells, preparing the cellular protein extract for western blotting, 
performing of western blotting and quantitation of the bands were described in Section 2.14. Beta-
actin was used as a control protein to normalise SelS protein expression. Thermo Scientific 
PageRuler Prestained Protein marker (M) from 10 to 180 kDa was used to estimate the molecular 
weight of β-actin (43 kDa) and SelS (21 kDa) proteins on the western blotting membrane (Figure 4.9). 
The example for western blot in Figure 4.9 shows obvious bands for SelS and β-actin and these 
bands represent each treatment (control C; IL-1β and LPS treatments) in triplicate.      
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Example of western blot for SelS and β-actin protein expression. Marker, C and 
three replicates of each treatment are shown.  
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Normalisation was used to correct for inter-experimental variability prior to analysis of SelS 
protein expression by haplotype or genotype. The data in Figure 4.10 show stable 
housekeeping protein (β-actin) expression under any treatment; none of the differences 
were statistically significant. There were large error bars in SelS protein expression but after 
the normalisation in which SelS values were divided by β-actin reference proteins for each 
sample, the error bars were reduced, showing that the β-actin was able to correct for the 
variability between the experiments. Although there appears to be a slight stimulation of 
SelS protein expression by LPS, this did not reach statistical significance. 
    
 
Figure 4.10 Normalisation of SelS protein expression. PBMCs extracted from whole blood of 
eleven individuals were cultured at a density of 2 × 106 cell/well and then stimulated in triplicate 
using either LPS or IL-1β for 8 hours. SelS protein expression was determined in lysate cells using 
western blotting. The values were expressed as mean ± SD. There were no significant differences. 
 
 
4.4.2 Expression of SelS protein in PBMC-derived macrophages based on SelS 
haplotype  
After correction for variability between experiments (SelS protein expressed as a ratio of β-
actin), relative SelS protein expression was analysed in terms of the SelS SNP haplotype of 
eleven individuals. Only one haplotype (CATG) was analysed because the other haplotypes 
did not reach the minimum number (at least 3 individuals per haplotype) for statistical 
comparisons. The haplotypes of those volunteers were shown in Table 4.1. The individuals 
were assigned as possessing at least one copy (+) of the CATG haplotype or none (-). There 
was no significant induction of SelS protein by either IL-1β or LPS in either + or – CATG 
haplotypes, and no significant difference between +/- CATG under any conditions, showing 
that there was no effect of that haplotype on SelS protein expression (Figure 4.11). 
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Figure 4.11 Normalised SelS protein expression and SelS fold change in LPS- and IL-1β-
induced monocyte-derived macrophages by CATG haplotype. PBMCs extracted from whole 
blood of eleven individuals were cultured at a density of 2 × 106 cell/well and then stimulated in 
triplicate using either LPS or IL-1β for 8 hours. SelS protein expression was determined in lysed cells 
using western blotting. The values were expressed as mean ± SD. There were no significant 
differences. 
 
  
4.4.3 Expression of SelS protein in PBMC-derived macrophages based on SelS 
genotype 
The effect of SelS genotype on relative SelS protein expression was also analysed for the 
same individuals, in case analysis by haplotype masked the effects of a single SNP. Similarly 
to SelS mRNA expression analysis by genotype, the comparison is between common 
homozygotes and heterozygous plus rare homozygotes for each SelS SNP. There was no 
significant difference in the SelS protein induction by either LPS or IL-1β for any of the SelS 
SNPs (SelS-1500 A/C, SelS+3705 G/A, SelS+5227 C/T or SelS+9000 C/G; Figure 4.12).       
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Figure 4.12 Induction of SelS protein expression in IL-1β- and LPS-induced monocyte-
derived macrophages by SelS genotypes. The cells were treated for 8 hours in triplicate. SelS 
protein expression was determined in lysate cells  using western blotting.  Mean ± SD; there were no 
significant differences. 
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4.5 Expression of BiP and CHOP mRNA in stimulated PBMCs-derived 
macrophages based on SelS haplotypes 
Because SelS is an ER-stress protein and its deficiency was reported (see Section 1.6.2) to 
induce ER-stress response, we investigated the ER-stress response induction following LPS 
or IL-1β treatment and compared it by SelS SNP haplotypes. To assess ER-stress response, 
we analysed mRNA expression of BiP and CHOP, two key markers of ER-stress. Consistent 
with the finding that there were no differences in SelS protein expression by SelS haplotype 
or genotype, there was no significant difference in BiP or CHOP mRNA expression or 
induction by either LPS or IL-1β by SelS haplotype (Figures 4.13 and 4.14).   
 
 
Figure 4.13 Relative BiP mRNA expression and fold induction by LPS- and IL-1β-induced 
monocyte-derived macrophages by SelS haplotypes. PBMCs-derived macrophages were 
stimulated for 8 hours in triplicate.  BiP mRNA expression was determined using QPCR and each 
QPCR assay was performed in duplicate. The data were expressed as mean ± SD;   no differences 
were statistically significant. Left figures are for Relative mRNA expression. Right figures are for fold 
induction. 
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Figure 4.14 Relative CHOP mRNA expression and fold induction by LPS- and IL-1β-induced 
monocyte-derived macrophages by SelS haplotypes. PBMCs-derived macrophages were 
stimulated for 8 hours in triplicate.  CHOP mRNA expression was determined using QPCR and each 
QPCR assay was performed in duplicate. The data were expressed as mean ± SD; no differences were 
statistically significant. Left figures are for Relative mRNA expression. Right figures are for fold 
induction. 
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4.6 Conclusion  
There was no significant difference in SelS mRNA expression between THP-1 or dTHP-1 cells, 
or following treatment with either IL-1β or LPS.  
SelS mRNA was upregulated in LPS-induced +CATG SelS haplotype in PBMC-derived 
macrophages, however the +CATG SelS haplotype did not show an increase in SelS protein 
concentration with either LPS or IL-1β stimulation. The SelS -1500 CC genotype was 
associated with higher LPS-induction of SelS in PBMC-derived macrophages. Overall, some 
SelS genotypes/haplotypes were associated with an effect on mRNA/protein expression, 
which may go some way to reveal underlying molecular mechanisms of CAD risk association. 
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Chapter 5: IL6 and IL-6R (CD126) genotype/haplotype-specific 
function differences in primary monocyte-derived macrophages of 
healthy volunteers  
5.1 IL6 and IL-6R genotype/haplotype determination 
The DNA samples from 43 healthy volunteers as described in Chapter 4 were used in this 
chapter for IL6 and IL-6R genotyping using the TaqMan assay.  A summary of the results is 
given in Table 5.1, and the individual results in Table 5.3. Genotype frequencies were in 
Hardy–Weinberg equilibrium. 
  
The program PHASE v2.1 (Stephens et al 2001; Stephens & Donnelly 2003) was used to 
reconstruct IL6 haplotypes (as for SelS in Chapter 4; performed by Dr Fiona Green). The Four 
common IL6 haplotypes that could be reconstructed by the programme with maximum 
confidence are shown in Table 5.2 The haplotypes of each individual volunteer are given in 
Table 5.3. Haplotypes are shown by SNP allele from 5’ to 3’, left to right. Fifteen of these 
volunteers donated sufficient blood for separation of PBMCs and subsequent differentiation 
and inflammatory stimulation.   
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Table 5.1 Summary of genotypes and rare allele frequencies for three IL6 SNPs.  
 
SNP Genotype 
(Number of 
subjects) 
Genotype 
(Number of 
subjects) 
Genotype 
(Number of 
subjects) 
Rare allele 
frequency 
IL6-6331 C/T 
rs10499563 
TT (25) TC (17) CC (1)  0.22 
IL6-597 G/A 
rs1800797 
GG (17) GA (18)  AA (8) 0.41 
IL6-572 G/C 
rs1800796 
GG (39) GC (3) CC (1) 0.06 
 
 
 
             Table 5.2 Common IL6 haplotypes with their frequencies and codes 
 
 
 
 
 
 
 
 
  
  
 
  
IL6 Haplotype Code Haplotype frequency 
TGG  1 0.33 
 TGC 2 0.06 
 TAG 3 0.39 
 CGG 4 0.22 
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Table 5.3. IL6 and IL-6R genotype/haplotype of individual healthy volunteers. Forty three healthy 
volunteers were genotyped for three IL6 and one IL-6R SNPs using the TaqMan assay. Haplotypes were 
reconstructed using the programme PHASE, and are as defined in Section 5.1. Volunteers highlighted in green were 
recalled for further blood donation for culture of primary monocyte-derived macrophages.  
 IL6 genotype/haplotype IL-6R genotype 
Common name -6331 C/T -597 G/A -572 G/C 
 
rs8192284A/C 
(Gln357/Asp358) 
 SNP ID rs10499563 rs1800797 rs1800796 Haplotype 
Index No. 
     1 TC GA GG 3 4 CC 
2 CC GG GG 4 4 CC 
3 TT GA GG 1 3 CC 
4 TC GG GG 1 4 CC 
5 TC GG GG 1 4 AA 
6 TC GA GG 3 4 CC 
7 TT GA GG 1 3 AC 
8 TT GA GG 1 3 AC 
9 TC GG GG 1 4 AC 
10 TT AA GG 3 3 AA 
11 TT GA GC 2 3 AC 
12 TT GG CC 2 2 AC 
13 TC GA GG 3 4 CC 
14 TT AA GG 3 3 CC 
15 TC GG GG 1 4 CC 
16 TT GG GG 1 1 CC 
17 TC GG GG 1 4 AC 
18 TT GG GG 1 1 CC 
19 TC GG GG 1 4 CC 
20 TC GA GG 3 4 AC 
21 TT GG GG 1 1 AC 
22 TT GG GG 1 1 CC 
23 TT AA GG 3 3 AC 
24 TT AA GG 3 3 CC 
25 TC GA GG 3 4 CC 
26 TC GG GG 1 4 CC 
27 TT GG GC 1 2 AC 
28 TT GA GG 1 3 AA 
29 TT GG GC 1 2 AA 
30 TC GG GG 1 4 AC 
31 TT GA GG 1 3 AC 
32 TT AA GG 3 3 CC 
33 TC GG GG 1 4 AA 
34 TT AA GG 3 3 CC 
35 TT GA GG 1 3 CC 
36 TT AA GG 3 3 AC 
37 TT AA GG 3 3 AC 
38 TT GA GG 1 3 AC 
39 TC GA GG 3 4 AC 
40 TT GA GG 1 3 CC 
41 TT GA GG 1 3 CC 
42 TC GA GG 3 4 AA 
43 TC GA GG 3 4 CC 
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5.2 Optimization of QPCR 
5.2.1 THP-1 cells    
The THP-1 cell line was used to optimize the IL6 mRNA QPCR and to measure relative IL6 
mRNA expression in undifferentiated/differentiated THP-1 cells, as it was for SelS in Chapter 
4. THP-1 cells were cultured, differentiated and stimulated as described in Chapter 4 and 
were harvested and total RNA extracted as described in Section 2.7.  
 
IL6 mRNA expression was quantified by RT-PCR and normalised to housekeeping gene MLN-
51 as previously described in Chapters 2 and 4. Standard curves for IL6 and MLN-51 mRNA 
were produced from serially diluted RNA of known concentration from LPS-stimulated, 
dTHP-1 cells as in Chapter 4 for SelS. 
 
5.2.2 Standard curves 
Representative standard curves for IL6 and MLN-51 are shown in Figure 5.1. The standard 
RNA samples with known nanogram (ng) amounts (100, 10, 1.0, 0.1 and 0.01) were plotted 
against the threshold cycle (ct) values (Mean ± SD) which are derived from amplification 
curves. A linear regression equation was used to measure the RNA quantities of unknown 
samples. Melt-curve analysis were also performed in each IL6 QPCR reaction.   
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(A) 
 
 
(B) 
 
Figure 5.1 Examples of standard curve for MLN-51 (A) and IL6 (B). Construction of standard 
curves for each gene was obtained from known quantities of total RNA (100, 10, 1.0, 0.1 and 0.01) 
extracted from dTHP-1 cells stimulated with LPS. These known amounts of RNA were plotted against 
the cycle threshold (ct) values, producing regression equation of line (y= mx + b) that was utilized to 
determine the amount of mRNA expression in vitro for each gene either in THP-1 cells or in primary 
cells. The r2 values were also derived to determine the ‘best fit’. 
 
 
 
5.2.3 Dissociation plot 
A melt curve or dissociation protocol was carried out for each QPCR assays to ensure that a 
specific product was produced during amplification. The temperature in each sample was 
increased from 58 °C to 95 °C. A specific product was detected and dissociated at 78 °C for 
IL6 as shown in Figure 5.2.  
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Figure 5.2 Dissociation plot of IL6 mRNA in duplicate samples. The dissociation curve/melting 
curve analysis is used to determine the melting temperature (Tm) of a PCR product and is the 
derivative of raw fluorescence data. The Tm of IL6 is 78ºC as shown in duplicate wells. The 
temperature is plotted against unit of SYBR Green fluorescence. The Tm was calculated by the ABI 
Prism 7500 software. 
 
5.2.4 MLN-51 housekeeping gene in THP-1 cells 
As shown in Section 4.2.4 and Figure 4.3, expression of the housekeeping gene MLN-51 was 
constant irrespective of inflammatory stimulus or differentiation status, so it could be used 
to normalize IL6 mRNA expression.  
 
5.2.5 Expression of IL6 mRNA in THP-1 cells   
The relative expression of IL6 was plotted against the housekeeping gene MLN-51 in 
monocytic and macrophage-likeTHP-1 cells to assess the differences in the expression of this 
gene between these two cell types. The results which are presented in Figure 5.3 show that 
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no significant difference was found between the monocytic THP-1 and macrophage-like 
THP-1 cells (P=0.7) and  the same outcome with IL-1β-induced THP-1 and dTHP-1cells. The 
only significant increase was detected in dTHP-1 stimulated with LPS (P=0.0015), and this 
was a very large stimulatory effect, at least 10-fold over baseline.  
 
 
 
Figure 5.3 Normalized IL6 gene expression in monocytic and in macrophage-like THP-1 
cells stimulated with either 2.5ng/ml IL-1β or 100ng/ml LPS in vitro in triplicate for 24 
hours. The expression of IL6 mRNA in THP-1 and dTHP-1 cells was obtained by QPCR analysis and 
each assay was performed in duplicate. The levels of IL6 mRNA expression were normalized to 
housekeeping gene MLN-51. Values are presented as Mean ± SD, The data are representative of 3 
independent biological repeats (n = 3). **P <0.01 
 
 
5.3 IL6 mRNA expression in stimulated primary monocyte-derived 
macrophages  
5.3.1 Normalisation of IL6 mRNA expression  
IL6 mRNA expression was analysed by QPCR in treated PBMC-derived macrophages 
extracted from whole blood of fifteen individuals.  The rationale was explained in Chapter 4 
(see Section 4.3.1) and the data are shown in Figure 5.4. This shows that large error bars in 
the expression  
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of MLN51 and IL6 and in their fold induction under each treatment might be due to the 
presence of variation between experiments and this variation probably was associated with 
the differences in the plated cell numbers. However, after normalisation of IL6 expression to 
MLN51, the large error bars reduced and this means that the normalisation did indeed 
correct for the experimental variability that is an important for accurate quantification of IL6 
(and other) mRNA expression.  
 
 
 
 
 
 
Figure 5.4 Normalisation of IL6 mRNA expression. PBMCs extracted from EDTA-whole blood 
fifteen individuals were culture at a density of 2 × 106 cell/well and the stimulated using either LPS or 
IL-1β in triplicate for 8 hours. IL6 mRNA expression was determined using QPCR and each QPCR 
assay was performed in duplicate.   The values were expressed as Mean ± SD, **P <0.01; ****P 
<0.0001 
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5.3.2 Validation of differentiation status (CD14 and CD11c expression) in 
monocyte-derived macrophages treated with proinflammatory stimulators 
for 8 or 12 hours by IL6 haplotype 
Cell surface expression of CD14 and CD11c were used to confirm the differentiation status 
of PBMC-derived macrophages, and to show that neither culture conditions nor 
inflammatory stimulation affected this differentiation, as described in Chapter 3. Here, the 
association of IL6 haplotypes with CD14/CD11c as markers of macrophage differentiation 
status was assessed to confirm that haplotype had no impact on the differentiation. PBMCs 
were isolated, cultured, stimulated, harvested and stained as described in Sections 2.7 and 
2.8, and analysed as described in Chapter 3. As expected, the data showed no differences in 
CD14/CD11c cell-surface expression by IL6 haplotype (data not shown). 
 
5.3.3 Expression of IL6 mRNA in stimulated PBMC-derived macrophages 
based on IL6 haplotype  
The effect of IL6 haplotype on relative IL6 mRNA expression in primary monocyte-derived 
macrophage induced by either IL-1β-and LPS for 8 hours was assessed by QPCR. The 
individuals were assigned as possessing at least one copy (+) of the particular haplotype or 
none (-). Selection of stimulation for 8 hours was because this is the time that gave 
maximum induction of IL6 mRNA expression (Beeton, PhD thesis, 2007).   
Considering the TGG haplotype first (Figure 5.5; Panels A and B), cells with + or –TGG 
haplotype both showed significant induction by IL-1β and LPS (Panel A) but there was no 
haplotype specific difference in this effect (Panel B);  Panels E and F of Figure 5.5 showed a 
similar result for the CGG haplotype, i.e. no significant difference between haplotypes. To 
confirm that there was no significant difference between haplotype, the combined 
individuals together in Figure 5.4 show a good confirmation that our experiments were 
working well. Panel C shows significant induction of the +TAG group with IL-1β whereas 
Panel D shows no significant haplotype difference; however the LPS induction was 
significantly higher for the +TAG group compared to those without the TAG haplotype 
(Panel D). Therefore, in the next Section, I show analysis of this effect by IL6 genotype in an 
attempt to dissect out any individual SNP effects. 
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Figure 5.5 Relative IL6 mRNA expression and IL6 fold induction in LPS- and IL-1β-induced 
monocyte-derived macrophages by IL6 haplotypes. PBMC-derived macrophages were 
stimulated for 8 hours in triplicate. IL6 mRNA expression was determined using QPCR and each QPCR 
assay was performed in duplicate. Panels A, C and E represent relative IL6 mRNA expression. Panels 
B, D and F refers to IL6 fold induction. *P<0.05; **P <0.01; ***P <0.001; ****P <0.0001 
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5.3.4 Expression of IL6 mRNA in PBMC-derived macrophages based on IL6 
genotype 
The effect of IL6 genotypes on IL6 mRNA expression was assessed to dissect the haplotype 
effect.  The IL6 genotypes of 15 individuals were shown in Table 5.3. Monocyte-derived 
macrophages were simulated using either LPS or IL-1β for 8 hours and IL6 mRNA expression 
was determined by QPCR, as for the experiments described in Section 5.3.3. Figure 5.6 
shows that there were no significant differences in IL6 level by IL6-6331 C/T or -597 G/A 
common genotypes versus rare and heterozygous genotypes induced by either IL-1β or LPS. 
However, the fold increase in IL6 mRNA expression was significantly higher in IL6-597 
GA+AA genotypes treated by LPS (P=0.018).  
 
 
Figure 5.6 Induction of IL6 mRNA expression in IL-1β- and LPS-induced monocyte-derived 
macrophages by IL6 genotype. The monocyte-derived macrophages was treated in triplicate with 
either IL-1β or LPS for 8 hours. IL6 mRNA expression was determined using QPCR and each QPCR 
assay was performed in duplicate.  *P<0.05. Mean ± SD  
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5.4 Expression of IL6 protein by IL6 haplotype  
5.4.1 TNF-α protein expression in cell culture supernatants of stimulated 
PBMC-derived macrophages 
TNF-α protein level was measured in activated monocyte-derived macrophages using an 
ELISA assay prior to using the Cytometric Bead Array (CBA), to assess whether any cells were 
non-responders and to determine the dilutions required for the CBA assay, including for IL6 
protein measurement. TNF-α is considered the primary cytokine released from activated 
macrophages compared to other cytokines, hence it’s use as an ‘indicator’ for the more 
expensive CBA assay.  
 
The PBMC-derived macrophages from nine individuals were cultured for 8 days and then 
treated for 8 or 12 hours with either IL-1β or LPS as before, but in this case the culture 
supernatants were collected for assay of secreted cytokines (see Section 2.10). TNF-α 
protein expression was undetectable (<0.1 pg/ml) for most of the samples. There was no 
detectable induction of TNF-α by IL-1β but there was a small induction by LPS; it was not 
possible to perform statistical analysis because of the large number of data points below the 
detection level of the assay. There was no significant IL6 haplotype-specific difference in the 
TNF-α protein production for either stimulation period (data not shown).  
 
5.4.2 Expression of secreted IL6 protein (CBA assay) by IL6 haplotype 
IL6 protein level was measured in the primary cell culture supernatants from unstimulated 
and stimulated monocyte-derived macrophages and analysed by IL6 haplotype. In all cases, 
there appeared to be some IL-1β stimulation of IL6 protein production but in no case did 
this reach statistical significance, whether stimulated for 8 hours (data not shown) or 12 
hours (Figure 5.7; panels A, C, E). There was clear stimulation by LPS that reached 
significance in some comparisons following 12 hours stimulation (Figure 5.7; panels A, C, E), 
however there were no significant differences in induction between any of the haplotypes 
and their controls (Figure 5.7; panels B, D, F).  
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Figure 5.7 The effect of IL6 haplotypes on IL6 cytokine production by monocyte-derived 
macrophage cells following 12 hours stimulation. PBMCs extracted from whole blood of nine 
individuals were culture at a density of 2 × 106 cell/well and the stimulated in triplicate using either 
LPS or IL-1β for 12 hours. IL6 protein level was determined in cell culture supernatants using the CBA 
assay. Panels A, C and E represent IL6 protein expression. Panels B, D and F refer to IL6 fold-
induction. The bar represents the mean. Wherever there was an undetectable value, the figure 0.1 
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was used to calculate the fold increase. IL6 protein expression was undetectable at <0.1 pg/ml.  
*P<0.05 
 
5.4.3 Expression of secreted IL6 protein (CBA assay) based on IL6 genotype 
Because the individuals  with A allele of the -597 G/A SNP induced higher IL6 mRNA 
expression following LPS stimulation (Figure 5.6), we decided to check whether this result is 
consistent with IL6 protein level. The data in Figure 5.8 showed apparently increased IL6 
protein in cells with the A allele compared with GG but it failed to reach statistical 
significance.      
 
 
Figure 5.8 Induction of IL6 protein expression in IL-1β- and LPS-induced monocyte-derived 
macrophages by IL6-597 genotype. The monocyte-derived macrophages was treated in triplicate 
with either IL-1β or LPS for 8 hours. IL6 protein expression was determined using western blotting. 
Wherever there was an undetectable value, the figure 0.1 was used to calculate the fold increase.  
IL6 protein expression was undetectable at <0.1 pg/ml. *P<0.05. Mean ± SD  
 
 
 
5.5 Expression of other inflammatory cytokines in PBMC-derived 
macrophages of different IL6 haplotype under an inflammatory stimulus. 
The CBA assay allowed us to examine the expression of several other cytokines, 
concomitantly with IL6, in these PBMC-derived macrophage supernatants.  Where the 
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assays gave meaningful data (i.e. above the detection threshold for the assay), the impact of 
IL6 haplotype on this expression was tested, on the basis that haplotype-determined 
differences in IL6 level may in turn influence expression of other cytokines. There were no 
detectable significant differences in IL6 protein concentration as described in Section 5.4.2, 
but the numbers were small and there were differences in mRNA (Section 5.3.3). 
 
The assays for IL-1β and IL-12p70 showed little or no detectable expression and therefore 
no further investigation was performed. The results for IL-8, IL-10 and TNF-α are given 
below. The data for IL-1β or LPS stimulation for 8 hours were not shown because they were 
either similar to the 12 hour data or showed no significant differences, as indicated in the 
text.  
 
5.5.1 Interleukin-8 
IL-8 has a central role in cardiovascular diseases including CAD through its chemotactic  
(chemoattractant) effect on inflammatory cells. IL-8 is a chemokine whose concentration 
increases at the site of inflammation, allowing inflammatory cells including monocytes and 
neutrophils to move to the infection site. IL-8 can also promote the activation of these 
inflammatory cells (Remick, 2005; Waugh and Wilson, 2008; Standiford et al., 1990; 
Gimbrone et al., 1989). Several studies have identified that IL-8 was present at the site of 
vascular injury and also in atherosclerotic plaques at different stages. For example, Rus et al. 
(1996) found that IL-8 mRNA level was increased in the human arterial atherosclerotic wall. 
Significantly increased IL-8 mRNA level was also identified in fibrous plaques compared to 
normal intima (Rus et al., 1996). Apostolopoulos et al. (1996) reported that macrophages 
are one of the main sources of IL-8 in the atherosclerotic plaque compared to normal and 
patient monocytes. Liu et al. (1997) also detected elevated IL-8 levels in foam cells 
associated with human atherosclerotic tissues. A more recently published study carried out 
by Inoue et al. (2008) identified increased the serum levels of ten cytokines in stable CAD 
and IL-8 was a strong independent predictor for CAD in healthy volunteers.  
IL-8 protein levels were measured in cell culture supernatants of monocyte-derived 
macrophages stimulated with I IL-1β or LPS for 8 (data not shown) or 12 hours (Figure 5.9) 
100 
 
using the CBA assay. The data showed comparable induction by IL-1β and LPS that reached 
statistical significance in some groups (Figure 5.9; panels A, C, E), but there were no 
significant differences between any of the IL6 haplotype groups and their controls (Figure 
5.9; panels B, D, F).  
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Figure 5.9 The effect of IL6 haplotypes on IL-8 cytokine production by monocyte-derived 
macrophage cells following 12 hours of stimulation. PBMCs extracted from whole blood of nine 
individuals were cultured at a density of 2 × 106 cell/well and the stimulated in triplicate using either 
LPS or IL-1β for 12 hours. IL-8 protein level was determined in cell culture supernatants using CBA 
assay. Panels A, C and E represent IL-8 protein expression. Panels B, D and F refers to IL-8 fold 
induction. Wherever there was an undetectable value, the figure 0.1 was used to calculate the fold 
increase.   The bar represents the mean. *P<0.05 
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5.5.2 IL-10 
In keeping with the role of cytokines in cardiovascular diseases including CAD, IL-10 is one of 
the pleiotropic cytokines expressed from Th1 cells, Th2 cells, T and B cells and macrophages 
in response to inflammatory stimuli. It is widely recognised as an anti-inflammatory cytokine 
because it inhibits the production of pro-inflammatory cytokines and monocyte-endothelial 
cell adhesion molecules (de Waal Malefyt et al., 1991; Mostafa et al., 2001). Adhesion of 
monocytes to endothelium is one of the first steps of atherosclerotic processes. In support 
of the IL-10 anti-inflammatory role, animal studies showed that increased expression of IL-
10 in locally stimulated T cells induced decreased atherosclerotic progression (Pinderski et 
al., 2002; Von Der Thusen et al., 2001) and lower IL-10 expression led to a more rapidly 
developing atherosclerotic plaque compared to control in mouse models (Mallat et al., 
1999; Pinderski Oslund et al., 1999). This IL-10 influence is in opposition to the effects of 
pro-inflammatory cytokines such as IL6 and interferon (Welsh et al., 2011). Studies in 
humans showed the presence of IL-10 mRNA expression in atherosclerotic plaque and 
suggested that it might be secreted by local macrophages (Mallat et al., 1999). It may have 
an indirect way to influence the stabilization of the atherosclerotic plaque, probably by 
inhibiting enzymes that induce the destabilization of atherosclerotic plaque such as matrix 
metalloproteinases. Some small clinical studies showed that there is some controversy 
about IL-10 plasma concentration in stable and unstable angina patients compared to 
controls. IL-10 levels were found to be unchanged (Nijm et al., 2005; Waehre et al., 2002), 
elevated ( Mizia-Stec et al, 2003; Rajappa et al., 2009) and decreased (Hong et al., 2005; 
Yamashita et al., 2003) in those patients compared to controls, suggesting that the studies 
were underpowered, that there IS no clinical relationship with plasma IL-10 levels and 
therefore perhaps local IL-10 production may be more important. 
 
IL-10 protein levels were determined by the CBA assay in cell culture supernatants from 
monocyte-derived macrophages treated with IL-1β or LPS for 8 or 12 hours. IL-10 protein 
level was only detectable on LPS stimulation, with some groups showing a significant 
increase (Figure 5.10; panels A, C). However there were no IL6 haplotype-specific significant 
differences following either 8 (data not shown) or 12 hours (Figure 5.10; panels B, D, F) pro-
inflammatory stimulation.  
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Figure 5.10 The effect of IL6 haplotypes on IL-10 cytokine production by monocyte- 
derived macrophage cells stimulated for 12 hours. PBMCs extracted from whole blood of nine 
individuals were cultured at a density of 2 × 106 cell/well and the stimulated in triplicate using either 
LPS or IL-1β for 12 hours. IL-10 protein level was determined in cell culture supernatants using CBA 
assay. Panels A, C and E represent IL-10 protein expression. Panels B, D and F refers to IL-10 fold 
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induction. Wherever there was an undetectable value, the figure 0.1 was used to calculate the fold 
increase. The bar represents the mean. *P<0.05 
5.5.3 Tumour necrosis factor alpha 
The cytokine TNF-α has also been found in the atherosclerotic lesion of CAD. It is a 
pleiotropic cytokine produced by immune cells such as monocytes and macrophages. It has 
pro-inflammatory actions in response to inflammatory stimuli, and is associated with 
cardiovascular events. For example, higher serum TNF-α concentration was detected in 
patients with cardiomyopathy, myocardial infarction, and chronic heart failure ( Levine et 
al., 1990). TNF-α may induce atheroma through its role in endothelium function and 
stimulation of adhesion molecules, chemokines and growth factors (Azzawi et al., 1999). 
TNF-α was found in 88% of atherosclerotic lesions compared to normal tissues (Barath et al., 
1990 A) and its mRNA expression was increased in severe lesions, suggesting it may 
contribute in the development of disease (Barath et al., 1990 B). Arbustini et al., 1991 
showed increased TNF- α protein levels in lipid-rich plaques with or without thrombosis.  
 
Similarly to the above cytokines, TNF-α protein concentration was determined in primary 
cell culture supernatants stimulated with IL-1β or LPS for 8 or 12 hours. As for IL-10, TNF-α 
concentration was undetectable at baseline or upon induction by IL-1β at 8 hours (data not 
shown) and at 12 hours (Figure 5.11). TNF-α concentration was significantly increased by 
LPS treatment for 8 hours (+TAG IL6 haplotype; P=0.015; data not shown). However, 
following 12 hours of LPS stimulation there was clear induction of TNF-α protein for all IL6 
haplotypes, some groups showing a significant effect (Figure 5.11; panels A, C, E). 
Interestingly, TNF-α was the only cytokine that showed a significantly lower induction by LPS 
in the IL6 +TAG haplotype compared to its control group at 12 hours (P=0.0476 ) (Figure 
5.11 C and D).   
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Figure 5.11 The effect of IL6 haplotypes on TNF-α cytokine production by monocyte-
derived macrophage cells stimulated for 12 hours. PBMCs extracted from whole blood of nine 
individuals were cultured at a density of 2 × 106 cell/well and the stimulated in triplicate using either 
LPS or IL-1β for 12 hours. TNF- α protein level was determined in cell culture supernatants using the 
CBA assay. Panels A, C and E represent TNF-α protein expression. Panels B, D and F refers to TNF-α 
fold-induction. Wherever there was an undetectable value, the figure 0.1 was used to calculate the 
fold increase.  The bar represents the mean. *P<0.05 
-T
G
G
-C
o
n
tr
o
l
+
T
G
G
-C
o
n
tr
o
l
-T
G
G
-I
L
1

+
T
G
G
-I
L
1

-T
G
G
-L
P
S
+
T
G
G
-L
P
S
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
IL 6  p ro m o te r  h a p lo ty p e /T re a tm e n t
T
N
F
- 
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
*
-T
G
G
-I
L
1

+
T
G
G
-I
L
1

-T
G
G
-L
P
S
+
T
G
G
-L
P
S
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
IL 6  p ro m o te r  h a p lo ty p e /T re a tm e n t
T
N
F
- 
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
-T
A
G
-C
o
n
tr
o
l
+
T
A
G
-C
o
n
tr
o
l
-T
A
G
-I
L
1

+
T
A
G
-I
L
1

-T
A
G
-L
P
S
+
T
A
G
-L
P
S
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
IL 6  p ro m o te r  h a p lo ty p e /T re a tm e n t
T
N
F
- 
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
*
*
-T
A
G
-I
L
1

+
T
A
G
-I
L
1

-T
A
G
-L
P
S
+
T
A
G
-L
P
S
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
IL 6  p ro m o te r  h a p lo ty p e /T re a tm e n t
T
N
F
- 
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l) *
-C
G
G
-C
o
n
tr
o
l
+
C
G
G
-C
o
n
tr
o
l
-C
G
G
-I
L
1

+
C
G
G
-I
L
1

-C
G
G
-L
P
S
+
C
G
G
-L
P
S
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
IL 6  p ro m o te r  h a p lo ty p e /T re a tm e n t
T
N
F
- 
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
*
-C
G
G
-I
L
1

+
C
G
G
-I
L
1

-C
G
G
-L
P
S
+
C
G
G
-L
P
S
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
IL 6  p ro m o te r  h a p lo ty p e /T re a tm e n t
T
N
F
- 
 C
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
A B
C D
E F
106 
 
5.6 Expression of IL-6R (CD126) mRNA in stimulated PBMCs-derived 
macrophages   
IL-6R expression was tested in PBMC-derived macrophages using flow cytometry and QPCR. 
For flow cytometry analysis, PBMCs were isolated, cultured, stimulated, harvested and 
stained as described in Sections 2.7 and 2.8. Gating of and subtraction of the isotype control 
for CD126 positive cells was carried out as for CD14 and CD11c. Interestingly, the results 
showed that there was very little expression of CD126 protein on PBMC-derived 
macrophages either at baseline or treated with either LPS or IL-1β for 8 or 12 hours (Figure 
5.12 A and B respectively), with only one or two percent of cells showing any expression.  
 
 
 
Figure 5.12. Expression of IL-6R (CD126) in PBMC-derived macrophages treated with IL-1β 
or LPS for 8 hours (Panel A) and 12 hours (Panel B). Data were presented as percentage of cells 
positive for CD126 and were expressed as mean ± SD 
 
 
To test whether this result was reflected in the IL-6R mRNA production, QPCR was peformed 
on two samples of different IL-6R genotype (Figure 5.13). IL-6R mRNA expression was very 
low and did not change significantly with pro-inflammatory stimulation, and was therefore 
C
o
n
tr
o
l
IL
-1

L
P
S
0
1
2
3
T re a tm e n t
P
e
r
c
e
n
t 
o
f 
c
e
ll
s
p
o
s
it
iv
e
 f
o
r
 C
D
1
2
6
C
o
n
tr
o
l
IL
-1

L
P
S
0
1
2
3
4
T re a tm e n t
P
e
r
c
e
n
t 
o
f 
c
e
ll
s
p
o
s
it
iv
e
 f
o
r
 C
D
1
2
6
A B
107 
 
consistent with the finding of very low IL-6R protein expression. This suggests that IL-6R is 
produced only at very low levels in these cells. 
 
 
 
 
 
 
Figure 5.13. Expression of IL-6R mRNA in PBMC-derived macrophages treated with either 
IL-1β or LPS for 8 hours. Data were expressed as mean ± SD. 
 
5.7 Impact of IL6 haplotypes on SelS mRNA expression and vice versa 
The impact of SelS of haplotypes on IL6 mRNA and vice versa was investigated in treated 
PBMC-derived macrophages extracted from 15 healthy volunteers. The impact of SelS 
haplotypes beyond IL6 mRNA expression did not show significant differences (data not 
shown). The data showed significant induction of IL6 mRNA expression at both SelS 
haplotypes for all haplotypes treated with either LPS or IL-1β but no haplotype specific 
differences. Similarly, IL6-TGG and IL6-CGG haplotypes did not show any haplotype-specific 
effect on SelS mRNA expression (data not shown). However, the individuals with IL6 
haplotype TAG have a significantly lower SelS level at baseline (P= 0.0484) and at IL-1β 
treatment (P=0.0088) (Figure 5.14); because their induction is to a similar degree, they 
maintain the difference independent of stimulation – the +TAG individuals always have 
lower SelS. The third SNP in this TAG haplotype is not really relevant as all are G, but when 
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we looked at this separately by the first and second SNPs (-6331 C/T and -597 G/A 
respectively), we found no effect on SelS expression by -6331 alleles but -597 A allele 
carriers had lower SelS level at baseline (P=0.0484) and following IL-1β stimulation 
(P=0.0088), and there was a trend that did not reach statistical significance for LPS  (Figure 
5.15). The point within red circle may be responsible for the significant difference. 
  
 
 
 
Figure 5.14 Impact of IL6-TAG haplotype on relative SelS mRNA expression and fold 
change in LPS- and IL-1β-induced monocyte-derived macrophages. PBMCs-derived 
macrophages were stimulated for 8 hours in triplicate.  SelS mRNA expression was determined using 
QPCR and each QPCR assay was performed in duplicate. *P<0.05. Mean ± SD.  
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Figure 5.15 Impact of IL6 genotypes of two IL6 SNPs (-6331 C/T and -597 G/A) beyond 
relative SelS mRNA expression and fold change in IL-1β- and LPS-induced monocyte-
derived macrophages. The monocyte-derived macrophages was treated in triplicate with either IL-
1β or LPS for 8 hours. SelS mRNA expression was determined using QPCR and each QPCR assay was 
performed in duplicate. IL6-597 A allele induced lower SelS expression at baseline (*P= 0.0484) and 
at IL-1β treatment (**P=0.0088). The point within red circle may be responsible for the significant 
difference. Mean ± SD.  
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5.8 Conclusion 
IL- 6 mRNA expression was induced strongly by LPS in differentiated THP-1 cells. This finding 
is consistent with the literature and shows the LPS was working as expected and the IL6 
mRNA assay was appropriate.  
IL6 mRNA was significantly up-regulated in IL-1β- and LPS-induced cells irrespective of IL6 
haplotype in PBMC-derived macrophages. LPS induction of IL6 mRNA expression was 
significantly greater in cells with the TAG haplotype compared to those without. 
Interestingly, IL6 mRNA expression level was significantly higher in IL6-597 GA+AA 
genotypes treated by LPS. IL6 protein production, however showed little induction by IL-1β 
but in some cases showed significantly higher expression following LPS-stimulation. There 
was no significant difference between haplotypes in the LPS-induction. The individuals with 
IL6 haplotype TAG (or IL6-597 A allele) not only had higher IL6 but also had significantly 
lower SelS level at baseline  and on IL-1β treatment. 
 
IL-8, IL-10 and TNFa protein expression was significantly induced by either IL-1β or LPS in 
some groups but there were no significant differences in fold-induction between any of the 
IL6 haplotype groups except for TNF-α, which was the only cytokine that showed a 
significantly lower induction by LPS in the IL6 +TAG haplotype compared to its control group 
at 12 hours. 
CD126 (IL-6R) expression was very low on PBMC-derived macrophages, suggesting that 
classical IL6 signalling may not occur in these PBMCs. 
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Chapter 6. Discussion  
Inflammation is a main component of atherosclerotic diseases and pro-inflammatory 
cytokine genes are therefore candidates for predisposition to atherosclerosis and to 
understand the role in the pathogenesis of CAD. Inflammatory process plays a vital role in 
activation of plaque vulnerability, in the acute coronary syndromes like myocardial 
infarction and unstable angina. Besides their potential role in pathogenesis, the circulating 
concentrations of these cytokines serve as markers for prognosis. Interleukin (IL) 6 is one of 
these pro-inflammatory cytokines implicated in CAD. Selenoprotein S (SelS), important in 
the ER-stress pathway, has recently been shown to be involved in the pathogenesis of CAD 
through up-regulation of pro-inflammatory cytokines including IL6, IL1β and TNF-α that are 
themselves associated with increased risk of CAD. Given the association of IL6 and SelS 
haplotypes/genotypes with increased risk of CAD, and the connection between their 
signalling pathways, I investigated whether these haplotypes/genotypes may be exerting 
their effect on CAD risk through their effect on expression of SelS and IL6 (see Sections 1.6.4 
and 1.7.5). I investigated the association of these IL6 and SelS haplotypes (IL6-6331 T/C, IL6-
597 G/A , IL6-572 G/C; SelS-1500 A/C, SelS+3705 G/A, SelS+5227 C/T, SelS+9000 C/G) on the 
expression of  their respective mRNA and proteins, and also the effect of both gene 
haplotypes on the other’s expression.  
 
In the present study, PBMCs-derived macrophages from fifteen healthy individuals were 
treated with either IL-1β or LPS to mimic the in vivo situation in the inflammatory lesions in 
the coronary arteries. Volunteers without known health problems were genotyped for 
selected IL6, IL-6R and SelS single nucleotide polymorphisms (SNPs). These were selected on 
the basis of available assays and documented linkage disequilibrium. Peripheral blood 
mononuclear cells (PBMCs) from those donors were isolated, cultured in vitro to 
differentiate them into macrophages, and treated with IL-1β or LPS. RNA was extracted 
from cells and MLN51 (housekeeping gene), IL6, IL-6R and SelS mRNA expression was 
quantitated. Cellular proteins were extracted, quantified, and analysed by Western blotting. 
Cell culture supernatants were assayed for cytokine production a flow-cytometry-based 
‘Cytokine Bead Array’. Phenotype and gene expression (mRNA and protein) were examined 
according to IL6, IL-6R and SelS genotype and haplotype.  
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Investigation the mRNA expression of IL6 and SelS was also assessed in THP-1 cells to 
optimise the system.  
 
6.1 SelS gene polymorphisms and SelS mRNA expression  
The THP-1 cell line was used in my study as a model of macrophage function to optimize the 
culture method and QPCR prior to using primary cells. According to Kohro et al., (2004), 
macrophage-like THP-1 cells are similar to primary monocyte-derived macrophage in their 
gene expression profiles. Therefore, the expressions of our target genes were initially 
assessed in differentiated and undifferentiated THP-1. THP-1 cells were differentiated to 
macrophage-like cells using PMA for 72 hours and then the cells were stimulated using 
either IL-1β or LPS for 24 hours because this is the time that gave maximum induction of IL6 
mRNA expression (Beeton, PhD thesis, 2007). PMA has been used to stimulate the protein 
kinase C pathway of mitogen activated protein kinase (MAP) and extracellular signal related 
kinase (ERK) in differentiating HL-60 cells to macrophages (Schultz et al., 1997) and ERK in 
the Jurkat T cell line (Bradshaw et al., 1996). However, in THP-1 cells it has been shown to 
activate the ERK and c-Jun kinase but not the p38 MAP kinase (Carter et al., 2001).  Our 
results showed no effect of cytokine stimulation on SelS mRNA expression in both 
monocytic THP-1 and macrophage-like THP-1 cells, suggesting that SelS gene expression did 
not change with differentiation or cytokine stimulation. Studies in a different cell-type, the 
hepatocarcinoma cell-line HepG2, have shown induction of SelS by IL-1β (Gao et al., 2006); 
this suggests a possible tissue specific difference in response.  
In view of the evidence (Section 1.6.4) for association of SelS SNP haplotype with an 
increase in some pro-inflammatory cytokines associated with several inflammatory diseases, 
I decided to investigate the effect of five SelS haplotypes derived from 4 SelS SNPs (-1500 
A/C,+3705 G/A , +5227 C/T, and +9000 C/G). Selection of these SNPs was mainly based on 
the findings in two different case-control studies carried out by Curran et al. (2005) and 
Allane et al. (2007). Curran and colleagues tested the effect of three SelS SNPs (-105G/A, 
+3705G/A and +5227C/T) in increasing the levels of several pro-inflammatory cytokines 
including IL6. They pointed out that impairment of SelS promoter activity either 
experimentally or through the effect of putatively functional SelS promoter SNPs that might 
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differentially interact with transcription factors could lead to a decrease in SelS expression, 
which in turn would increase the levels of some pro-inflammatory cytokine including IL6. In 
support of this, Curran et al. used siRNA to impair the SelS promoter activity and they found 
that inhibition of SelS by siRNA elevated the production of cytokines including IL6 in mouse 
macrophage RAW264.7 cells. For the role of SelS SNPs in impairment of SelS promoter 
activity, Curran et al. also found that the -105 G/A SelS promoter SNP showed a strong 
association with higher production of IL-1β, IL6 and TNF-α (P=0.000016, P=0.0005, 
P=0.00089 respectively) and the A allele of SelS-105 SNP was found to be associated with 
decreased expression of SelS and increased plasma levels of these proinflammatory 
cytokines. This inhibition in SelS expression may be resulted from the interaction of A allele 
with the ER stress response element (ERSE) in the SelS promoter region. Allane et al. also 
investigated the effect of five SelS haplotypes derived from two SNPs (-105 G/A and +5227 
C/T) which previously studied by Curran et al. together with three additional SNPs (-1500 
A/C; +6218 T/C and +9000 C/G) on increase the risk of several inflammatory diseases such as 
CHD, CAD and stroke (see Section 1.6.4). They concluded that haplotype 2 (H2) (Figure 1.6) 
was associated with CAD risk in males and also in combined analysis of both male and 
female cohorts. Haplotype 4 (H4) was associated with increased risk of stroke in combined 
data of female cohorts and also with increased CHD risk in males.  
 
However, it is important to note that the present study is not  simply a repeat of the above 
studies. For example, Curran et al. did not test the effect SelS haplotypes on the mRNA 
expression of this gene. Allane et al. also showed the effect of SelS SNP haplotype on 
increasing the level of IL6 but they did not investigate the correlation between SelS 
haplotype and its expression.  
 
My results showed that overall there was no significant induction of SelS mRNA by IL1 or 
LPS. Most of the haplotype comparisons showed no significant difference in induction, 
suggesting no effect of the haplotypes of SNPs that I had been able to genotype. The only 
exception was that SelS mRNA from individuals with the +CATG haplotype was significantly 
induced by LPS, whereas that from the –CATG haplotype was not. This is probably a function 
of the relatively small numbers in this study. The only significant difference in SelS mRNA by 
SelS genotype was that the +C group of -1500 A/C SNP showed significantly showing 
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stronger LPS induction than the AA group. The C allele of this SNP is found in Haplotype 4 
associated with increase the risk of stroke and CHD as shown in Allane et al. study.  
However, this study and Curran et al. focused on the effect of the functional SelS SNP, -105 
G/A,  and showed that the SNP is within a putative ER stress response element in the SeS 
promoter and that the presence of the A allele led to substantially lower transcriptional 
induction by tunicamycin, an ER stress inducer. We did not include the -105 G/A SNP in our 
study because I was unable to genotype it, even though I used two different techniques 
(TaqMan and RFLP) with several different conditions. I followed the protocol of other 
studies and I also corresponded with the authors (Shibata et al., 2009) who confirmed to me 
that it is difficult to genotype.    
  
There was no significant difference at baseline or on induction of SelS protein by either IL-1β 
or LPS in either + or – CATG haplotypes, showing that there was no effect of that haplotype 
on SelS protein expression, which is consistent with SelS mRNA expression results. However, 
the reason for conflicting data associated with significantly LPS-induced SelS mRNA 
expression for +CATG but not with SelS protein expression may in part be because of the 
smaller number of samples in the protein experiment (9 compared with 15 for the mRNA), 
but also the protein measurement is less well controlled as no standard curve was used. 
 
In conclusion, there was no haplotype-specific effect on SelS expression and further larger 
studies will be needed to fully address the effect of these SNPs on SelS gene expression, 
especially the -105 SNP and other putatively functional SelS SNPs.  
 
 
6.2 IL6 gene polymorphisms and IL6 mRNA expression  
Putatively functional promoter IL6 SNPs have been repeatedly associated with IL6 gene 
expression (Section 1.7.5). The promoter region from -225 to -113, which includes the 
common -174 G/C polymorphism, contains regulatory elements that ensure induction of 
transcription by IL-1 or TNF-α (Ray et al., 1988).  Indeed, following activation by IL-1, 
transcription is enhanced in the IL6-174 G allele compared to the C allele in transfected 
HeLa cells; this SNP can therefore be considered functional (Fishman et al., 1998). This SNP 
in strong linkage disequilibrium (LD) with the -597 SNP genotyped in the present study. The 
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carriers of different genotypes have different IL6 plasma levels, which reductions in a 
sequence of GG>GC>CC in healthy individuals (Fishman et al., 1998) or in patients with brain 
vessel malformations (Chen et al., 2006), while CC carriers were shown to have greater IL6 
concentrations in days following coronary artery bypass graft surgery, suggesting a different 
pattern during inflammatory responses (Brull et al., 2001). This influence might be partially 
explained by linkage disequilibrium (LD) with another functional promoter SNP in the IL6 
gene and this SNP is -6331 T/C, located in the binding site for transcription factor Oct-1 
Section 1.7.5; Smith et al., 2008). Other SNPs in the IL6 gene have also been shown to affect 
its expression in interaction with -174 G/C. They include the -597 G/A SNP that is in strong 
LD with -174 G/C, which was confirmed in several studies (Terry et al., 2000; Muller-
Steinhardt et al., 2007; Ma´chal et al., 2014). Following the administration of LPS, bacterial 
surface molecules capable of stimulating foam cell development (Peluso et al., 2012 ), a 
lower production of IL6 was detected in individuals with -597 G and -174 G haplotype 
compared to -597 A and -174 C haplotype (Muller-Steinhardt et al., 2007). The IL6-572 C 
allele is also in LD with the -174G allele (Brull et al., 2001).  These SNPs are located adjacent 
to cis-acting regulatory elements involved in controlling IL6 expression at the level of 
transcription, suggesting that they might affect the interaction of proteins with the DNA at 
these sites (Tanabe et al., 1988). The Brull et al group has also revealed that -572 C allele 
carriers and -174 CC homozygotes had significantly greater IL6 levels following coronary 
artery bypass graft surgery (CABG). 
 
 
According to the literature (e.g. Beeton, 2007; Terry et al., 2000), there are three important 
factors that might control in IL6 gene expression, or any gene, in vitro. These factors include 
type of stimulus, period of induction and cell type. The literature and present research 
showed that the SNPs and/or haplotypes influence the transcriptional activity of the IL6 
promoter. 
The present data showed that IL6 mRNA expression was induced strongly by LPS in 
differentiated THP-1 cells. This finding is consistent with previous results in this lab (Beeton, 
2007), which showed significant induction in IL6 gene expression after treatment with LPS 
for 24 hours. In early reports, it was proposed that treating THP-1 monoytic cells with 
116 
 
100nM PMA for 48 hours resulted in increased IL-1 receptor antagonist (IL-1ra) an anti-
inflammatory cytokine, which decreased IL-1β binding (Bienkowski et al., 1990). It was later 
shown that soluble IL-1ra was degraded more slowly in monocytic THP-1 cells treated with 
LPS, suggesting a role in the down-regulation of the pro-inflammatory cytokine IL-1β (Learn 
et al., 2000). Although the THP-1 cells in this study were not endotoxin tolerant (pre-treated 
with LPS), up-regulation of IL-1ra in PMA differentiated THP-1 cells could explain the low 
response of THP-1 cells to IL-1β.   
 
IL6 mRNA expression in PBMCs-derived macrophages showed significant induction overall 
by IL1 and LPS. For the three common haplotypes tested, cells with at least one copy of the 
TAG haplotype showed significantly higher LPS induction than cells without the TAG 
haplotype (Figure 5.5). Analysis of individual SNPs showed that the third SNP (-572G/C) in all 
haplotypes is not really relevant because all have G, but when I looked at the allele effect of 
other two SNPs (-6331 C/T and -597 G/A) separately as shown in Figure 5.6, cells containing 
at least one of the -597 A alleles showed significantly higher LPS induction of IL6 mRNA 
expression compared to the GG homozygotes, whereas there was no difference for the -
6331 SNP. This suggests that, in the present data, the TAG haplotype-specific effect is 
actually due to the presence of the -597A allele.    
 
Our lab previously showed that it was the haplotype that determined IL6 promoter 
efficiency (Terry et al., 2000), but the present study did not directly measure the -174 G/C 
SNP, although there is high LD with the -597G/A SNP, nor did it measure the AnTn 
polymorphism at position 373, that was an important factor in the Terry data, but Terry et al 
did not measure the -6331 SNP, so those findings may be incomplete. Terry et al. found  
that the significantly increased IL6 expression with GG9/11G haplotype (derived from IL6-
597 G/C, -572 G/C, -373 AnTn and -174 G/C) was not a consequence of -174 G allele alone 
because the other 174 G-containing haplotypes did not show the same effect. This means 
that the combination of different alleles for these four different polymorphisms was 
responsible for this increase.  Thus the present data, obtained from primary human cells 
where the SNPs are in their natural chromatin context, may not be inconsistent with the 
literature, and it would be interesting to genotype the additional SNP and the -373AnTn 
polymorphism to complete the analysis. 
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It seems possible that differences in the level of IL6 mRNA expression may be due not just to 
individual SNPs but may be associated with the interaction of several, forming functional IL6 
promoter haplotypes, that may in turn be explained by differential interactions with  
transcription factors, if these SNPs are located in or near the binding site(s) for such 
transcription factors.  
 
Smith et al. (2008) showed that the -6331T allele was associated with significantly higher 
plasma IL6 concentration in one cohort 6 hours post coronary artery bypass graft surgery 
(P=0.02) in another post periodontal therapy (P=0.0001). There was a similar trend in a third 
cohort of healthy people (P=0.07). The possible explanation for the inconsistent findings is 
that Smith et al measured IL6 in plasma, although in two cohorts they measured it after an 
acute inflammatory event. In the Smith et al study, luciferase reporter assays were also 
carried out to determine the effect of -6331C/T and -174C/G alleles on IL6 mRNA expression 
in two different cell lines (HeLa and Huh7) stimulated with/without IL-1β. The results 
showed that the -6331 T allele was associated with increased IL6 expression in both HeLa 
and Huh7 cell lines when both co-transfected with the transcription factor Oct1 and 
stimulated with IL-1β.  These data are not confirmed by the data from the present study 
where we found no association of IL6 mRNA with the -6331 SNP.  Smith’s data suggested 
little transcriptional effect of the -174 SNP, which is also inconsistent with the present study 
as we found the strongest association with the -597 SNP that is in LD with the -174 SNP. The 
reasons for these discrepancies are not clear, but the experimental systems were very 
different, in particular the cell-types, the macrophages used in the present study being more 
relevant to atherosclerosis than epithelial cells. 
 
 However, the Smith et al. study was not entirely consistent with Chen et al., (2013) (Section 
1.7.5). Chen et al. showed that reporter gene expression driven by the -6331 C allele or the 
CC haplotype for both IL6 -6331C/T and -572C/G was higher (1.44- and 1.35-fold higher, 
respectively), compared with the respective T and G alleles in both the human lung cancer 
cell line A549 and the human bronchial epithelial cell line HBE, stimulated with or without 
IL-1. Therefore, these results suggested the biological importance of these SNPs on IL6 
promoter activity, although there are clearly some cell type specific differences between the 
studies because Chen found the -6331 C allele to be associated with increased IL6 promoter 
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function in lung-derived epithelial cell lines, whereas Smith found increased expression from 
the -6331 T allele through Oct 1 binding in HeLa (epitheliod cervix carcinoma) and Huh7 
(liver carcinoma) cell lines (Chen et al., 2013; Smith et al., 2008). None of these cell lines are 
relevant to atherosclerosis, whereas the primary, peripheral blood-derived, monocyte-
derived macrophages used in this thesis are, in contrast, directly relevant.   
 
From the literature, we might expect that the influence of one SNP synergizes with the 
effect of another and therefore, the difference caused by one variant may not be easy to 
determine. However the data from the present study suggest otherwise, that in the PBMC-
derived macrophages, only the -597 SNP is a major determinant of IL6 mRNA and protein 
expression. A complete explanation awaits analysis of potential transcription factor binding 
and/or interactions, and epigenetic and chromatin structural investigations. 
 
The IL6 protein level in PBMC-cell culture supernatants did not show any significant 
haplotype-specific differences at 8 or 12 hours stimulation. This result is consistent with IL6 
mRNA expression data at 8 hours induction by IL-1β or LPS for all IL6 haplotypes except 
+TAG IL6 haplotype. The -597 SNP showed significant induction with LPS for A allele carriers, 
and although the induction for the GG homozygotes appeared lower, this did not reach 
statistical significance. This may be because a smaller number of samples (9 donors) were 
used to detect IL6 protein compared with IL6 mRNA expression (15 samples) and is a much 
smaller number than used in the Smith (2008) study. The lack of significance may also be 
due to instability of IL6 protein in the culture conditions. 
 
The IL6 +TAG haplotype showed a significantly lower induction of TNF-α by LPS compared to 
its control group at 12 hours. This was the only cytokine whose proinflammatory induction 
was influenced by IL6 genotype. Interestingly higher LPS-induced IL6 was associated with 
lower LPS-induced TNF-α, which is consistent with the literature (Schindler et al., 1990 and 
Aderka et al., 1989 )  and suggests that IL6 autocrine/paracrine signalling is operating in 
these cells. It is likely this is not classical IL6 signalling because little/no expression of the 
IL6R gp80 was found. Schindler et al., 1990 and Aderka et al., 1989 studies showed that IL6 
induced inhibition the  production of TNF-α induced by LPS in cultured human monocytes, 
U937 cells, and in mice in vivo.   
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In conclusion, functional promoter IL6 SNPs affect IL6 gene expression if these SNPs locate 
in or near the binding site(s) for such transcription factors that play an important role in 
regulation of gene expression. IL6-174 is one of these important SNPs that has a strong 
evidence about its effect on IL6 gene expression. Our interesting data TAG haplotype-
specific effect is actually due to the presence of the -597A allele.    
 
 
6.3 Impact of IL6 haplotypes on SelS mRNA expression and vice versa 
No impact of SelS haplotypes on IL6 mRNA expression was observed. The data showed 
significant induction of IL6 mRNA expression at both SelS haplotypes for all haplotypes 
treated with either LPS or IL-1β but no haplotype specific differences. This is not surprising 
because we found no effect of SelS haplotype on SelS level and hence, there was nothing to 
feed through and affect the IL6 induction, but we investigated this because it was possible 
that there were haplotype-specific differences in SelS that we were unable to detect by the 
techniques that we used but may influence SelS production, and therefore possibly IL6 
production, over a person’s lifetime.  
 
The IL6-597 A allele was associated with significantly higher LPS stimulation of IL6 mRNA 
expression as shown in Figure 5.6 and lower SelS mRNA expression as shown in Figure 5.15. 
It is important to know that we had only a small number of -597 GGs (n=3) and the 
significant difference may be driven by one of these (red circle in Figure 5.15). 
Proinflammatory cytokines play an important role in activation of SelS expression.  Gao et al. 
2006 have shown that SelS promoter activity, SelS mRNA and protein expression can be 
activated by proinflammatory cytokines TNF and IL-1β in HepG2 cell lines after 8 hours 
treatment. They identified two binding sites for NF-B transcription factors and they 
concluded that SelS is a target gene for NF-B. SelS mRNA expression can be activated by 
fasting in P.obesus in vivo and by ER-stress and glucose deprivation in vitro (Walder et al., 
2002; Gao et al., 2004) and SelS SNPs (Curran et al., 2005). The SelS promoter contains an 
ERSE element and Gao et al found that this element was stimulated 2-2.5 fold in HepG2 
stressed by tunicamycin and thapsigargin, confirming that this element is functional and is 
responsive to ER stress. Although there is a binding site for NF-kB and the ERSE element in 
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the SelS promoter, proinflammatory cytokines and ER stress do not regulate the SelS mRNA 
expression in cooperative manner and this might be due to overlapping of one of the NF-B 
binding site with ERSE element, suggesting mutually exclusive binding of NF-B and ATF6 to 
this region. Another reason is that NF-B is induced partially by ER stress via production of 
reactive oxygen or Ca2+ disturbance (Pahl, 1999). Activation of SelS expression by ER stress 
supports the normal function of  SelS, which is to protect the cells from ER stress through 
removal of misfolded proteins from ER to cytosol for degradation by proteolysis. 
In conclusion, this result is novel because it is evidence of the impact of the IL6 TA(G) 
haplotype beyond IL6. It suggests that the IL6 TA(G) haplotype leads to higher IL6, that, 
perhaps over a person’s lifetime, leads to lower SelS levels that could increase ER stress and 
in turn increase inflammation through activation of NF-B, eliciting a vicious circle in carriers 
of the -597 A allele. This has not been shown before, to our knowledge, as a possible 
mechanism of action of IL6 in atherosclerosis and provides a potential explanation for 
genetic epidemiological findings.   
 
6.4 Conclusion, limitations of the study and future work 
In conclusion, SelS mRNA was up-regulated in LPS-induced +CATG SelS haplotype in PBMC-
derived macrophages. +CATG SelS Haplotype did not increase the SelS protein concentration 
in either LPS or IL-1β stimulated PBMC-derived macrophages at 8 hours time point. SelS-
1500 AA genotype was associated with high SelS fold induction in PBMC-derived 
macrophages treated by LPS. The individuals with +TAG IL6 haplotype (or IL6-597 A allele) 
show greater induction with pro-inflammatory stimuli. In contrast, PBMCs from people with 
the IL6 TAG haplotype (or –597A allele) have lower SelS at baseline and following IL-1β (and 
probably also LPS) stimulation.  
However, this study presented several limitations that should be addressed. These include 
small size of sample that could affect some of the results that demonstrated no statistical 
significance and the statistical significance might be increased with a larger number of 
donors. Age, ethnic background, gender, and body mass index as well as lifestyle habits, 
environmental and other genetic factors, and their interactions have been reported as 
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influencing the SNP haplotype-dependent individual expression of IL6. Unmeasured 
circulating IL6 levels within individuals may partially explain the observed effect of IL6 gene 
variants. Furthermore, in this study, I was unable to genotype the functional promoter SelS-
105 SNP that has been reported as a strong marker for increased production of several 
cytokines including IL6. This SelS SNP plus addition functional SelS or IL6 SNPs in or near to 
transcription factor binding sites should be studied but the relevant genetic variants in LD 
should be taken into account. Taken together, the next studies should focus on the impact 
of TAG IL6 haplotype on both IL6 and SelS expression by in vitro and in vivo studies, and 
case-control or cohort studies with larger numbers of sample will be required to confirm this 
effect. The SelS-105 G/A (rs28665122) SNP effect together with other SelS SNPs should be 
investigated on SelS itself and IL6 level in the future work. Despite all these limitations, this 
study is unique in having evidence for the impact of IL6 haplotype/genotype beyond IL6 
levels, and suggests an additional mechanism for the action of IL6 during atherosclerosis, as 
well as a possible reason for association of IL6 genetic variation with coronary artery 
disease. 
 
Chromatin immunoprecipitation should be used to determine if the transcription factors bind in the 
promoter regions that might contain functional SNPs.  This approach is utilised to provide a more 
detailed picture of the dynamic process of chromatin remodelling that play an important role in 
gene expression. Some transcription factor binding databases should also be used to determine if 
there is a consensus on transcription factors to look for with chromatin immunoprecipitation. These 
databases include  MATInspector (http://www.genomatix.de), TFSEARCH 
(http://www.cbrc.jp/htbin/nph-tfsearch), PROMOTERSCAN (http://zeon.well.ox.ac.uk) and TFBIND 
(http://tfbind.hgc.jp/).  
 
The effect of more IL6 and SelS promoter SNPs on their expression should also be investigated. IL6-
174 is one of these very important SNP that have a strong effect on IL6 expression based on several 
reported studies. 
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 APPENDIX Ι: Annotated Selenoprotein S (SelS) gene  
 Legand  
ATG/ TAG start/stop codon 
EXONS: Upper case 
Exon 1  154bp 
Exon 2  135bp 
Exon 3  107bp 
Exon 4  90bp 
Exon 5  76bp 
Exon 6  93bp 
Exon 7  637bp 
Introns: LOWER case.  
SNPs  
Primers  
  
                                                       rs8025174 
-2100 acaaatcttt gcaatttagg atcttcttcc ataactaagt tttgtgggtt  -2051 
-2050 ttttttcttt tcttttcttt cttttttaga cagtcttgct ctgtcatcca  -2001 
-2000 ggctgtggag tgcagtggta caatcttagc tcactgcaac ctctgcctcc  -1951 
-1950 caggttcaag cgattctcct gcctcagcct ccctagtagc tgggattaca  -1901 
-1900 ggcgcccgcc atcacacctg gctaattttt gtatttttag tagagacagg  -1851 
-1850 gtttcaccat gttagccagg ctggtcttga actcctgacc tcaggtgatc  -1801 
-1800 catgcacctc ggcctcccaa agtgctggga ttacaggcgt gagccaccgt  -1751 
-1750 gcctggccaa atttttttgt agagatggga tcttgctgtg ttgcccaggc  -1701 
 -1700 tggtcttgaa ctcctggcct caagtgatcc tcctgcctca gcctcctaaa  -1651 
-1650 gtgcaatagg attacaggca agagccacca ctcctggccc actgcaacat  -1601 
-1600 tcttgaagct ctcaagtctt catctgacac cttgtcaaga tggggaactc  -1551 
-1550 ttgtgttaaa ccatcctgtt aagttactgt ataaaaataa aactgctccc  -1501 
-1500 aagcattgat tgaaactgtt ttggtatgag tttcctgaga gaaaagtgag  -1451 
-1450 gccctaacca tttttttcca tgaactatga ccccagtacg gtatacctaa  -1401 
-1400 tgtccttcac agcctaacaa aatagttgag gcaaccctgc tcatcctgtc  -1351 
-1350 tagtttatca gtatttagat gtaaggcgga tttaaagcta atctgggact  -1301 
-1300 gagaattgca actaattcca tagaagtcat tcaatttagc acataaatgt  -1251 
-1250 tcctgcaaga tgccagagca agtgagaaat catctgtagc aaagcaaaga  -1201 
-1200 gtggtgatgg ttcatcacct tttacaacgg aaaggcaaac atgaagaagg  -1151 
-1150 aaattctccc tcctaaaatt cctcattaaa tcgataagct atcttcacag  -1101 
 -1100 cctttatgga taacatccag agtcctcggt tcatctgagg agtccatttt  -1051 
-1050 caaggtggcc aacagggaag aagagctttc aggcttctct ttgctatggc  -1001 
-1000 tcatgaatgc caggtcccct ttattgcttt ctgaacacac tgctgggaaa  -951 
 -950 gcttgatgag gtcagtgctc aaatccctgc agctgtcccc cttgaggaac  -901 
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 -900 ttcttggcaa acctgcattg aagaaacact gattgcgttc acgcttcatg  -851 
 -850 tcatggtttg ccttccccac actgctcctg gcgacagtgg tgacgcagca  -801 
 -800 ctcggatgtt gtcacctatt cattattttt tcagttctat tcccaattcc  -751 
 -750 caacccttct tttgaaacac agctaggtat gtgcacttca aatgctccag  -701 
 -700 aaaaacccaa ggtcacattt caaataggat ggttatggtc accataaagg  -651 
 -650 tggtgacgtt tgagtggtgg aagagggtgc gggacggcgt tgcaggcaga  -601 
 -600 ggaacacagc caggacacta ttataagtaa ctctgtgatc gtgtcttgtg  -551 
 -550 gtgatacagt ataattcaac acaggttaga gcagttacta tgatcgttct  -501 
 -500 ttcctaaaag gctttgattt tggagaaaga accttgagga tcggtgggga  -451 
 -450 ctttcttggc ctgaaaggta tcaccagcag caggagcagg aggctgctca  -401 
 -400 catttcgtgt cttcacttgg ggtggacgtt ggctgcaacc ctcaaatgct  -351 
 -350 gggagtcgtc aaccaactga gccctgttgt ccaatgtgcc ccgggcaagg  -301 
 -300 atgtgggtgc aaatcctgct tccgggcgac cactgacttc cttggcttca  -251 
-250 gtgtccaatt agaaaaaaaa aagaaagtag aaattcggta agaaatccgt  -201 
 -200 gaacgaggtc cgtcctccac ccccgactca agccaagaga tagcacagaa  -151 
 -150 cgttcccaca cgcgctgtcc cggccccggc gagcgtagcc gggatttctc  -101 
 -100 ccccgccacg cccctcggcc acgcccccct gcgtttggcc cagcgacggg  -51 
                        -105 (rs28665122) 
  -50 gcggggtcgg cctgcgattg gccgggacca cgaccgcgtc cgggcgcgcc  -1 
    1 ACGTGTGCGT AGGAGCGCAC CGGAAGCGCC CGGCTGGAGG CGCGGCGGCA  50 
 1051 GGGCTGGGCG GCGGCGGCGG CGGCGGTCAT GGAACGCCAA GAGGAGTCTC  100 
 1101 TGTCCGCGCG GCCGGCCCTG GAGACCGAGG GGCTGCGCTT CCTGCACACC  150 
 1151 ACGGgtgagt cgttgcgggg cagccgggcg cgcgccgcca cttttgcgac  200 
 1201 gcgcagccat gatgggtggg tcgtccgccg ctgcaccggg cgccggagcc  250 
 1251 tgggaggcct gggaacggtc gggcgttggc gcttacgcgg accttgggca  300 
 1301 gcaggcccgg accttgcgcg gaggcttctc gggagccgca cttccctggg  350 
 1351 cggctcggct gtcccttgtt tgcgcaagtc ttttttgcga accaagccct  400 
 1401 tcctgtggta gttactgggg tcactcggcc gttggcgttt gcctctggga  450 
 1451 cccgtcccac acagccccat acacactcct gactccccgc gctgtcaccc  500 
1501 ctttctatgt ggctctgaaa ggcctttgcc ttcctgattc agattagttg  550 
 1551 ctcttcattc ttcaaaaccc agttgctgtg ccctccacac tctaactgcc  600 
 1601 cccgactccc cagatggttg ggaagtctca cttctcagtg atccctgaat  650 
 1651 tgtcgcactt cttgagttcg tgttttaacg atctacttag gaggcttttt  700 
 1701 cctcagccta gaccatgaag gctttgaggg caggagttac actttgtgtt  750 
 1751 tgttgagtct tatggaaagg tcaactagta gtgtcatttt tagttttttg  800 
 1801 aaaactgttt ttcttttcag TGGGCTCCCT GCTGGCCACC TATGGCTGGT  850 
              F_primer    rs185738361 G/C 
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 1851 ACATCGTCTT CAGCTGCATC CTTCTCTACG TGGTCTTTCA GAAGCTTTCC  900 
 1901 GCCCGGCTAA GAGCCTTGAG GCAGAGGCAG CTGGACCGAG CTGCGGCTGC  950 
 1951 TGTGGgttag tgcctgataa ccgaaatgaa agcggtggtt ttgcacctcc  1000 
 2001 tttatattaa gagttagtct cttagtaaaa gtaagagggg ccacacagga  1050 
 2051 agaccctgtc tctatttaaa aaaaaaaaaa atagccggga gtggcggcac  1100 
 2101 gcacctgtag tcccagctgc tcaggaggct gaggcgggat aatcacttga  1150 
 2151 gtccagggag tcaaagctgc agtgggctat gctcgggcca cactacactc  1200 
 2201 cagcctgggc aattgattga gaccttgtct ttaaaaaaaa aaaaaaaaaa  1250 
 2251 aaagtaggaa gtatatggtt ctcggtgggg cgcggtggct cacacctgta  1300 
 2301 atcccagcac tttgggaagc cgaggcagga ggatgacttg aggtcagggg  1350 
 2351 ttcgagaaca gcctggccaa catggtgaaa ccctgtctct actaaaaata  1400 
 2401 caaatattag tggggcgtgg tgacgggcac ctgtaatccc agctattagg  1450 
 2451 gtggctgagg caggagaaat cgcttgaacc tgggagctgg agattgcagt  1500 
 2501 gagctgagat tgtgccactg cactccagcc tgggcaacag agtgagactg  1550 
 2551 tcttttcttt cttttttttt tttttttcta tgagatggag tctagccttg  1600 
 2601 ttgcaaagag cgagactcta tgagtagacg ttatgaatag aaatgagttc  1650 
 2651 atttctattc ataatgctat ttggaaggat ttttcttttc tgtagaaaca  1700 
 2701 aatacttaag aatcttctgc gctaattaag ggatggataa tgatttagaa  1750 
 2751 aactttatat ttccttggta gtcttccagg attctagtca gcctagagac  1800 
 2801 tgtgggtgtc actgaggtat ccaagatgtg ctctgtgtgg ccactatccc  1850 
 2851 aggctttatg aatcggaatt gctcagggga actcagaaat tggcatttct  1900 
 2901 aacagatttc tggtgatgta gatatttcgg gctaaaatcc gtggctcagc  1950 
 2951 aacagacccc tgccccctga agcagtaaaa tgtatgcaga ggggttagga  2000 
 3001 gtacttatgt aaaaatatgt tgtttcattg tctgatatcc atacctcttt  2050 
 3051 atacttttaa taatatggac actcaaaagt ttctatttta tattgtacac  2100 
 3101 agtgctttat ctccattttt ttctgacatt ttagAACCTG ATGTTGTTGT  2150 
                                    R_primer 
 3151 TAAACGACAA GAAGCTTTAG CAGCTGCTCG ACTGAAAATG CAAGAAGAAC  2200 
 3201 TAAATGCGCA AGTTGAAAAG CATAAGGAAA AACTGAAACA Agtatgaact  2250 
 3251 ggtttcagtt tgaatgtgtg catagaaatt gtctgaggtt tagtggctaa  2300 
 3301 cgatgcctgt gtctgtgttg tctataagct tctaggacca ggtcctatcc  2350 
 3351 cattagattc aataagcatt tcagttccta ccatgtaagt attggtgata  2400 
 3401 tcaagaagaa tacacgattg ttagggaaca ctagatgtgt gaatatatta  2450 
 3451 ccatgaaagg tccagagcac aaaaggaggg acaggctgga gcagggagca  2500 
 3501 tgtgagtgtg tgtgtgcatg tgcctgtgtc ttccccatta ccaaaaatgt  2550 
 3551 cctgacagga gtgagtttca gaagaatgga gtcagtaatc tttttcatga  2600 
 3601 aacattttgc tttctttaat agtgtacaaa aaccaaagct gctctatgtg  2650 
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 3651 agttaaactc acactaccag atcacaacag ttttattaac taaagaaaac  2700 
 3701 gagggtgaag tttgttctga aagacattta aattaagaat tatcagagtt  2750 
 3751 agctttgtct ttgagagaaa tggcagcttc tgaattcttt ctgtaaaatg  2800 
 3801 tgattgtttc tcagCTTGAA GAAGAAAAAA GGAGACAGAA GATTGAAATG  2850 
 3851 TGGGACAGCA TGCAAGAAGG AAAAAGTTAC AAAGGAAATG CAAAGAAGCC  2900 
 3901 CCAGgtgact ggagacctcg gccggctggc atgcggtaga tgaagattgc  2950 
 3951 caagtagaat gttttaattg cttcttacac tactgtgtgt gttcaaacag  3000 
 4001 GAGGAAGACA GTCCTGGGCC TTCCACTTCA TCTGTCCTGA AACGGAAATC  3050 
 4051 GGACAGAAAG CCTTTGCGGG GAGGAGgtaa gcaccactga tgtcaaatgt  3100 
 4101 taacagattt tcaacactta caggatatag ttacctttta ggaacaagat  3150 
 4151 tgtttgtttc tttgtccata aattaagact aattccttag gattgtgaag  3200 
 4201 attcaataaa ggaaacagat gcaaatcacc tcctaggtcc tcactaagta  3250 
 4251 cttagaagga ttgtacttat agtattctaa cttgatcctt ctgcagcccc  3300 
 4301 gtagagggag agctaagtag ggtgaggaat tgtctgccaa tcttcagatg  3350 
 4351 agtgtcaagg agctggaaca cagtggtttt ggtctttctg gctgggacca  3400 
 4401 ccttgtttct tgcaaataac aaggagtagc agacagatgc tcatccaaag  3450 
 4451 ctgcttcctg tgtgcagcac tgccccgggg actctggatg atgccacagc  3500 
 4501 agtctgtctt catcccatcc ctgagaattt caaatctggg aagatgggac  3550 
 4551 tcacaaacga aaataagcaa tccttggtga ttctggctaa gagttgcaag  3600 
 4601 ttactgctga ggaaggaaag aacaaacaca ctagaacact gtaggaacca  3650 
 4651 aggcggaaga ttttgtatcc tccataggag gagaggggca ccgcagaggc  3700 
 4701 cctgatggtg tctttgagga ctgaggaaag actggggcat gggctccaag  3750 
                                   +3705 (rs4965814) 
 4751 gcagcagggc cacagacttg gctgacctta aacgctgagc tgtaatcccc  3800 
 4801 tttgtgtcag aagactaaac ctggcttgct gtagagaagg tgatgcatct  3850 
 4851 ggaaagaaaa tgctattttt aaatggtcct gccggaagct tatttttaga  3900 
 4901 cacatagagg tgatatttag gagaggaatg gaaatcgtag aagatggaat  3950 
 4951 gcagggtgtg cttgcctgca cggcctcttt cagcatcccc agcatttctg  4000 
 5001 agctgggact tttgactagc ctggctttac aaataaggaa actgaggcac  4050 
 5051 agtgtttaat tgcccaaaga ttccactata agtaaggagt aaaagtaaca  4100 
 5101 tttaagttct gggtggccct agaaccttag cactcaacca ggttaccagt  4150 
 5151 tgtgcactga ctttgggaag ctcatgaggg agtggggtgg ttgggggtag  4200 
 5201 ggaaggatac agaagacccc gttctgactg gtagaagtga caagtttgac  4250 
 5251 tcttgatttt ttttaatctg ttttctgtag cgtgaacagc ccttatttga  4300 
 5301 atgtatgagt tttagtaagc actgtgatag gaggattcat atacttaaat  4350 
 5351 caggccctct tgagagagtt ttttggtgac ccttttgcat gtgtttcgga  4400 
 5401 ggttgggaca aagaagctga atgacttttt tccccaccag acaatcagtt  4450 
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 5451 caaatggcaa tcacaatata aaggtttttt tttttttcac atagctaaaa  4500 
 5501 ggttttttta aatgtccctt aggatctgta tctttgcagt gctttgcgtg  4550 
 5551 tcactctcat aattttattg tggatataca atgttcccag attttcagat  4600 
 5601 ttttatcaat actgttgtgc tgcttttctg tcctcccagG TTATAACCCG  4650 
 5651 TTGTCTGGTG AAGGAGGCGG AGCTTGCTCC TGGAGACCTG GACGCAGAGG  4700 
 5701 CCCGTCATCT GGCGGATGAG GCTAAGAATC TTgttagtgt cacttttgac  4750 
 5751 attagcaaga tgaaccctta accctcgatt caattgcctt acgcacgctt  4800 
 5801 ttcacagtga ctagccaagg ggaggtgggg ttgatttctg ttcctaacta  4850 
 5851 cacctgcata tgtcagggct ccagtcagca aaaggtatag atgttgcctc  4900 
 5901 taggcatgag gtcattggtc acattctact tggagacagt gattgcattc  4950 
 5951 attgatttca tggttaattg ctagttggta ggtaaaggcc tctagatgat  5000 
 5001 tagcaatctt gataaaagag gcctagtaat gttcttttga ggttagaaat  5050 
 5051 ccttgctgct aggacagtct ctgtgacagg ttgcgttgaa tgatgtcttc  5100 
 5101 cttatcaatg gtgagcccac cagtgaggat tactgatgtg gacagttgat  5150 
 5151 ggggtttgtt tctgtatatt tatttttatg tacagaactt tgtaaaaacg  5200                         
 5201 aaactattta aaaaacaaga ataacatttt tagcatcttt attcaaggag  5250 
 5251 atttatggac ttcaatttgt ctatcaaaca ttaaatagct ttttattaca  5300 
    +5227 C/T(rs4965373) 
 5301 acctctaact attacttatt tctctattta ttattactca cccaaaataa  5350 
 5351 gtctggcaag tggcagacag ctgccgtgat tttgaaagtt gacagactcc  5400 
 5401 ttggggttca tccacaaaat tgggtgcttg gagtcgagtt gccgaattac  5450 
 5451 tgggataaag aaacatcgtg cctcaaggtt cctcataggc tgaccaggtt  5500 
 5501 tctacgtgac ctctcagtta ttcccttacg ccatgactca tcttttacgc  5550 
 5551 tcttgtccag aggcactatc agcagttttg gataaagagc caaacagtaa  5600 
 5601 atattttaga ctttacaggc cacatatgat ctctgtcaca tagtcttagg  5650 
 5651 tttttatatt tttaaaggat tgtttttaaa aaagattctc tgctcatggg  5700 
 5701 ctggatttgg gctgaatgct gtagtgtgtg gaccccgtct agatcatcag  5750 
 5751 aaggaaaaac attaaccttc agaatagggg gtaattcgct gcaaaagtac  5800 
 5801 tatagaatgg tctcatacat aaattagtca acatttgtta tctcctgcag  5850 
 5851 GTAGAATATT CCGTGGTTGC TTCTTGACCA AGGGAAATAC AGTCTGGCTG  5900 
 5901 TGAGAGACTT AAAATCTCTT GAGGAGCGCT CTGGAGAATG GCTGAAGGAG  5950 
 5951 AGGAAACAGG AGCCTTGAGC AGTGTAATTA CAAACAAATA GGTTGGCATA  6000 
 6001 GTCTTAAGTC TTTGAGTCTA GAGAGATTTG AGTTTTGTTT TGCCTGTGGA  6050 
 6051 GGCAATTGGG GGTTTCAGGT CAAAGAGAGG GTCAGTGGAA ACAAGGGTGG  6100 
 6101 GCCTTGTGAG GTGTGGGGAA GCCCTGGGAC CCTCACTCCC CTTCCAGTGT  6150 
 6151 GTAACTGGAT TGGCTCCCAC CAGCCCAGAA GATTTACGAC GTGGGAAATG  6200 
 6201 GTATACTTGG ATTAAAATAT TTCATCCAGA TTTGTTTACA TCTAGAGAGA  6250 
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 6251 ACCCCTTGTA GGTTATAAGG AAACTTTTTA ACATTCTTCC TTGAATATAT  6300 
 6301 TTTCTGTAGC TGAAAATGTT TGTGAAGTGG CTGTCAACTA CACATCGCAT  6350 
 6351 GAGTAGAGGG GCTCTGGGTC GGGGTTTCAT ATGCAGCAGA GCAGCTCCCT  6400 
 6401 TGCTGCCGTC CATCAAGAGC CCTCAACACA AGAGTTTGTT ATAAATAGAA  6450 
 6451 ATAAACGACA AAAAGTAGAG GGGTATGTTT AAGTACActa ttagatgtga  6500 
 6501 ctgactacct tgaaacctga tttttttcca tggggagaaa cagtgcttga  6550 
 6551 attctgcatg ccccccttgc atctagcacc ttttggtagg ggtggaagga  6600 
 6601 gggtgtcagg gagaatgatt aggagataat ggaggggagg ggaaacttgc  6650 
 6651 gttgtgtaat agcatttgaa gagcacttac cacgtggcag gagtgtccat  6700 
 6701 ttctgtttga tccccctaga atcctatgaa acgggtatgt tactaacctt  6750 
 6751 ggttttcaga aactgaagct tagatgggct tagtaactgg tccacaacgc  6800 
 6801 tactcgctgt agtctacttc atccttgtgt tcatattagc caaaggcctt  6850 
 6851 aagtcatcaa ggtgtgggaa gcttcttgca gctaatgaaa cagttatgtg  6900 
 6901 gccaggcaca gtggctcacg cctgtaatcc caccagccaa gatgggtgga  6950 
 6951 tcacctgagg tcaggagttc gagaccagcc tgactaatat ggtaaaaccc  7000 
 7001 tgtctctact aaaaatacaa aaaattagct gggcatgatg gcatatgcct  7050 
 7051 gtaatcccag ctccttggga ggctgaggca ggagaattgc ttgaacgtgg  7100 
 7101 gaggtggagg tggaggttgt gatgagccaa gatcgtgcca ttgcactcca  7150 
 7151 ccctgggcaa caagagcaaa actccatctc caaaaaaaaa aaaaaaaaaa  7200 
 7201 aagttatgtg aagtaataat acagtgaaaa tcacattaca gatctagggc  7250 
 7251 attaagcatt tcagaaaggt ggactgagct tgccagggaa agcaggtctt  7300 
 7301 ggacctttct tgaaaaaatg agaaattggg ggcagaggtg caaatgccaa  7350 
 7351 aagctgaggc ccctggggaa gaagggacgg ccagagccat aaaaaccatg  7400 
 7401 cttcaaacct aggccatgtg ctcaccttgt ccaccagcag aggctgctgt  7450 
 7451 ggggctcgcg gtgtgtcctg gcagttggca ggagttt                7487  
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APPENDIX ΙΙ:  Annotated interleukin 6 (IL6) gene 
legand    
ATG/TAG start/stop codon/TATA box 
EXONS: Upper case 
Exon 1:135 bp 
Exon 2:191 bp 
Exon 3:114 bp 
Exon 4:147 bp 
Exon 5:597 bp 
Lower case: introns 
5’UTRs and 3’UTRs 
SNPs 
Primers  
 
 
 
    1 gtttccttct agcttctttt gatttcaaat caagacttac agggagaggg   50 
   51 agcgataaac acaaactctg caagatgcca caaggtcctc ctttgacatc  100 
  101 cccaacaaag aggtgagtag tattctcccc ctttctgccc tgaaccaagt  150 
  151 gggcttcagt aatttcaggg ctccaggaga cctggggccc atgcaggtgc  200 
  201 cccagtgaaa cagtggtgaa gagactcagt ggcaatgggg agagcactgg  250 
  251 cagcacaagg caaacctctg gcacagagag caaagtcctc actgggagga  300 
  301 ttcccaaggg gtcacttggg agagggcagg gcagcagcca acctcctcta  350 
  351 agtgggctga agcaggtgaa gaaagtggca gaagccacgc ggtggcaaaa  400 
  401 aggagtcaca cactccacct ggagacgcct tgaagtaact gcacgaaatt  450 
         -597A/G (rs1800797)              -572G/C (rs1800796) 
  451 tgaggatggc caggcagttc tacaacagcc gctcacaggg agagccagaa  500 
  501 cacagaagaa ctcagatgac tggtagtatt accttcttca taatcccagg  550    
  551 cttggggggc tgcgatggag tcagaggaaa ctcagttcag aacatctttg  600 
  601 gtttttacaa atacaaatta actggaacgc taaattctag cctgttaatc  650 
  651 tggtcactga aaaaaaattt tttttttttc aaaaaacata gctttagctt  700 
  701 attttttttc tctttgtaaa acttcgtgca tgacttcagc tttactcttt  750 
  751 gtcaagacat gccaaagtgc tgagtcacta ataaaagaaa aaaagaaagt  800 
  801 aaaggaagag tggttctgct tcttagcgct agcctcaatg acgacctaag  850 
                             rs1800795 (-174G/C) 
  851 ctgcactttt ccccctagtt gtgtcttgcc atgctaaagg acgtcacatt  900 
  901 gcacaatctt aataaggttt ccaatcagcc ccacccgctc tggccccacc  950 
  951 ctcaccctcc aacaaagatt tatcaaatgt gggattttcc catgagtctc 1000 
          Exon 1                         5’ UTRs 
 1001 AATATTAGAG TCTCAACCCC CAATAAATAT AGGACTGGAG ATGTCTGAGG 1050 
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        -1 
 1051 CTCATTCTGC CCTCGAGCCC ACCGGGAACG AAAGAGAAGC TCTATCTCCC 1100 
 1101 CTCCAGGAGC CCAGCTATGA ACTCCTTCTC CACAAgtaag tgcaggaaat 1150  
1151 ccttagccct ggaactgcca gcggcggtcg agccctgtgt gagggagggg 1200 
 1201 tgtgtggccc agggagggct ggcgggcggc cagcagcaga ggcaggctcc 1250 
                                                         Exon 2 
 1251 cagctgtgct gtcagctcac ccctgcgctc gctcccctcc ggcacagGCG 1300 
 1301 CCTTCGGTCC AGTTGCCTTC TCCCTGGGGC TGCTCCTGGT GTTGCCTGCT 1350 
 1351 GCCTTCCCTG CCCCAGTACC CCCAGGAGAA GATTCCAAAG ATGTAGCCGC 1400 
                            F_primer  
 1401 CCCACACAGA CAGCCACTCA CCTCTTCAGA ACGAATTGAC AAACAAATTC 1450 
 1451 GGTACATCCT CGACGGCATC TCAGCCCTGA GAAAGGAGgt gggtaggctt 1500 
 1501 ggcgatgggg ttgaagggcc cggtgcgcat gcgttcccct tgcccctgcg 1550 
 1551 tgtggccggg ggctgcctgc attaggaggt ctttgctggg ttctagagca 1600 
 1601 ctgtagattt gaggccaacg gggccgacta gactgacttc tgtatttatc 1650 
 1651 ctttgctggt gtcaggaagt tcctttcctt tctggaaaat gcagaatggg 1700 
 1701 tctgaaatcc atgcccacct ttggcatgag ctgagggtta ttgcttctca 1750 
 1751 gggcttcctt ttccctttcc aaaaaattag gtctgtgaag ctcctttttg 1800 
 1801 tcccccgggc tttggaagga ctagaaaagt gccacctgaa aggcatgttc 1850 
 1851 agcttctcag agcagttgca gtactttttg gttatgtaaa ctcaatggct 1900 
 1901 aggattcctc aaagccattc cagctaagat tcatacctca gagcccacca 1950 
 1951 aagtggcaaa tcataaatag gttaaagcat ctccccactt tcaatgcaag 2000 
 2001 gtattttggt cctgtttggt agaaagaaaa gaacacagga ggggagattg 2050 
 2051 ggagcccaca ctcgaattct ggttctgcca aaccagcctt gtgatcttgg 2100 
 2101 gtaaattccc taccacctct ggactccatc agtaaaattg ggcgtggact 2150 
 2151 aggtgatctc atagatcctt cctgctggaa cattctatgg cttgaattat 2200 
 2201 attctcctaa ttattgtcaa aattgctgtt attaagtatc tactgtgtgc 2250 
 2251 caggcacttt aaataaatat tgtgtctaat cttcaaaaca aatttgcaag 2300 
 2301 gaaggttttt ggagataagg aaactgagac tcaggattaa gtaacacacc 2350 
 2351 taaagtcaca ggtgagcttg gaactgaacc caagtgtgcc cccactccac 2400 
 2401 tggaatttgc ttgccaggat gccaatgagt tgtagcttca tttttcttag 2450 
 2451 agactttcct ggctgtggtt gaacaatgaa aaggccctct agtggtgttt 2500 
                                                         Exon 3 
 2501 gttttaggga cacttaggtg ataacaattc tggtattctt tcccagACAT 2550 
                                                  R_primer 
 2551 GTAACAAGAG TAACATGTGT GAAAGCAGCA AAGAGGCACT GGCAGAAAAC 2600            
 2601 AACCTGAACC TTCCAAAGAT GGCTGAAAAA GATGGATGCT TCCAATCTGG 2650 
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 2651 ATTCAATGAG gtaccaactt gtcgcactca cttttcacta ttccttaggc 2700 
 2701 aaaacttctc cctcttgcat gcagtgcctg tatacatata gatccaggca 2750 
 2751 gcaacaaaaa gtgggtaaat gtaaagaatg ttatgtaaat ttcatgagga 2800 
 2801 ggccaacttc aagctttttt aaaggcagtt tattcttgga caggtatggc 2850 
 2851 cagagatggt gccactgtgg tgagatttta acaactgtca aatgtttaaa 2900 
 2901 actcccacag gtttaattag ttcatcctgg gaaaggtact ctcagggcct 2950 
 2951 tttccctctc tggctgcccc tggcagggtc caggtctgcc ctccctccct 3000 
 3001 gcccagctca ttctccacag tgagataacc tgcactgtct tctgattatt 3050 
 3051 ttataaaagg aggttccagc ccagcattaa caagggcaag agtgcaggaa 3100 
 3101 gaacatcaag ggggacaatc agagaaggat ccccattgcc acattctagc 3150 
 3151 atctgttggg ctttggataa aactaattac atggggcctc tgattgtcca 3200 
 3201 gttatttaaa atggtgctgt ccaatgtccc aaaacatgct gcctaagagg 3250 
 3251 tacttgaagt tctctagagg agcagaggga aaagatgtcg aactgtggca 3300 
 3301 attttaactt ttcaaattga ttctatctcc tggcgataac caattttccc 3350 
                          Exon 4 
 3351 accatctttc ctcttagGAG ACTTGCCTGG TGAAAATCAT CACTGGTCTT 3400 
 3401 TTGGAGTTTG AGGTATACCT AGAGTACCTC CAGAACAGAT TTGAGAGTAG 3450  
3451 TGAGGAACAA GCCAGAGCTG TGCAGATGAG TACAAAAGTC CTGATCCAGT  3500 
 3501 TCCTGCAGAA AAAGgtgggt gtgtcctcat tccctcaact tggtgtgggg 3550 
 3551 gaagacaggc tcaaagacag tgtcctggac aactcaggga tgcaatgcca 3600 
 3601 cttccaaaag agaaggctac acgtaaacaa aagagtctga gaaatagttt 3650 
 3651 ctgattgtta ttgttaaatc tttttttgtt tgtttggttg gttggctctc 3700 
 3701 ttctgcaaag gacatcaata actgtatttt aaactatata ttaactgagg 3750 
 3751 tggattttaa catcaatttt taatagtgca agagatttaa aaccaaaggc 3800 
 3801 gggggggcgg gcagaaaaaa gtgcatccaa ctccagccag tgatccacag 3850 
 3851 aaacaaagac caaggagcac aaaatgattt taagatttta gtcattgcca 3900 
 3901 agtgacattc ttctcactgt ggttgtttca attctttttc ctacctttta 3950 
 3951 ccagagagtt agttcagaga aatggtcaga gactcaaggg tggaaagagg 4000 
 4001 taccaaaggc tttggccacc agtagctggc tattcagaca gcagggagta 4050 
 4051 gacttgctgg ctagcatgtg gaggagccaa agctcaataa gaaggggcct 4100 
 4101 agaatgaaac ccttggtgct gatcctgcct ctgccatttc tacttaagcc 4150 
 4151 agggtttctc atatgttaac atgcatggga attccctggg catcttcttg 4200 
 4201 tggtgtggag tctgacttag caagcctcgg gtgggtttga gggtcaaatt 4250 
 4251 tctaccaggc ttatatccct ggtgatgctg cagaattcca ggaccacact 4300 
 4301 tggaggttta aggccttcca caagttactt atcccatatg gtgggtctat 4350 
 4351 ggaaaggtgt ttcccagtcc tctttacacc accggatcag tggtctttca 4400 
 4401 acagatccta aagggatggt gagagggaaa ctggagaaaa gtatcagatt 4450 
131 
 
 4451 tagaggccac tgaagaaccc atattaaaat gcctttaagt atgggctctt 4500 
 4501 cattcatata ctaaatatga actatgtgcc aggcattatt tcatatgaca 4550 
 4551 gaatacaaac aaataagata gtgatgctgg tcaggcttgg tggctcatgc 4600 
 4601 ctgtattccc taaactttgg gagcctaagg tgagaactcc ttgaactcct 4650 
 4651 aaggccagga gttcaagacc agcctggata acatagcaag accccatctc 4700 
 4701 tacaaaaaac caaaaccaaa caaacaaaaa tgatagtggt gcttccctca 4750 
 4751 ggatgcttgt ggtctaatgg gagacagaac agcaaaggga tgattagaag 4800 
 4801 ttggttgctg tgagccaggc acagtgctga tataatccca gcgctatggg 4850 
 4851 aggctgaggt gggtggatca tttgaggcca ggagtttaag accagcctgg 4900 
 4901 tcaacatggt aaaaccccat ctctacttaa aaatacaaaa aagttagcca 4950 
 4951 ggcatggtgg catacacctg taacccagct actcaggagg ctgaggcaca 5000 
 5001 tgaatcactt gaacccagga ggcagaggtt gctgtgcacc actgcactcc 5050 
 5051 agcctgggtg acagaacgag accttgactc aaaaaaaaaa aaaagaagtt 5100 
 5101 tgttgctatg gaagggtcct actcagagca ggcaccccag ttaatctcat 5150 
 5151 tcaccccaca tttcacattt gaacatcatc ccatagccca gagcatccct 5200 
 5201 ccactgcaaa ggatttattc aacatttaaa caatcctttt tactttcatt 5250 
                  Exon 5 
 5251 ttccttcagG CAAAGAATCT AGATGCAATA ACCACCCCTG ACCCAACCAC 5300 
 5301 AAATGCCAGC CTGCTGACGA AGCTGCAGGC ACAGAACCAG TGGCTGCAGG 5350 
 5351 ACATGACAAC TCATCTCATT CTGCGCAGCT TTAAGGAGTT CCTGCAGTCC 5400 
                                  3’ UTRs 
 5401 AGCCTGAGGG CTCTTCGGCA AATGTAGCAT GGGCACCTCA GATTGTTGTT 5450 
 5451 GTTAATGGGC ATTCCTTCTT CTGGTCAGAA ACCTGTCCAC TGGGCACAGA 5500 
 5501 ACTTATGTTG TTCTCTATGG AGAACTAAAA GTATGAGCGT TAGGACACTA 5550 
 5551 TTTTAATTAT TTTTAATTTA TTAATATTTA AATATGTGAA GCTGAGTTAA 5600 
 5601 TTTATGTAAG TCATATTTAT ATTTTTAAGA AGTACCACTT GAAACATTTT 5650 
 5651 ATGTATTAGT TTTGAAATAA TAATGGAAAG TGGCTATGCA GTTTGAATAT 5700 
 5701 CCTTTGTTTC AGAGCCAGAT CATTTCTTGG AAAGTGTAGG CTTACCTCAA 5750 
 5751 ATAAATGGCT AACTTATACA TATTTTTAAA GAAATATTTA TATTGTATTT 5800 
 5801 ATATAATGTA TAAATGGTTT TTATACCAAT AAATGGCATT TTAAAAAATT 5850 
 5851 CAGCAA                                                 5856 
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APPENDIX ІІІ: Conference abstracts  
 
Genetics of inflammatory mediators, in particular interleukin 6 and selenoprotein S, that 
have a role in coronary artery disease. Hamad AlHomidani, Kikki Bodman-Smith, Abdelali 
Agouni, Fiona Green.  British Society for Cardiovascular Research conference (BSCR) in 
Reading. September 2014. 
Genetics of inflammatory mediators, in particular interleukin 6 and selenoprotein S, that 
have a role in coronary artery disease. Hamad AlHomidani, Kikki Bodman-Smith, Abdelali 
Agouni, Fiona Green. The European section of the International Society of Heart Research 
conference (ISHR) in Bordeaux, France. July 2015. 
 
Published abstracts from conference proceedings 
 AlHomidani H, Bodman-Smith K, Agouni A, Green FR. (2014) 'GENETICS OF INTERLEUKIN 6 
AND SELENOPROTEIN S THAT HAVE A ROLE IN INFLAMMATION AND CORONARY ARTERY 
DISEASE'. ELSEVIER IRELAND LTD ATHEROSCLEROSIS, Queens Coll, Cambridge, ENGLAND: 
Autumn Meeting of the British-Atherosclerosis-Society (BAS) 237 (2), pp. E3-E3 
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Project: Inflammation-related genetic variation in a group of healthy volunteers. 
Supervisor: Dr Fiona Green, Mr Hamad Alhomidani 
Background and project: 
Coronary artery disease (CAD) is an inflammatory disease caused by a number of different genetic 
and environmental factors. Interleukin-6 (IL6) is a pro-inflammatory cytokine implicated in CAD and 
produced by several cell types, and it has a spectrum of actions. Four IL6 promoter single nucleotide 
polymorphisms or SNPs (-597, -572, -373 and -174) may be associated with CAD through increased 
IL6 production. A polymorphism in the soluble IL-6 receptor (sIL-6r) is known to affect the plasma 
level of sIL-6r and this is associated with severity of CAD. Recently, the selenoprotein S (SelS) gene 
has also been identified to be involved in up-regulation of pro-inflammatory cytokines including IL6, 
IL-1β and TNF-α and SelS SNPs are associated with increased risk of CAD.  We have shown in 
preliminary experiments that the macrophages from people with different IL6 polymorphisms 
respond differently to an inflammatory stimulus but more data are required. This project will be to 
genotype a group of healthy volunteers for these SNPs, analyse the data, and then to recall 
volunteers of specific genotypes to analyse the response of their macrophages to an inflammatory 
stimulus. The project will involve genotyping by TaqMan, data analysis, cell culture and quantitative 
PCR. 
References: 
1. Libby, P. (2008). Role of inflammation in atherosclerosis associated with rheumatoid arthritis. 
Am J Med 121, S21-31. 
2. Watkins, H., and Farrall, M. (2006). Genetic susceptibility to coronary artery disease: from 
promise to progress. Nat Rev Genet 7, 163-173. 
3. Terry, C.F., Loukaci, V., and Green, F.R. (2000). Cooperative influence of genetic 
polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275, 18138-18144. 
4. Chamorro, A., Revilla, M., Obach, V., Vargas, M., and Planas, A.M. (2005). The -174G/C 
polymorphism of the interleukin 6 gene is a hallmark of lacunar stroke and not other ischemic 
stroke phenotypes. Cerebrovasc Dis 19, 91-95. 
5. Curran, J.E., Jowett, J.B., Elliott, K.S., Gao, Y., Gluschenko, K., Wang, J., Abel Azim, D.M., Cai, 
G., Mahaney, M.C., Comuzzie, A.G., et al. (2005). Genetic variation in selenoprotein S 
influences inflammatory response. Nat Genet 37, 1234-1241. 
6. Alanne, M., Kristiansson, K., Auro, K., Silander, K., Kuulasmaa, K., Peltonen, L., Salomaa, V., 
and Perola, M. (2007). Variation in the selenoprotein S gene locus is associated with coronary 
heart disease and ischemic stroke in two independent Finnish cohorts. Hum Genet 122, 355-
365. 
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Project: Analysis of a coronary artery disease susceptibility locus in the horse. 
Supervisor: Dr Fiona Green, Dr Priti Chivers, Mr Hamad Alhomidani 
Background and project: 
Recent whole-genome scans in coronary artery disease have implicated a region on chromosome 
9p21. An overlapping region has also been implicated in type 2 diabetes. This region contains several 
known genes as well as a long, non-coding RNA (ANRIL or CDKN2BAS), but the whole region is not 
well annotated in the genome databases. A project student last year used bioinformatic analysis and 
found strong conservation of large parts of this sequence in the horse genome, although hitherto 
ANRIL/CDKN2BAS, was believed to be restricted to primates.  
The project will be to test whether this horse homologue is actually expressed in horse RNA from a 
variety of tissues/blood. The project will use bioinformatics including primer design, but will be 
mainly laboratory based and will include extraction of RNA from horse blood/tissue and assay of the 
expression of specific conserved exons of ANRIL/CDKN2BAS in the horse by quantitative PCR. 
References: 
1. Samani NJ et al for the WTCCC and Cardiogenics Consortium. Genomewide association 
analysis of coronary artery disease. N Engl J Med. 2007 Aug 2;357(5):443-53. 
2. Helgadottir A et al for DeCode Genetics. A common variant on chromosome 9p21 affects the 
risk of myocardial infarction. Science. 2007 Jun 8;316(5830):1491-3.  
3. Broadbent HM et al for the PROCARDIS consortium. Susceptibility to coronary artery disease 
and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 
9p. Hum Mol Genet 2008; 17 (6): 806-14. [Fiona Green co-author] 
4. Schunkert H et al. Large-scale association analysis identifies 13 new susceptibility loci for 
coronary artery disease. Nat Genet. 2011 Mar 6;43(4):333-8.  
5. Peden J et al for the Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide 
association study in Europeans and South Asians identifies five new loci for coronary artery 
disease. Nat Genet. 2011 Mar 6;43(4):339-44. [Fiona Green co-author] 
6. Wang F et al. Genome-wide association identifies a susceptibility locus for coronary artery 
disease in the Chinese Han population. Nat Genet. 2011 Mar 6;43(4):345-9. 
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APPENDIX IV: 
Staff / Student Volunteer Donor Consent Form Donor details:  
Surname  First Name(s)  
Date of Birth  Sex  
I have read the donor information sheet: YES/NO  
I agree to provide a blood sample for use by:  
I have be informed of the following:  
The quantity of blood to be taken  (specify amount)  
The frequency of blood donations – if repeat 
donations are required  
(specify frequency)  
The use that will be made of the sample  (specify use)  
Any tests for disease, or markers of  
disease, which will be undertaken while  
the sample can be identified as  
originating from me  
(specify which, if any)  
I agree to the sample being stored for  
possible further uses in future  
YES/NO  
(For regular donors) I understand I should not give blood if I develop one of the conditions 
listed in the Donor information sheet YES/NO  
Donor signature:  Date:  
Signature of person taking blood:  Date:  
Name and contact details of person taking blood  
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